Dedifferentiation and redifferentiation of canine articular chondrocytes by Penny, Jasmine Rachel
Penny, Jasmine Rachel (2015) Dedifferentiation and 
redifferentiation of canine articular chondrocytes. PhD 
thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/28985/1/Dedifferentiation%20and%20Redifferentiation%20of
%20Canine%20Articular%20Chondrocytes_PhD%20Thesis_Jasmine%20Penny.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
1 
 
 
 
 
 
DEDIFFERENTIATION AND 
REDIFFERENTIATION OF CANINE 
ARTICULAR CHONDROCYTES 
 
 
JASMINE RACHEL PENNY, BSc. (Hons) 
 
 
Thesis submitted to the University of Nottingham for 
the degree of Doctor of Philosophy 
 
 
JULY 2015 
 
1 
 
Abstract 
 
Articular cartilage can be damaged directly through injury or 
osteoarthritis (OA).  This tissue is very poor at regenerating itself due to 
its avascular nature and the immobility of chondrocytes within the 
tissue.  There are a range of surgical techniques to repair cartilage 
lesions.  Cellular therapies such Autologous Chondrocyte Implantation 
(ACI) and later modifications have been used to repair cartilage lesions 
for the past two decades.   However, there is currently no completely 
successful treatment of cartilage lesions, with the newly generated 
cartilage often possessing very poor mechanical properties.  Also, cell-
based therapies require large numbers of chondrocytes which have to 
be expanded in monolayer.  A consequence of this expansion is a loss 
of the chondrocyte phenotype (dedifferentiation).   The overall aim of 
this thesis was to develop a greater understanding of chondrocyte 
dedifferentiation and redifferentiation in vitro using canine chondrocytes.  
Dogs can also suffer with OA and have been used extensively as a 
model for OA.  Firstly, canine chondrocytes were expanded in 
monolayer up to P5 to confirm dedifferentiation.  These cells were 
shown to have lost their typical chondrocytic phenotype through 
decreased expression of collagen type II and increased expression of 
collagen type I and CD44.  A considerable part of this element of the 
thesis also involved identifying antibodies that would cross-react with 
the target canine antigens.  The next aim of the thesis was to 
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redifferentiate dedifferentiated chondrocytes through three-dimensional 
(3D) culture.  Initial problems with high density pellet culture led to the 
selection of a supporting material.   Alginate was chosen as it is a 
naturally occurring polymer which has previously been used to culture 
chondrocytes in 3D.  After making several adjustments to the set-up 
and downstream analysis of the beads, chondrocytes from different 
passages were seeded into them.  Alginate beads seeded with P2 
chondrocytes appeared to contain cells with a more chondrocyte-like 
phenotype compared to P3- and P4-seeded beads.  However, 
expression of collagen type I was still relatively high in P2-seeded 
beads, indicating 3D culture alone is not enough to induce complete 
redifferentiation.  Therefore, the final aim of this thesis was to enhance 
the redifferentiation of dedifferentiated canine chondrocytes.   Two initial 
FRQGLWLRQVZHUHVHOHFWHGDGGLWLRQRIȝJPODVFRUEDWH WR WKHFXOWXUH
medium and incubating the beads under reduced oxygen conditions 
(2.4%). Culturing the beads under reduced oxygen conditions (2.4%) 
appeared to enhance redifferentiation.  However addition of ascorbate 
to the culture medium had mixed results.  This culture system can now 
be further adapted and modified to better enhance chondrocyte 
redifferentiation.  This work could include combining the two conditions 
already tested as well as adding growth factors to the culture medium.   
More successful maintenance of the chondrocyte phenotype in vitro, 
could potentially lead to better articular cartilage regeneration both in 
vitro and in vivo. 
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1. Introduction 
 
1.1 Types of Cartilage 
 
There are three main types of cartilage, hyaline, elastic and 
fibrocartilage (Salter, 1998, Umlauf et al., 2010).  According to a review 
of the history of the understanding of cartilage by Benedek (2006), this 
tissue was first documented by Aristotle in the fourth century BC who 
recognised it only in the ears and nostrils.  Articular cartilage was first 
described by Galen in 175 BC (Benedek, 2006). 
 
1.1.1 Hyaline Cartilage 
 
Hyaline cartilage is the most abundant out of the three types (Umlauf et 
al., 2010). Articular cartilage is a form of hyaline cartilage present in 
synovial joints (Figure 1.1) (Martel-Pelletier et al., 2008, Umlauf et al., 
2010). This tissue is avascular, aneural and acts as a load-bearing 
material, allowing the frictionless movement of joints (Martel-Pelletier et 
al., 2008).   
 
Although articular cartilage is the focus of this project, the next two 
sections will provide a brief overview of the features of fibrocartilage 
and elastic cartilage; the two other main types of cartilage. 
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1.1.2 Fibrocartilage 
 
Fibrocartilage can be found in the intervertebral discs and menisci 
(Salter, 1998), tendons, ligaments and the temporomandibular joint 
(Benjamin and Ralphs, 1998, Benjamin and Ralphs, 2004, Hagandora 
et al., 2012, Murphy et al., 2013).  Fibrocartilage is avascular and 
aneural and contains cells which are large, round or oval and 
embedded within the extracellular matrix (ECM) (Benjamin and Ralphs, 
2004).  Fibrocartilage contains densely packed collagen fibres and is a 
highly ordered tissue (Nerurkar et al., 2011); however, it is difficult to 
distinguish from other tissues due to it having no clear boundaries and 
there is some suggestion that it should be thought of as a translational 
tissue (Benjamin and Ralphs, 2004).  A recent study aimed to see if a 
spectrum of cartilage tissues, from fibrous to hyaline, could be 
engineered using porcine chondrocytes from costal cartilage (Murphy et 
al., 2013).  The authors clearly demonstrate a decrease in collagen type 
I staining with increasing length of aggregate culture; however the 
images for collagen type II are less clear.  The quantitative data shows 
an increase in the overall collagen content and in collagen type II 
expression with increasing aggregate culture length.  Collagen type I 
expression was too low to be detected quantitatively.  Overall the 
results would appear to suggest that the chondrocytes begin to 
synthesise a more fibrous tissue before progressing to a more hyaline-
like tissue (Murphy et al., 2013).  A characteristic feature of 
fibrocartilage is that it contains both type I and type II collagen 
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(Benjamin and Ralphs, 2004).  The ratio of these collagens can vary 
depending on the location of the tissue (Benjamin and Ralphs, 2004).  
Aggrecan and versican have been found in fibrocartilage (Benjamin and 
Ralphs, 2004).  The former is associated with regions rich in collagen 
type II, whereas the latter is associated with collagen type I rich areas 
(Benjamin and Ralphs, 2004).  Decorin and biglycan have also been 
found in tendon and intervertebral disc fibrocartilage (Benjamin and 
Ralphs, 2004). 
 
1.1.3 Elastic Cartilage 
 
Cartilage that contains high levels of elastic fibres is known as elastic 
cartilage (Hall, 2005).  The elastic cartilage of the mammalian external 
ear, the pinna, is the most studied (Hall, 2005).  Auricular chondrocytes 
secrete an elastin-rich matrix and contain matrix vesicles related to this 
purpose (Hall, 2005).  Elastic cartilage is also found in the larynx (Salter, 
1998).  Up to 20% of the dry weight of this tissue can be elastic fibres 
(Salter, 1998).   
 
Nielsen and Bytzer (1979), studied elastic cartilage  of the rat epiglottis.  
Chondrocytes were described to be in lacunae which were surrounded 
by territorial matrix (Nielsen and Bytzer, 1979).  This matrix was 
observed to be between 0.6 and 1.2µm thick and there was a clear 
boundary between this and the interterritorial matrix (Nielsen and Bytzer, 
1979).  Cox and Peacock (1977) looked at elastic cartilage from the 
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ears of rabbits.  The authors claim that there is a difference between 
cartilage at the tip and base of the ear.  It is also stated that features of 
the cartilage change with age.  It is difficult to confirm these statements 
from the figures presented (Cox and Peacock, 1977).   
 
Before discussing the features of articular cartilage, the overall structure 
of the synovial joint will be reviewed.  
 
1.2 The Synovial Joint 
 
Where two or more parts of the skeleton come together, this is called a 
joint (Benjamin, 1999).  A synovial joint has a cavity that is surrounded 
by a fibrous capsule which links the two or more skeletal elements 
together (Benjamin, 1999) (Figure 1.1).   These capsules are fibrous 
connective tissues, made of collagen fibres (Ralphs and Benjamin, 
1994) and are commonly strengthened by ligaments (Benjamin, 1999).  
In some cases capsules are strengthened by tendons; an example of 
this is the extensor tendon in the finger (Benjamin, 1999).  The 
orientation of fibres within the capsule and the thickness of the capsule 
itself varies depending on the level of stress it is exposed to (Ralphs 
and Benjamin, 1994).  For example, the  anterior part of the capsule in 
the hip joint is thicker than the posterior part because the centre of 
gravity passes behind the joint, which can also often hyperextend 
(Ralphs and Benjamin, 1994).    It is important to note that not all joints 
in the body are synovial; there are also cartilaginous and fibrous joints 
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(Benjamin, 1999).  Examples of such joints include those between the 
vertebral bodies (cartilaginous) and sutures linking bones in the skull 
cap (fibrous) (Benjamin, 1999).  The capsule and surrounding ligaments 
act together to limit joint movement and hold the bones together 
(Benjamin, 1999).  All the non-articular surfaces within the joint are lined 
with the synovial membrane, which secretes and absorbs synovial fluid 
(Benjamin, 1999).  In healthy joints, this fluid is relatively acellular and 
pale yellow in colour (Ropes et al., 1939, Ropes et al., 1940).  This fluid 
is responsible for lubricating the joint and delivers some of the nutrients 
to the articular cartilage (Benjamin, 1999).  In fact, nutrients have to 
pass from synovial capillaries through the synovial membrane into the 
synovial fluid (Buckwalter and Hunziker, 1999).  This fluid then has to 
move through the cartilage matrix in order to reach the chondrocytes 
(Buckwalter and Hunziker, 1999).  The synovial membrane usually 
consists of one to three layers of synoviocytes and is supported by 
vascular connective tissue (Benjamin, 1999).  Both the synovium and 
capsule are innervated, the latter more so than the former (Ralphs and 
Benjamin, 1994).  These nerves are the same nerves which supply the 
muscles acting on the joint (Ralphs and Benjamin, 1994).  
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Figure 1.1: A synovial joint.  This diagram showing the main features of a synovial 
joint was adapted from (Benjamin, 1999, Setton, 2008). 
 
The shape and position of the articular surfaces and associated 
muscles and ligaments all influence the stability of the joint (Benjamin, 
1999).  Joints are most stable when there is maximum possible contact 
between the bones within the joint; this is called the close-packed 
position (Benjamin, 1999).  When in this position, the capsule and 
ligaments are at their most tense (Benjamin, 1999). 
 
Normal function of the synovial joint is dependent on the smooth, low 
friction gliding and load bearing surface provided by the articular 
cartilage (Buckwalter and Hunziker, 1999).  Although articular cartilage 
can differ in thickness, cell density, matrix composition and mechanical 
Ligament 
Joint capsule 
Synovial cavity 
Articular cartilage 
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properties between species and even within an individual; all synovial 
joints have the same general structure and components and perform 
the same functions (Buckwalter and Hunziker, 1999).  The structure of 
articular cartilage will now be reviewed in detail. 
 
1.3 Cartilage Structure: Zones of Articular Cartilage  
 
It is universally recognised that articular cartilage can be split into four 
zones.  However there are slight differences in the literature in the 
nomenclature of these zones.  Some authors divide articular cartilage 
into the superficial, middle, deep and calcified zones (Poole et al., 1987, 
Dowthwaite et al., 2004, Goldring and Goldring, 2005, Martel-Pelletier 
et al., 2008, Karlsson and Lindahl, 2009), whereas others refer to the 
superficial zone, transitional zone, middle or radial zone and calcified 
zone (Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, 
LeBaron and Athanasiou, 2000, Temenoff and Mikos, 2000, Goldring 
and Goldring, 2005, Umlauf et al., 2010) (Figure 1.2).   
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Figure 1.2: The structure of articular cartilage.  There are four zones in articular 
cartilage but the nomenclature of the zones in articular cartilage varies in the literature 
(see section 1.3). 
 
1.3.1 Superficial Zone 
 
The first zone, the superficial zone, is the thinnest of the four 
(Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, Martel-
Pelletier et al., 2008) and represents about 10% of the tissue (LeBaron 
and Athanasiou, 2000).  This zone comprises of two layers (Buckwalter 
and Mankin, 1998, Buckwalter and Hunziker, 1999, LeBaron and 
Athanasiou, 2000, Temenoff and Mikos, 2000).  The upper layer is a 
thin, acellular film consisting of fine fibrils with a small amount of 
polysaccharide called the lamina splendens (Buckwalter and Mankin, 
1998, Buckwalter and Hunziker, 1999, LeBaron and Athanasiou, 2000, 
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Temenoff and Mikos, 2000).  Underneath this layer is the cellular part of 
the zone.  Here, the chondrocytes have a flatter, more disc-like 
morphology and they are aligned parallel to the articular surface 
(Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, 
LeBaron and Athanasiou, 2000, Temenoff and Mikos, 2000, Goldring 
and Goldring, 2005, Martel-Pelletier et al., 2008).  Although these cells 
secrete surface zone proteoglycan (Dowthwaite et al., 2004), they 
produce a matrix that is high in collagen and low in proteoglycan 
content compared to deeper zones (Buckwalter and Mankin, 1998, 
Buckwalter and Hunziker, 1999, Martel-Pelletier et al., 2008).  The 
collagen fibrils in this zone are relatively thin and are parallel to the 
articular surface (Buckwalter and Mankin, 1998, Buckwalter and 
Hunziker, 1999, LeBaron and Athanasiou, 2000, Temenoff and Mikos, 
2000, Goldring and Goldring, 2005, Martel-Pelletier et al., 2008) (Figure 
1.3).  This zone has a greater tensile stiffness compared to the other 
zones because of the dense network of collagen fibrils parallel to the 
surface (Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, 
LeBaron and Athanasiou, 2000, Temenoff and Mikos, 2000).  Although 
it is stated throughout the literature that there are four zones in articular 
cartilage,  a recently published paper claims that there is an additional 
zone before the superficial zone referred to as the most superficial zone 
(Fujioka et al., 2013).  In fact, the authors suggest that this zone is split 
into three layers. However they do admit that some layers were only 
visible using certain techniques and indicate that the second layer might 
be an artefact caused by sample preparation (Fujioka et al., 2013). 
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Figure 1.3: Collagen fibril orientation and thickness in articular cartilage. Fibril 
diameter increases with depth and orientation changes from parallel in the superficial 
zone to perpendicular in the deep zone. This figure was adapted from (Buckwalter and 
Hunziker, 1999, Buckwalter et al., 2005) 
 
1.3.2 Middle Zone 
 
As stated previously, the next zone is either referred to as the middle 
zone or the intermediate zone.  This zone is the largest section of 
articular cartilage; it can be between 40% and 60% of the total cartilage 
height and weight (Goldring and Goldring, 2005, Martel-Pelletier et al., 
2008).  The chondrocytes in this zone are more rounded (Buckwalter 
and Mankin, 1998, Buckwalter and Hunziker, 1999, Martel-Pelletier et 
al., 2008) and secrete cartilage intermediate layer protein (Dowthwaite 
et al., 2004, Karlsson and Lindahl, 2009).  They also have more 
synthetic organelles, Golgi membranes and endoplasmic reticulum than 
those in the superficial zone (Buckwalter and Mankin, 1998, Buckwalter 
and Hunziker, 1999, LeBaron and Athanasiou, 2000, Temenoff and 
Mikos, 2000).  The matrix in this zone consists of thicker collagen fibrils 
(Goldring and Goldring, 2005, Martel-Pelletier et al., 2008), which are 
Superficial Zone Middle Zone Deep Zone 
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aligned obliquely or randomly to the articular surface (Temenoff and 
Mikos, 2000) (Figure 1.3).  Although the collagen fibrils are thicker, the 
overall concentration of collagen is lower in this zone compared to the 
superficial zone (Buckwalter and Mankin, 1998, Buckwalter and 
Hunziker, 1999, LeBaron and Athanasiou, 2000, Temenoff and Mikos, 
2000).  Water content is also lower but proteoglycan concentration is 
higher (Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, 
LeBaron and Athanasiou, 2000, Temenoff and Mikos, 2000). 
 
1.3.3 Deep Zone 
 
The third zone can be called the middle (in literature where the second 
zone is referred to as the transitional zone), radial or deep zone.  
Chondrocytes in this zone are also spheroid in shape and are organised 
in columns (Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 
1999, LeBaron and Athanasiou, 2000, Temenoff and Mikos, 2000).  
They secrete a matrix that contains the biggest collagen fibrils 
(Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999, Martel-
Pelletier et al., 2008), which are aligned perpendicular to the articular 
surface (Figure 1.3) and extend into the tidemark (Buckwalter and 
Mankin, 1998, Buckwalter and Hunziker, 1999, Temenoff and Mikos, 
2000).  There are also collagen fibrils in a different alignment 
surrounding individual chondrocytes or stacks of chondrocytes in the 
territorial matrix (see section 1.4.2) (Buckwalter and Mankin, 1998, 
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Buckwalter and Hunziker, 1999, Temenoff and Mikos, 2000, Martel-
Pelletier et al., 2008).  Interestingly, cell density decreases from the 
superficial zone to the deep zone (Goldring and Goldring, 2005) but the 
cell volume increases.  In fact, chondrocytes in the second and third 
zones have twice the cell volume of the cells in the superficial zone 
(Goldring and Goldring, 2005). 
 
1.3.4 Calcified Zone 
 
The final zone is separated from the upper layers by a tidemark 
(Hollander et al., 2010).  The main function of this calcified zone is to 
anchor the articular cartilage to the subchondral bone (Martel-Pelletier 
et al., 2008)  In addition to this, it acts as a mechanical buffer between 
the subchondral bone and uncalcified articular cartilage (zones one to 
three) (Goldring and Goldring, 2005).   The chondrocytes in this layer 
have a more hypertrophic phenotype and secrete type X collagen and 
alkaline phosphatase (ALP) (Martel-Pelletier et al., 2008).  They are 
also smaller in volume than the cells in zones two and three and have 
small quantities of Golgi complex membranes and endoplasmic 
reticulum (Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 
1999, Temenoff and Mikos, 2000). 
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The structure and components of the ECM will now be discussed in 
greater detail, beginning with the regions of the matrix followed by its 
components. 
 
1.4 Cartilage  Extracellular Matrix (ECM) 
 
The majority of articular cartilage is composed of extracellular matrix 
(ECM), which contains water, type II collagen and proteoglycans 
(Stockwell, 1978, Hollander et al., 2010). Although water represents 
70% of the wet weight of unloaded cartilage, it is unevenly distributed 
throughout the tissue, with the highest concentration (80%) near the 
cartilage surface (Martel-Pelletier et al., 2008, Hollander et al., 2010).   
 
1.4.1 Regions of ECM: Pericellular Matrix 
 
There are three distinct areas of articular cartilage ECM; the pericellular, 
territorial and interterritorial regions (Poole et al., 1987, Buckwalter and 
Mankin, 1998, Buckwalter and Hunziker, 1999, Youn et al., 2006).  
Immediately surrounding the chondrocyte is the pericellular matrix 
(Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999).  The 
cell membrane appears to be attached to this matrix (Buckwalter and 
Mankin, 1998, Buckwalter and Hunziker, 1999).  This matrix has a high 
concentration of proteoglycans (Poole et al., 1980, Buckwalter and 
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Mankin, 1998, Buckwalter and Hunziker, 1999) but also contains non-
collagenous proteins such as the anchorin CII, which is a cell-
membrane-associated molecule (Buckwalter and Hunziker, 1999).  In a 
study by Poole et al (1980), staining for proteoglycan was more intense 
in the pericellular matrix surrounding chondrocytes nearer the articular 
surface compared to deeper zone cells.  Staining was also intense 
around those cells close to the junction with the subchondral bone.  
This group also looked for link protein and found clear, defined 
pericellular staining in the middle zone of the cartilage (Poole et al., 
1980).  Link protein is a small glycoprotein which aids the stabilisation 
of aggrecan aggregates (Kiani et al., 2002).  Poole and colleagues 
(1987), showed that there is a difference in the pericellular matrix 
between zones in adult human articular cartilage.  In the middle and 
deep zones, the pericellular matrix appeared to be surrounded by a 
capsule.  This capsule was absent in the superficial zone (Poole et al., 
1987)  7KH DXWKRUV DGRSWHG WKH WHUP µFKRQGURQ¶ LQ WKLV VWXG\ ZKLFK
refers to the chondrocyte, pericellular matrix and capsule being one 
functional unit (Poole et al., 1987).   This group also studied the 
morphology and structure of chondrons isolated from canine tibial 
cartilage (Poole et al., 1988).  They showed that single chondrons 
appeared to have two different structures.  In some chondrons there 
was a loosely woven tail at one pole of the chondrocyte; in others the 
chondron appeared ovoid in shape.  These latter chondrons would often 
have channels at one pole.  Clusters of chondrocytes were shown to 
have a dense capsular sheath separating individual cells but the whole 
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stack was surrounded by a continuous sheath (Poole et al., 1988) 
(Figure 1.4). 
 
 
 
 
 
 
 
 
 
Figure 1.4: Chondron morphology. Single chondrons either have a loosely woven 
tail (a) or an ovoid structure (b).  Columns of chondrocytes are surrounded by a single 
capsule but individual cells are separated by a dense sheath.  This figure was devised 
based on the data presented in (Poole et al., 1988). 
 
Another study by Poole et al (1991), aimed to identify further features of 
canine chondrons by immobilizing isolated chondrons in thin layers of 
agarose gel and subjecting them to immunohistochemical analysis.  
The authors observed strong staining for collagen type VI in the matrix 
immediately next to the cell (Poole et al., 1991).  They acknowledge 
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that different fixatives had different effects in the sample and admit to 
reaching a compromise of using a fixative that preserved the 
ultrastructure of the chondron but reduced epitope activity (Poole et al., 
1991).  Single keratan sulphate chains were observed in the tail of the 
chondron and in the parts of the capsule between two adjacent 
chondrons (Poole et al., 1991).  Bovine chondrons have also been 
shown to stain positively for collagen types VI and II as well as keratin 
sulphate and chondroitin-6-sulphate (Wang et al., 2008).  Depending on 
the enzyme treatment of the chondrons, keratan sulphate epitopes 
associated with core protein were detected in marginal regions with 
weak staining around the chondrocyte itself; or staining was intense 
throughout the capsule including immediately surrounding the 
chondrocyte.  Expression of epitopes of glycosaminoglycan attachment 
region of the core protein and hyaluronate binding region of the core 
protein was high throughout the chondron (Poole et al., 1991).  Youn et 
al (2006), found that the volume of the chondron increased from the 
superficial zone to the deep zone.  However, when related to the 
volume of the enclosed cell, the volume of the pericellular matrix 
remained constant throughout the zones.  Interestingly, this group also 
found that in the deep zones, the volume of the pericellular matrix 
increased as the cell number per cluster increased.  However the 
opposite was seen in the ratio of pericellular matrix volume: cell volume 
(Youn et al., 2006). 
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Knudson (1993) studied the formation of the pericellular matrix by 
embryonic chick tibial chondrocytes and adult rat chondrocytes.  It was 
found that monolayer chondrocytes stripped of their pericellular matrix 
reformed this matrix within 30 minutes after being incubated with 
hyaluronan and aggrecan, whereas incubating with hyaluronan alone 
for two hours generated no matrix.   This suggests that hyaluronan and 
aggrecan interact together to keep the pericellular matrix attached to 
the cell surface.  Cells were also incubated with hyaluronan 
hexasaccharide (HA6) in this study.  This competes for the hyaluronan 
binding sites on the cell surface (Knudson, 1993).  When HA6 was 
added to the cells in excess, no pericellular matrix was formed.  
Therefore, hyaluronan must be able to bind to the receptors on the cell 
surface to anchor the matrix to the cell but in addition, an aggregating 
proteoglycan is also required to form the pericellular matrix (Knudson, 
1993). 
 
Non-fibrillar collagens such as collagen type VI are also present (Poole 
et al., 1991, Poole et al., 1992, Arican et al., 1996, Buckwalter and 
Mankin, 1998, Buckwalter and Hunziker, 1999, Soder et al., 2002).  
One study showed that collagen type VI was confined to the pericellular 
matrix in healthy canine cartilage but was present beyond the 
pericellular matrix in osteoarthritic cartilage (Arican et al., 1996).  
Chondrocytes can have cytoplasmic extensions which reach into and 
go through the pericellular matrix into the territorial matrix (Buckwalter 
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and Mankin, 1998, Buckwalter and Hunziker, 1999).   The pericellular 
matrix is between 1 and 2µm; this thickness varies around the 
chondrocyte with the thickest covering at the poles of the ovoid-shaped 
cell (Stockwell, 1975).  Interestingly, it has been shown that there is a 
clear distinction between the pericellular matrix and other matrix areas 
in older cartilage, whereas in younger cartilage these regions seem to 
merge together (Stockwell, 1975).   
 
1.4.2 Regions of ECM: Territorial Matrix 
 
The territorial matrix surrounds the pericellular matrix around the 
individual cells and columns of chondrocytes (Buckwalter and Mankin, 
1998, Buckwalter and Hunziker, 1999).  It has been described as 
forming a cocoon around the cells (Mittelstaedt et al., 2011).  The 
collagen fibrils in this area are thin and adhere to the pericellular matrix 
(Buckwalter and Mankin, 1998, Buckwalter and Hunziker, 1999).  This 
network possibly provides mechanical protection for the chondrocytes 
during loading of the tissue (Buckwalter and Mankin, 1998, Buckwalter 
and Hunziker, 1999).  The boundary between the territorial matrix and 
interterritorial matrix is difficult to distinguish because there are many 
collagen fibrils connecting the two areas (Buckwalter and Mankin, 1998, 
Buckwalter and Hunziker, 1999). 
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Hughes and colleagues (2005),  conducted a study on mouse articular 
cartilage and found that the territorial matrix in the middle zone was 
made of sheets of randomly oriented collagen fibrils.  A similar sheet-
like pattern was observed in the deep zone.  Here the collagen fibrils 
appeared to mainly align parallel to each other and perpendicular to the 
articular surface.  In addition to this, there were also collagen fibrils 
weaving in and out of the collagen sheets (Hughes et al., 2005).  This 
zone was also shown to extend into the calcified zone (Hughes et al., 
2005). 
 
1.4.3 Regions of ECM: Interterritorial Matrix 
 
The majority of the volume of articular cartilage is taken up by the 
interterritorial matrix (Buckwalter and Mankin, 1998, Buckwalter and 
Hunziker, 1999, Youn et al., 2006).  This part of the matrix is mainly 
composed of type II collagen and aggrecan (Youn et al., 2006).  The 
collagen fibrils here have the largest diameter and are oriented 
perpendicular to the articular surface (Buckwalter and Mankin, 1998, 
Buckwalter and Hunziker, 1999). 
 
Having discussed the various regions of articular cartilage, the 
components within this tissue will be reviewed in the subsequent 
sections. 
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1.4.4 Components of ECM: Collagens 
 
Collagens are a key component of articular cartilage ECM.  Although 
there are several types present (VI, IX, X, XI, XII and XIV), collagen 
type II is the most abundant (Aigner and Stove, 2003, Goldring and 
Goldring, 2005, Martel-Pelletier et al., 2008).  
 
1.4.4.1 Type II collagen 
 
Collagen type II corresponds to about 80% of the total collagen in 
articular cartilage (Aigner and Stove, 2003).  It is a triple helical collagen 
FRPSRVHG RI WKUHH LGHQWLFDO SRO\SHSWLGH FKDLQV Į>,,@3 (Goldring and 
Goldring, 2005, Martel-Pelletier et al., 2008).  These chains are 
synthesised as pro- Į-chains, which may have large propeptides at the 
C- and N- termini (Martel-Pelletier et al., 2008).  There are short 
telopeptide regions between the propeptides and the helix-forming 
sections (Martel-Pelletier et al., 2008).  The propeptides are essential 
for formation of the triple helix, which occurs within the chondrocyte 
(Martel-Pelletier et al., 2008).  This procollagen is then released from 
the cell and the propeptides are removed by a procollagen-N-protease 
and procollagen-C-protease from the N- and C- termini respectively 
(Martel-Pelletier et al., 2008, Ricard-Blum, 2011).  There are two types 
of type II procollagen that can be formed, IIA and IIB (Martel-Pelletier et 
al., 2008). These two forms result from the alternative splicing of RNA 
45 
 
at exon two (Ryan and Sandell, 1990, Nah et al., 2001).  This exon 
codes for a cysteine-rich globular region of the peptide (Ryan and 
Sandell, 1990, Nah et al., 2001).  Type IIA collagen is normally found in 
newly formed cartilage and contains a 69 amino acid cysteine-rich 
domain (Bruckner and van der Rest, 1994). Expression of procollagen 
types IIA and IIB has been shown in the chicken limb bud; with the 
former predominating at days four and seven.  However, by day nine 
type IIB was the predominant form (Nah et al., 2001).  Although, type 
IIA expression is usually associated with chondrogenic precursor cells, 
it has been detected in OA cartilage (Aigner et al., 1999, Nah et al., 
2001).  In addition to this, one research group has suggested that type 
IIA procollagen could be a marker of dedifferentiated chondrocytes 
(Gouttenoire et al., 2010).  They found that type IIA procollagen 
expression increased with increasing passage of embryonic 
chondrocytes and such expression was upregulated by TGF-ȕ7KH\
also demonstrated that type IIB procollagen was upregulated by BMP-2.  
However, the authors only observed the chondrocytes up to P2 and 
refer to P1 chondrocytes as dedifferentiated.  It would be useful to 
measure expression over a longer time period to ensure a consistent 
pattern of expression is seen with increasing passage.  The same group 
have also shown that expression of type IIB procollagen by embryonic 
murine rib cage chondrocytes decreases from passage one to passage 
six (Gouttenoire et al., 2004). 
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Following processing (removal of the propeptide), collagen molecules 
are assembled into fibrils (Martel-Pelletier et al., 2008).  Molecules are 
joined by aldimine-derived cross-links that go from the telopeptide of 
one molecule to the triple helix of another (Martel-Pelletier et al., 2008).  
These links are modified to pyridinoline cross-links which can be 
markers for mature collagen (Martel-Pelletier et al., 2008).  Cross-links 
stabilize the fibril and over time other, nonaldimine-derived cross-links 
accumulate in the fibrils (Martel-Pelletier et al., 2008).  These links help 
the  collagen fibrils resist proteolytic degradation (Martel-Pelletier et al., 
2008).  The collagen triple helix is resistant to most proteases but can 
be cleaved by collagenases (Martel-Pelletier et al., 2008). 
 
1.4.4.2 Type XI collagen 
 
This is another fibrillar collagen and is also specific to cartilage 
(Goldring and Goldring, 2005, Martel-Pelletier et al., 2008).  In adult 
cartilage it constitutes 3% of the total collagen content (it is about 10% 
in foetal cartilage) (Eyre et al., 2006, Martel-Pelletier et al., 2008).  
7KUHH GLIIHUHQW Į-chains make up the triple helix Į1[XI]Į2[XI]Į3[XI] 
(Martel-Pelletier et al., 2008, Ricard-Blum, 2011, McAlinden et al., 
2014).  This collagen is synthesised in a similar way to collagen type II 
but only the C-propeptide is removed (Martel-Pelletier et al., 2008).  
Type XI collagen molecules form heterotypic molecules with type II 
collagen molecules (Martel-Pelletier et al., 2008).  In fact, a recent 
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paper has shown that in homozygous knock-in mice which exclusively 
express type IIA procollagen, these IIA molecules covalently cross-link 
to type XI molecules forming a heteropolymer of type IIA and type XI 
collagen (McAlinden et al., 2014).  Another study has shown that type 
XI collagen has a high affinity for the heparan sulphate and dermatan 
sulphate (Vaughan-Thomas et al., 2001).  This group also found that 
binding of type XI collagen to chondrocytes was reduced in the 
presence of heparin or heparinase, indicating that this collagen binds to  
the cell surface proteoglycan heparan sulphate (Vaughan-Thomas et al., 
2001). 
 
1.4.4.3 Type IX collagen 
 
Type IX collagen is a fibril-associated collagen with interrupted triple 
helix (FACIT) (Martel-Pelletier et al., 2008).  It is also composed of three 
GLIIHUHQW Į-chains, Į1[IX]Į2[IX]Į3[IX] (Martel-Pelletier et al., 2008, 
Parsons et al., 2011, Ricard-Blum, 2011).  Each of these chains contain 
three triple-helical sequence regions that are separated by non-triple-
helical sections (Olsen, 1997).  Collagen type IX is synthesised in two 
forms; the long form contains a large amino-terminal globular domain 
whereas the short form lacks this region (Olsen, 1997).  The former is 
the major type in cartilage and the latter can be found in tissues 
including the vitreous and early limb buds (Olsen, 1997).  Collagen type 
IX is present at the surface of type II/type XI heterotypic fibrils (Olsen, 
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1997, Martel-Pelletier et al., 2008) and has been shown to have a high 
affinity for binding to fibronectin (Parsons et al., 2011).  Like type XI 
collagen, this molecule represents 10% of the total foetal collagen (Eyre 
et al., 2006, Martel-Pelletier et al., 2008).  However, this is reduced to 
1% in adult cartilage (Eyre et al., 2006, Martel-Pelletier et al., 2008).   
 
1.4.4.4 Type VI collagen 
 
This is a non-fibrillar collagen also present in but not specific to articular 
cartilage (Martel-Pelletier et al., 2008).  It only represents around 1% of 
the total collagen (Eyre et al., 2006, Martel-Pelletier et al., 2008).  It is 
composed of three alpha chains (Į1[VI]Į2[VI]Į3[VI])  and has a central 
triple helix region with large non-helical terminal sections (Pullig et al., 
1999, Martel-Pelletier et al., 2008).  
 
 
1.4.4.5 Type X collagen 
 
Type X collagen is a short chain collagen produced by hypertrophic and 
growth plate chondrocytes (Sutmuller et al., 1997, Shen, 2005) and is 
often used as a marker for chondrocyte hypertrophy (Kwan, 1999, 
Studer et al., 2012).  The growth plate is vital for the longitudinal growth 
of bones (Mackie et al., 2011, Michigami, 2013).  Growth plate 
chondrocytes go through several processes during bone elongation 
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(Mackie et al., 2011, Michigami, 2013).  Firstly, they proliferate forming 
ordered, parallel columns (Michigami, 2013).  Then they produce high 
levels of cartilaginous matrix before exiting the cell cycle and adopting a 
more hypertrophic phenotype (Mackie et al., 2011, Michigami, 2013).  
Once terminally differentiated, these hypertrophic cells undergo 
apoptosis and the cartilage matrix is mineralised (Mackie et al., 2011, 
Michigami, 2013).  
 
As well as expressing collagen type X, hypertrophic chondrocytes also 
have an increased cell volume and express other markers including 
alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2) 
and matrix metalloproteinase-13 (MMP-13) (Studer et al., 2012).  Type 
X collagen is abundant in the pericellular matrix of hypertrophic 
chondrocytes (Chambers et al., 2002). 
 
Collagen type X is composed of three identical Į>;@ FKDLQV which 
contain three distinct regions (Barber and Kwan, 1996, Sutmuller et al., 
1997).  These are a short non-collagenous amino-terminal domain, a 
collagenous domain and a collagenous carboxyl-terminal domain 
(Sutmuller et al., 1997).  The C-terminal domain is much larger than the 
N-terminal region and is not removed following secretion into the ECM; 
this is different to processing of fibrillar collagens (Barber and Kwan, 
1996). 
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1.4.5 Components of ECM: Proteoglycans 
 
Proteoglycans make up 5-10% of the wet weight of articular cartilage 
(Martel-Pelletier et al., 2008).  The most abundant proteoglycan present 
is aggrecan (Umlauf et al., 2010), representing  about 90% of the total 
mass of cartilage proteoglycans (Buckwalter and Mankin, 1998). 
Aggrecan is a large chondroitin sulphate proteoglycan (Umlauf et al., 
2010) which is associated with hyaluronic acid and link protein to form 
large aggregates (Martel-Pelletier et al., 2008).   
 
An aggrecan molecule has several important regions, namely the G1, 
Interglobular, G2, GAG attachment and G3 domains (Figure 1.5).  The 
globular G1 domain is at the N-terminus and it is through this region 
that aggrecan binds non-covalently to hyaluronic acid (Valiyaveettil et 
al., 2005).  The molecular weight of this region is about 37kDa and it is 
formed by an N-terminal immunoglobulin-like repeat and two 
proteoglycan tandem repeats (Aspberg, 2012).  The interaction 
between link protein and the G1 domain is mediated by the 
immunoglobulin-like repeat and the tandem repeats form part of the 
interaction with hyaluronic acid (Kiani et al., 2002).  This domain has 
been shown to be abundant in canine knee articular cartilage and was 
found to be more highly expressed in cartilage compared to other 
tissues in the canine knee joint (Valiyaveettil et al., 2005).  The next 
region, which separates the first and second globular domains (G1 and 
G2 respectively) is about 150 amino acids long and is known as the 
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interglobular domain (Kiani et al., 2002, Valiyaveettil et al., 2005, 
Aspberg, 2012).  This domain is unique to aggrecan and is involved in 
the physiological turnover of the molecule (Kiani et al., 2002). 
 
The second globular domain is also unique to aggrecan and consists of 
two proteoglycan tandem repeats which are similar to those in the G1 
domain (Kiani et al., 2002, Aspberg, 2012).  After this domain is the 
GAG attachment region, which contains a keratan sulphate rich section 
followed by a long chondroitin sulphate region (Valiyaveettil et al., 2005).  
Each aggrecan molecule contains approximately 100 chondroitin 
sulphate chains and up to 60 keratan sulphate chains (Kiani et al., 
2002).  The former are usually about 20kDa, whereas the latter are 
normally smaller, being between 5kDa and 15kDa (Kiani et al., 2002).  
The final region is the third globular domain (G3), which contains four 
structural motifs: two epidermal growth factor-like repeats, a C-type 
lectin domain and a complimentary regulatory protein (Kiani et al., 2002, 
Aspberg, 2012).  It is generated by the alternative splicing of exons 
during post-transcriptional processing (Kiani et al., 2002).  The G3 
region is not always present in mature aggrecan as it is readily lost 
soon after synthesis (Dudhia, 2005); in fact, the number of aggrecan 
molecules containing an intact G3 domain decreases with age (Dudhia, 
2005). 
 
Synthesis of aggrecan begins in the nucleus with the transcription of the 
gene encoding the protein core (Figure 1.5) (Mankin et al., 1994).  The 
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resulting mRNA is then translated in the rough endoplasmic reticulum 
(RER) and the protein is synthesised at the ribosome (Mankin et al., 
1994).  This protein core is then transported to the Golgi apparatus 
where glycosaminoglycan chains are added (Mankin et al., 1994).  
Following this, the glycosylated protein is transported to the plasma 
membrane via secretory vesicles, where it is released into the matrix 
(Mankin et al., 1994).  Link protein is synthesised in a similar way to 
aggrecan whereas the large, non-sulphated glycosaminoglycan 
hyaluronic acid is synthesised at the plasma membrane (Mankin et al., 
1994, Roughley, 2006, Martel-Pelletier et al., 2008). Formation of the 
proteoglycan aggregate occurs in the pericellular matrix (Roughley, 
2006, Martel-Pelletier et al., 2008). 
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Figure 1.5: Structure and synthesis of aggrecan.  (a)  Aggrecan molecules 
possess three globular domains (G1, G2 andG3), an interglobular domain (IGD) and a 
GAG attachment region containing chondroitin sulphate and keratan sulphate. (b)  
Synthesis of aggrecan begins with transcription of genes in the nucleus, followed by 
translation at the Rough Endoplasmic Reticulum (RER).  The glycosaminoglycan 
chains are then added in the Golgi Apparatus and the glycosylated protein is then 
transported to the plasma membrane through secretory vesicles and released into the 
matrix.  Link protein is synthesised in a similar way but hyaluronic acid is produced at 
the plasma membrane. This means that the aggregate of aggrecan, link protein and 
hyaluronic acid can only be assembled in the pericellular matrix.  Diagrams in this 
figure have been adapted from (Mankin et al., 1994, Kiani et al., 2002) 
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Each aggregate consists of a hyaluronic acid filament which can have 
up to 100 aggrecan molecules attached to it (Heinegard et al., 2005, 
Roughley, 2006).  Interestingly, aggrecan is rarely completely intact in 
articular cartilage; it is cleaved at different sites to generate fragments 
of varying lengths (Valiyaveettil et al., 2005, Roughley, 2006).    The link 
protein in these aggregates has several functions; including stabilising 
the aggregate and mediating a conformational change in newly formed 
aggrecan, enabling it to bind to the hyaluronic acid filament (Roughley, 
2006, Martel-Pelletier et al., 2008).   
 
Aggrecan is an integral part of the cartilage matrix and has been 
described as an osmotically active protein (Dudhia, 2005).  The 
presence of the chondroitin sulphate and keratan sulphate chains within 
aggrecan, gives the molecule a high negative charge (Dudhia, 2005, 
Aspberg, 2012).  In fact, there can be up to 9000 negative charges per 
aggrecan (Seror et al., 2011).  This negative charge brings water into 
the tissue creating a high osmotic pressure (Dudhia, 2005, Seror et al., 
2011, Aspberg, 2012).  This occurs because the anionic groups on the 
GAG chains carry mobile counter ions, such as Na+ alongside them 
(Kiani et al., 2002).  As a result, a large difference in ion concentration 
is generated between cartilage and the surrounding tissue and water is 
drawn in (Kiani et al., 2002).  The incoming water causes the aggrecan 
abundant network to expand but the level of expansion is restricted by 
the stiff collagen fibres which results in the generation of a swelling 
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pressure (Kiani et al., 2002, Dudhia, 2005).  This pressure enables 
cartilage to deform reversibly under mechanical load (Dudhia, 2005). 
 
Other proteoglycans present in cartilage include decorin, biglycan, 
fibromodulin and lumican, which are all types of small leucine-rich 
repeat proteoglycans (SLRPs) (Roughley, 2006, Martel-Pelletier et al., 
2008).  SLRPs are part of the leucine-rich repeat superfamily (McEwan 
et al., 2006).  The leucine-rich repeat (LRR) in the SLRP family is 
unique in that it is flanked by clusters of cysteines (Hocking et al., 1998).  
At the N-terminus there are four cysteine residues within a sequence of 
20 amino acids, whereas at the C-terminus there are two cysteine 
residues (Hocking et al., 1998).  SLRPs can be classified into groups 
based upon the arrangement of the cysteine residues at the N-terminus 
(Hocking et al., 1998, McEwan et al., 2006) (see Table 1.1).  The LRR 
region within SLRPs varies in length; it can be between 20 and 29 
amino acids long, with 24 being the most common (Hocking et al., 1998, 
McEwan et al., 2006). The number of repeats also varies (see Figure 
1.6).  Each LRR contains a characteristic motif of 11 amino acids, L-x-x-
L-x-L-x-x-N-x-L, with L being leucine, N being asparagine and x 
representing any other amino acid.  Another distinctive component of 
6/53V LV WKH ³HDU´ UHSHDW (Chen and Birk, 2011).  This region is near 
the C-terminus and it is where the LRR extends laterally from the main 
body of the proteoglycan (McEwan et al., 2006).  For decorin, biglycan, 
fibromodulin and lumican this is located at LRR-11 (McEwan et al., 
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2006)  ,QRVWHRJO\FLQDQGHSLSK\FDQWKLV³HDU´UHSHDWFDQEHIRXQGDW
LRR-7 (McEwan et al., 2006). 
 
Class 
of 
SLRP 
Arrangement of 
cysteine residues 
Proteoglycans 
1 Cx3CxCx6C decorin, biglycan, asporin 
2 Cx3CxCx9C keratocan, osteoadherin, lumican, 
fibromodulin 
3 Cx2CxCx6C opticin, epiphycan, osteoglycin 
 
Table 1.1: Classes of small leucine-rich repeat proteoglycans (SLRPs).  These 
proteins can be classified into groups based on the arrangement of the cysteine 
residues at the N-terminus.  C ± cysteine, x ± any other amino acid. Table created 
based on information in (Hocking et al., 1998, McEwan et al., 2006). 
 
Figure 1.6: The LRRs of the SLRPs biglycan, decorin, fibromodulin and lumican.  
The box labelled N represent the N-terminus where the cluster of four cysteine 
residues reside.  The boxes containing the numbers 20-27 are individual LRR regions 
and the figures relate to the number of amino acids within that particular repeat.  The 
(VWDQGVIRU WKH³HDU´UHSHDWUHJLRQZKLFK OLHVFORVH WRWKH C-terminus.  Figure was 
adapted from (McEwan et al., 2006). 
N 21 2721 24 24 21 24 25 24 24 23 E
N 21 2721 24 24 21 24 26 24 24 23 E
N 21 2620 24 26 21 24 23 24 25 20 E
N 21 2620 24 26 21 22 25 24 25 20 E
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Fibromodulin, lumican, decorin and biglycan have all been shown to be 
expressed at similar levels in canine articular cartilage (Yang et al., 
2012).  Expression of all of these SLRPs, except the latter has been 
shown in bovine articular, nasal and engineered cartilage with lumican 
being upregulated in the engineered cartilage (Kafienah et al., 2008).  
Another group assessed the effect of culture environment on the 
expression of aggrecan, decorin and biglycan by rabbit chondrocytes 
(Demoor-Fossard et al., 1998).  Expression of all of these 
proteoglycans was shown to be higher in alginate compared to 
monolayer cultures.  Decorin expression was significantly reduced in 
monolayer cultures incubated with TGF-ȕ EXW DGGLWLRQ RI 7*)-ȕ WR
alginate cultures had little impact.  Biglycan expression was only slightly 
increased in monolayer and alginate with TGF-ȕ LQFXEDWLRQ $VLPLODU
pattern was also seen for aggrecan expression.  IL-ȕ LQGXFHG D
reduction in expression of decorin in monolayer and alginate. Biglycan 
expression was also reduced in these monolayer cultures but IL-ȕKDG
little impact on expression of this SLRP in alginate cultures.  Aggrecan 
expression was considerably reduced in monolayer in this group but a 
slight increase was seen in IL-ȕ WUHDWHG DOJLQDWH FXOWXUHV  7KLV
suggests that physical environment and growth factors have a 
combined effect on the expression of proteoglycans by cultured 
chondrocytes.  It must be noted however, that these results represent 
mRNA expression and may not represent protein levels within the 
cultures (Demoor-Fossard et al., 1998). 
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Decorin is the most abundant of the SLRPs in articular cartilage 
(Monfort et al., 2006).  It contains a core protein associated with a 
single chain of dermatan or chondroitin sulphate (Monfort et al., 2006, 
Lorda-Diez et al., 2014).  This proteoglycan is present throughout the 
pericellular and intercellular matrices (Demoor-Fossard et al., 1998, 
Goldring and Goldring, 2005, Roughley, 2006, Martel-Pelletier et al., 
2008)   'HFRULQ REWDLQHG LWV QDPH GXH WR WKH IDFW WKDW LW µGHFRUDWHV¶
collagen fibrils (Chen and Birk, 2011).  It has high and low affinity 
binding sites for collagen at LRRs 4-6 and at the C-terminus 
respectively (Chen and Birk, 2011).  This SLRP is involved in the 
regulation of collagen fibrillogenesis and also has a role in maintaining 
tissue integrity through binding with fibronectin and thrombospondin 
(McEwan et al., 2006, Monfort et al., 2006, Chen and Birk, 2011).  It 
binds to collagen type II and also connects collagen type VI filaments, 
forming fibrils (Buchanan and Gay, 1996, Chen and Birk, 2011).  
Decorin can also bind to a variety of growth factors including TGF-ȕ
IGF-1 and FGF-2 as well as interacting with tyrosine kinase receptors 
(Chen and Birk, 2011).   
 
Fibromodulin and lumican are present in the interterritorial matrix and 
biglycan is present in the pericellular matrix (Goldring and Goldring, 
2005, Roughley, 2006, Martel-Pelletier et al., 2008).  Whereas decorin 
and biglycan can be referred to as dermatan sulphate proteoglycans, 
fibromodulin and lumican are keratan sulphate proteoglycans (Knudson 
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and Knudson, 2001, Roughley, 2006).  Both fibromodulin and lumican 
interact with collagen fibrils and do so at the same region of the 
collagen molecule, however this site is separate from the site where 
decorin binds (Roughley, 2006).  Biglycan and decorin have 55% amino 
acid identity, with many of the other residues being chemically similar 
(Hocking et al., 1998).  Biglycan primarily interacts with collagen type VI 
but can also bind to fibronectin (Buchanan and Gay, 1996, Demoor-
Fossard et al., 1998). 
 
Now the ECM of cartilage has been reviewed, another key element of 
articular cartilage to be examined is the chondrocyte. 
 
1.5 The Chondrocyte 
 
The cells present in articular cartilage are chondrocytes and only count 
for 2% of the tissue (Stockwell, 1978, Goodrich and Nixon, 2006, 
Martel-Pelletier et al., 2008, Hollander et al., 2010, Umlauf et al., 2010).  
Cell density has been reported to vary between species, with rabbit 
articular cartilage having a cell density of 12.8x104 cells/mm3 and 
bovine articular cartilage having 4.7x104 cells/mm3 (Stockwell, 1978).  A 
study looking at human articular cartilage found that cell density 
decreases with age (Stockwell, 1967).  They reported counts of 76 and 
61 cells per 0.22mm2 from two day and six week old humans 
respectively (Stockwell, 1967).  However, counts from humans aged 
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between 17 and 89 years old ranged from 7 to 16 cells per 0.22mm2.  
This study also looked at the different regions of articular cartilage and 
found a greater number of cells in the superficial zone compared to 
deeper zones (Stockwell, 1967).  Similar findings were observed by 
another research group comparing cartilage from infants (26 weeks 
gestation ± six days postnatal), children (two ± six years old) and adults 
(31 and 35 years old) (Gilmore and Palfrey, 1988).  They found that cell 
density was higher in infants compared to children and adults and 
although counts were similar between children and adults, they were 
marginally higher in children samples (Gilmore and Palfrey, 1988).  This 
group also demonstrated that cell density decreases in the deeper 
zones of articular cartilage (Gilmore and Palfrey, 1988). 
 
In a more recent study, DNA content in bovine cartilage was shown to 
decrease with age, indicating a decrease in cell number (Erickson et al., 
2011).  Researchers compared cartilage from foetal (second or third 
trimester), juvenile (three to six months) and skeletally mature (two to 
three years) cows.   The authors also showed that collagen content 
increased significantly with aging, however the exact type of collagen 
measured is not specified (Erickson et al., 2011).  Histological images 
suggest that proteoglycans and GAGs increase with age but the images 
presented are not very clear (Erickson et al., 2011).   
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The next few sections will detail the development of articular cartilage, 
how chondrocytes are identified in culture and the methods used to 
attempt to maintain chondrocyte phenotype in culture. 
 
1.5.1 Origin of the Chondrocyte (MSC Differentiation)/ 
Chondrogenesis 
 
Chondrogenesis is a stage of embryogenesis which results in the 
formation of cartilage (Cancedda et al., 2000, Goldring et al., 2006, 
Pelttari et al., 2008, Mobasheri et al., 2009, Onyekwelu et al., 2009, 
Boeuf and Richter, 2010, Penny et al., 2012).  Most of this cartilage 
undergoes endochondral ossification to form endochondral bone 
(Cancedda et al., 2000, Goldring et al., 2006, Pelttari et al., 2008, 
Mobasheri et al., 2009, Onyekwelu et al., 2009, Boeuf and Richter, 
2010, Penny et al., 2012). 
 
Different types of cartilage arise from mesenchymal stem cells from a 
range of sources.  Craniofacial cartilage arises from neural crest cells, 
intervertebral disc, rib and sternum cartilage (referred to as the axial 
skeleton) originate from somites in the paraxial mesoderm and articular 
cartilage is derived from the lateral plate mesoderm (Goldring, 2005, 
Goldring and Goldring, 2005). 
 
Chondrogenesis is summarised in Figure 1.7 and begins with the 
condensation and proliferation of MSCs (Cancedda et al., 2000, 
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Goldring and Goldring, 2005, Goldring et al., 2006, Pelttari et al., 2008, 
Mobasheri et al., 2009, Boeuf and Richter, 2010, Penny et al., 2012).  
This condensation is initiated by TGF-ȕ DQG LQ WKH HDUO\ VWDJHV RI
chondrogenesis, this growth factor stimulates the production of N-
cadherin and fibronectin, thereby promoting cellular interactions 
(Demoor et al., 2014).  Another study assessing TGF-ȕ H[SUHVVLRQ
during cartilage development found that TGF-ȕ7*)-ȕDQG7*)-ȕ
are expressed throughout development (up to eight months) (Hayes et 
al., 2001).  This study used Monodelphis domestica (grey, short-tailed 
opossum) as a model animal because offspring are born at early 
developmental stages (Hayes et al., 2001).  At two months of 
development, the structure of articular cartilage was clearly visible and 
staining of all three TGF-ȕVZDVSUHVHQWWKURXJKRXW%\HLJKWPRQWKV
this staining was only present in the superficial layer (Hayes et al., 
2001).   BMP-2 is also involved in the condensation of MSCs (Demoor 
et al., 2014).  Another important protein involved in chondrogenesis is 
the transcription factor Sox9 (Bernstein et al., 2009b, Demoor et al., 
2014).  Cells expressing Sox9 form aggregates and this factor also 
induces the expression of cartilage specific markers as well as 
stimulating the expression of Sox5 and Sox6 (Bernstein et al., 2009b, 
Demoor et al., 2014).  Following condensation, chondroprogenitors 
proliferate, differentiate and mature; some also undergo terminal 
differentiation into hypertrophic chondrocytes (Goldring et al., 2006, 
Vinatier et al., 2009, Penny et al., 2012).  A recent study determined a 
range a markers identifying cartilage-committed mesenchymal cells 
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(referred to as prechondrocytes by the authors) (Wu et al., 2013).  
These cells were identifiable by negative expression of CD31, CD34, 
CD45, CD235a and CD324 (collectively referred to as LIN), low or 
negative expression of CD146 and CD166, low expression of CD44 and 
positive expression of CD73 and BMPPR1B (Wu et al., 2013).  High 
levels of mRNA expression for Sox9, aggrecan and collagen type II was 
detected in these prechondrocytes (Wu et al., 2013). Differentiated 
chondrocytes secrete an extracellular matrix characteristic of hyaline 
cartilage (Pelttari et al., 2008, Penny et al., 2012).  Biomechanics also 
has a key role in driving chondrogenesis and this is reviewed in 
(Responte et al., 2012). 
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Figure 1.7: Differentiation of MSCs down the chondrogenic lineage.  Black boxes 
indicate the stages of differentiation.  The red boxes detail growth factors expressed 
by the cells they are underneath.  Abbreviations: BMP: bone morphogenetic protein, 
FGF: fibroblast growth factor, Hh: hedgehog, IGF: insulin-like growth factor, PTHrP: 
parathyroid hormone-related protein, VEGF: vascular endothelial growth factor. 
Diagram is adapted from  (Vinatier et al., 2009). 
 
1.5.2 Native Chondrocyte Phenotype 
 
When embedded in native articular cartilage, chondrocytes have two 
distinct morphologies.  Those found in the surface zone have a disc like 
morphology, whereas those present in the remaining three zones have 
a rounded morphology (Buckwalter and Mankin, 1998, Buckwalter and 
Hunziker, 1999, LeBaron and Athanasiou, 2000, Temenoff and Mikos, 
2000, Goldring and Goldring, 2005, Martel-Pelletier et al., 2008).  One 
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group attempted to identify the different fractions of chondrocytes 
present within the entire depth of cartilage tissue (Min et al., 2002).  The 
authors identified four distinct fractions of cells; fraction one had large 
cells with small nuclei, fraction two contained small cells with small 
nuclei, fraction three possessed large cells with large nuclei and the 
fourth fraction had small cells with large nuclei (Min et al., 2002).  
Collagen type II was found to be expressed by cells in all fractions, 
except fraction four.  However, western blot analysis suggested weaker 
expression in fractions one and three.  Fraction two cells appeared to 
have the highest expression of proteoglycans (Min et al., 2002).  In a 
recent paper describing the phenotype of native articular chondrocytes, 
expression of nine specific cartilage markers and seven non-specific 
cartilage markers was identified (see Table 1.2) (Demoor et al., 2014).  
Expression of the specific markers was considerably higher than the 
non-specific ones, with COL2B and COL2A1 being the most abundant 
(Demoor et al., 2014). 
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Specific Cartilage Markers Non-specific cartilage markers 
COL2A Cbfa1 
COL2A1 HIF-Į 
COL2B OSTCN 
ACAN COL10A1 
SOX9 HTRA1 
COL11A1 COL3A1 
COL9A1 COL1A1 
Integrin-ȕ  
HIF-Į 
 
Table 1.2: Markers of native chondrocytes. Native articular chondrocytes were 
found to express both specific and non-specific cartilage genes. COL2A, type IIA 
collagen; COL2A1, type II collagen; COL2B, type IIB collagen; ACAN, aggrecan; 
SOX9, SRY-type HMG box 9; COL11A1 type XI collagen; COL9A1, type IX collagen; 
HIF-Į and HIF-Į, hypoxia inducible factor 1 alpha and 2 alpha; Cbfa1, core binding 
factor 1, OSTCN, osteocalcin; COL10A1, collagen type X; HTRA1, high temperature 
requirement 1; COL3A1, collagen type III; COL1A1, collagen type I.  Table compiled 
using data presented in (Demoor et al., 2014). 
 
Chondrocytes are an important cell source for cellular treatment of 
cartilage damage and as such their phenotype in vitro has been 
extensively studied.  The following sections will review the markers 
used to identify chondrocytes in vitro and how the chondrocytic 
phenotype is lost during monolayer expansion. 
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1.5.3. Chondrocyte Phenotype in vitro and Dedifferentiation 
 
There is considerable interest in the phenotype of chondrocytes in vitro 
due to their use in cellular treatments for cartilage damage.  Articular 
cartilage is very poor at regenerating itself and as such cell and tissue 
engineering strategies are being extensively explored to repair 
damaged cartilage (see section 1.7).  Autologous Chondrocyte 
Implantation (ACI) is a technique used to repair articular cartilage 
defects larger than 4cm2 (Schulze-Tanzil, 2009, Oldershaw, 2012).  ACI 
is described in further detail in section 1.7.2.  All forms of the ACI 
method involve isolation and expansion of chondrocytes in monolayer 
culture before being placed into the defect (Brittberg, 2008, Brittberg, 
2010, Zeifang et al., 2010, Oldershaw, 2012).   A major problem with 
the large cell requirements for these techniques is that the cells begin to 
lose their phenotype (dedifferentiate) during in vitro expansion.   
 
Dedifferentiation has been described as the reversion of differentiated 
cells into more primitive progenitor cells (Ebeling and Fischer, 1922, 
Chen et al., 2005, Eguizabal et al., 2013).   However in the field of 
chondrocyte biology, dedifferentiation usually refers to loss of the 
chondrocytic phenotype and adoption of a more fibroblastic phenotype.   
Loss of the chondrocyte phenotype whilst undergoing in vitro expansion 
has been reported in many species including, humans (Archer et al., 
1990, Schnabel et al., 2002, Goessler et al., 2006, Yang et al., 2006b, 
Tew et al., 2008), goats (Darling and Athanasiou, 2005), cows (Brodkin 
68 
 
et al., 2004, Shao et al., 2013), pigs (Watt, 1988) and rabbits (Malemud 
and Papay, 1984, Baici et al., 1988).   
 
In many cases, the chondrocyte phenotype is assessed by the 
production of specific ECM components, namely collagen type II and 
aggrecan.  Collagen type I is also commonly used as a marker for 
dedifferentiation, although it has been shown that in vivo articular 
chondrocytes express this matrix protein (Kolettas et al., 1995).  In fact, 
some researchers have found the ratio of collagen type II to collagen 
type I expression accurately represents the phenotype of chondrocytes 
in culture (Hamada et al., 2013).  Although it is common to assess 
expression of collagen types I and II and aggrecan when looking at 
chondrocyte phenotype in monolayer, a wide variety of proteins have 
been studied (Tables 1.4 and 1.5). 
 
Some studies have tried to identify specific markers for chondrocytes 
and dedifferentiated chondrocytes.  Rai and colleagues (2009), looked 
at the expression of aggrecan, Sox9, cartilage acidic protein 1 
(CRTAC1), cartilage oligomeric matrix protein (COMP) and collagen 
types I and II in canine chondrocytes grown in monolayer and alginate.  
They found that expression of all markers decreased from passage zero 
to passage five, except for collagen type I where the opposite was seen 
(Rai et al., 2009)  $OWKRXJK H[SUHVVLRQ RI WKH ODWWHU ZDVQ¶W REVHUYHG
until passage three (Rai et al., 2009). Aggrecan, Sox9, CRTAC1, 
COMP expression increased when the cells were cultured in alginate 
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(Rai et al., 2009).  This group also aimed to generate a cell line which 
maintained the chondrogenic phenotype for longer; however limited 
data is presented for the cells transfected with human reverse 
transcriptase telomerase (hTERT) and redifferentiation appears to more 
successful in the unaltered chondrocytes (Rai et al., 2009).  Having said 
this, the transfected cells continued to grow up to passage 20 whereas 
senescence was observed at passage seven with the non-transfected 
cells (Rai et al., 2009). 
 
A more recent study compared the secretomes of articular 
chondrocytes and MSCs expanded in monolayer (Polacek et al., 2011).  
The categories of proteins in the secretomes of both cell types were 
present at similar levels (Table 1.3), with 65 specific proteins being 
identified in both secretomes.  These proteins included, collagen alpha 
2 (I), biglycan, decorin, COMP and IGF.  A total of 26 proteins were 
exclusively detected in the chondrocyte secretome including clusterin 
and proteoglycan-4.  The MSC secretome contained 14 proteins which 
were not detected in the cartilage secretome.  These included the 
proteins collagen alpha-1 (XI chain) and BMP-1 (Polacek et al., 2011).  
These results give a good indication of what proteins articular 
chondrocytes are producing whilst in monolayer culture; however it 
must be noted that the authors used cryopreserved chondrocytes, so a 
different secretome may be observed in freshly cultured chondrocytes. 
 
 
70 
 
Category Portion of articular 
chondrocyte 
secretome (%) 
Portion of MSC 
secretome (%) 
ECM  components 45 43 
Enzyme inhibitors and 
anabolic agents 
7 12 
Growth factors 15 9 
Inflammatory regulators 14 12 
Intracellular components 5 9 
Metabolic enzymes 4 6 
Proteases and catabolic 
agents 
10 9 
Table 1.3: The secretomes of chondrocytes and MSCs in monolayer culture.  
Data in this table was taken from (Polacek et al., 2011). 
 
A few papers have assessed the change in chondrocyte markers 
between freshly isolated chondrocytes to cells that have undergone 
multiple passages (Diaz-Romero et al., 2005, Cheng et al., 2011, 
Hamada et al., 2013). Tables 1.4 and 1.5 summarise markers that have 
been found to increase (1.4) and decrease (1.5) during monolayer 
culture of chondrocytes.  For the functions of these proteins, refer to 
Table 1.6. 
 
Cheng and colleagues (2011) found nine genes were expressed at 
significantly higher levels in bovine cartilage compared to passage six 
bovine chondrocytes, whereas there were 13 markers found to be 
significantly upregulated in the passaged cells (Table 1.4)  The authors 
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do acknowledge that mRNA expression was measured and that this 
may not result in the production of functional protein for all these 
markers (Cheng et al., 2011).   
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Increased expression with increasing culture length 
Marker References 
BMP-4 (Cheng et al., 2011) 
Cathepsin B (Baici et al., 1988) 
Cadherin II (Cheng et al., 2011) 
CD10 (Diaz-Romero et al., 2005) 
CD44 (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD49c (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD49e (Diaz-Romero et al., 2005) 
CD49f (Diaz-Romero et al., 2005) 
CD51/61 (Diaz-Romero et al., 2005) 
CD81 (Diaz-Romero et al., 2005) 
CD90 (Cheng et al., 2011, Hamada et al., 2013) 
CD99 (Diaz-Romero et al., 2005) 
CD105 (Diaz-Romero et al., 2005) 
CD151 (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD166 (Diaz-Romero et al., 2005) 
Dickkopf Homolog 3 (Cheng et al., 2011) 
Fibromodulin (Cheng et al., 2011) 
Fibronectin (Brodkin et al., 2004) 
HIF-Į (Cheng et al., 2011) 
IGF binding protein (Cheng et al., 2011) 
Secreted Phosphoprotein 1 (Cheng et al., 2011) 
S-100 (Cheng et al., 2011, Lehmann et al., 2013) 
Tenascin C (Cheng et al., 2011) 
TGF-ȕ (Cheng et al., 2011) 
Twist Basic Helix-Loop-
Helix Transcription Factor 1 
 
Type I collagen (Archer et al., 1990, Brodkin et al., 2004, 
Darling and Athanasiou, 2005, Gosset et al., 
2008, Tew et al., 2008, Rai et al., 2009, 
Munirah et al., 2010, Cheng et al., 2011, 
Nadzir et al., 2011, Hoshiba et al., 2012, 
Lehmann et al., 2013) 
Type III collagen (Schnabel et al., 2002, Cheng et al., 2011) 
Versican (Cheng et al., 2011, Ma et al., 2013) 
Vitronectin (Cheng et al., 2011, Hoshiba et al., 2012) 
 
Table 1.4: Markers found to be upregulated during monolayer expansion of 
chondrocytes. 
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Decreased expression with increasing culture length 
Marker References 
Aggrecan (Gosset et al., 2008, Rai et al., 2009, Cheng 
et al., 2011, Hoshiba et al., 2012) 
Cartilage Oligomeric Matrix 
Protein 
(Rai et al., 2009) 
CD14 (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD49a (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD54 (Diaz-Romero et al., 2005, Hamada et al., 
2013) 
CD106 (Diaz-Romero et al., 2005) 
Clusterin (Cheng et al., 2011) 
Early Growth Response 1 (Cheng et al., 2011) 
Link Protein (Cheng et al., 2011) 
Melanoma Inhibitory Activity (Cheng et al., 2011) 
Sox9 (Tew et al., 2008, Rai et al., 2009, Munirah et 
al., 2010, Cheng et al., 2011, Ma et al., 
2013) 
Superficial Zone Protein (Darling and Athanasiou, 2005, Cheng et al., 
2011) 
Type II collagen (Archer et al., 1990, Schnabel et al., 2002, 
Brodkin et al., 2004, Darling and Athanasiou, 
2005, Yang et al., 2006b, Eleswarapu et al., 
2007, Gosset et al., 2008, Tew et al., 2008, 
Rai et al., 2009, Munirah et al., 2010, Cheng 
et al., 2011, Hoshiba et al., 2012, Lehmann 
et al., 2013, Ma et al., 2013) 
Type IX collagen (Munirah et al., 2010, Ma et al., 2013) 
Type X collagen (Munirah et al., 2010) 
Type XI collagen (Munirah et al., 2010, Cheng et al., 2011) 
 
Table 1.5 Markers found to be downregulated during monolayer expansion of 
chondrocytes. 
 74 
 
74
 
Protein Function* 
Aggrecan Major proteoglycan present in cartilage with a key role in compression resistance. 
Cartilage Oligomeric Matrix Protein A noncollagenous ECM protein which can facilitate the interaction between chondrocytes and their 
matrix as well as contributing to the structural integrity of cartilage. 
Cathepsin B Protease involved in the intracellular degradation of proteins. 
Cadherin II An adhesion protein, also known as N-cadherin, with multiple functions.  It has a role in 
synaptogenesis in the brain and other neural tissues and also stimulates fibroblast growth factor 
receptor 1.a   
CD10 Involved in the cleavage of the glycine-phenylalanine bond through the destruction of opioid peptides. 
CD14 Involved in the innate response to LPS and upregulation of other cell surface molecules. 
CD44 Hyaluronic acid receptor which has an involvement in cell migration and tumour growth progression. 
CD49a Į-subunit of an integrin. The LQWHJULQĮȕLVDUHFHSWRUIRUFROODJHQDQGODPLQLQ 
CD49c Į-VXEXQLWRIDQLQWHJULQ7KHLQWHJULQĮȕLVDUHFHSWRUIRUILEURQHFWLQFROODJHQHSLOLJULQ
thrombospondin, laminin and chondroitin sulphate proteoglycan 4. 
CD49e 7KHĮVXEXQLWRIDQLQWHJULQ7KHLQWHJULQĮȕLVDUHFHSWRUIRUILEULQRJHQDQGILEURQHFWLQ 
CD49f 7KHĮVXEXQLWRIDQLQWHJULQ:KHQFRPELQHGZLWKȕLWLVDUHFHSWRUIRUODPLQLQLQSODWHOHWVEXWZKHQ
FRPELQHGZLWKȕLWLVDUHFHSWRUIRUODPLQLQLQHSLWKHOLDOFHOOV 
CD51/61 ,QWHJULQĮȕZKLFKLVDUHFHSWRUIRUYLWURQHFWLQ 
CD54 Has a role in leukocyte trans-endothelial migration by binding to leukocyte adhesion protein. 
CD81 A member of the transmembrane 4 superfamily that forms complexes with integrins and may be 
involved in signal transduction. 
CD90 May be involved in cellular interactions during synaptogenesis and other processes in the brain. 
CD99 A cell surface glycoprotein with roles in transmembrane protein transport, T-cell adhesion and 
leukocyte migration. 
CD105 The major glycoprotein present in vascular endothelium.  It may have an important role in binding 
endothelial cells to integrins. 
CD106 Assists the adherence of leukocytes to endothelial cells and is crucial for cell-cell recognition. 
CD151 Has a major role in the assembly of the glomerular and tubular basement membranes of the kidney. 
CD166 A cell adhesion molecule which binds to CD6 and has a role in neurite extension. 
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Protein Function* 
Clusterin An extracellular chaperone that prevents the aggregation of non-native proteins.  It is also involved in 
protecting cells from cytolysis by complement and apoptosis. 
Dickkopf Homolog 3 Locally inhibits Wnt regulated processes so is important in vertebrate development.  In adults, it has a 
role in bone formation and disease. 
Early Growth Response 1 Regulates the transcription of genes whose products are needed for mitogenesis and differentiation. 
Fibromodulin May have a role in the assembly of the ECM.  Has an impact on the rate of fibril formation. 
Fibronectin A glycoprotein that binds to numerous compounds including collagen and actin and cell surfaces.  It 
has a role in cell adhesion, cell motility and maintenance of cell shape. 
HIF-Į ĮVXEXQLWRI+,)-1.  HIF-1 is an essential transcription factor for the regulation of cellular and systemic 
responses to hypoxia. 
IGF Binding Protein Extends the half-life of IGFs and can stimulate or inhibit the growth of promoting effects of IGFs on 
cells in culture. 
Link Protein Stabilises the binding of proteoglycan monomers to hyaluronic acid in the ECM of cartilage. 
Melanoma Inhibitory Activity Inhibits the growth of melanoma cells in vitro and some other neuroectodermal tumours. 
S-100 Has a role in regulating cell cycle progression, differentiation and other cell processes. 
Secreted Phosphoprotein 1 A key component of mineralised matrix which binds tightly to hydroxyapatite. 
Sox9 Transcription factor involved in skeletal development. 
Superficial Zone Protein Is involved in the boundary lubrication within articulating joints and also prevents the deposition of 
protein onto articular cartilage. 
Tenascin C Protein present in the ECM and is thought to be involved in guiding migrating neurons during 
GHYHORSPHQW,WLVDOVRDOLJDQGIRUVHYHUDOLQWHJULQVLQFOXGLQJĮȕDQGĮȕ 
TGF-ȕ Has roles in embryogenesis and cell differentiation. 
Twist Basic Helix-Loop-Helix 
Transcription Factor 
Regulates the transcription of a variety of genes.  It inhibits myogenesis and regulates cranial suture 
patterning and fusion. 
Type I collagen Present in many connective tissues and is particularly abundant in bone, tendon and skin.  Major role 
is to provided tensile strength.b 
Type II collagen Found in cartilage and the vitreous humour of the eye.  Has key roles in embryonic skeletal 
development and compression resistance in cartilage. 
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Protein Function* 
Type III collagen Is present in most connective tissues and has roles in regulating cortical development and inhibiting 
neuronal migration. 
Type IX collagen Provides structural support in hyaline cartilage and the vitreous of the eye. 
Type X collagen Specifically produced by hypertrophic chondrocytes. Thought to be involved in facilitating calcification. 
c
 
Type XI collagen May be an important component in fibrillogenesis by controlling the lateral growth of type II collagen 
fibrils. 
Versican A proteoglycan present in the ECM which has roles in many processes including cell adhesion and 
proliferation and tissue morphogenesis and maintenance. 
Vitronectin It interacts with GAGs and proteoglycans and encourages cell adhesion and spreading. 
 
Table 1.6: Proteins observed when studying the phenotype of chondrocytes in monolayer culture.  This table details the functions of the proteins listed 
in tables 1.4 and 1.5.  *Details given in the function column were obtained from Genecards - http://www.genecards.org/.  Some functions were not available 
on Genecards and were obtained from other sources; a: (Gelse et al., 2003), b:(van Roy, 2014), c (Shen, 2005). 
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Another paper compared human chondrocytes at passage zero and 
passage four (Hamada et al., 2013).  They found that expression of 
CD44, CD49c and CD151 increased across the passages, whereas 
expression of CD14, CD49a and CD54 decreased (Hamada et al., 
2013).  Expression of CD26 fluctuated throughout culture but was 
higher at passage four compared to passage zero (Hamada et al., 
2013).  The authors then sorted cells for high CD54 expression and low 
CD44 expression and examined the ability of these cells to express 
collagen types I and II and aggrecan (Hamada et al., 2013).  As 
expected, the expression of collagen type II and aggrecan was higher in 
the sorted cells compared to unsorted cells and expression of collagen 
type I was lower (Hamada et al., 2013).  However, none of these results 
were statistically significantly different, this may be due to the small 
sample size tested and the authors acknowledge that there were 
difficulties in obtaining samples (Hamada et al., 2013). 
 
Even though there are similarities between the markers found in all of 
these papers, it must be recognised that there are still differences 
between isolation and culture techniques between groups and such 
differences may impact on the expression of chondrocyte markers 
(Oseni et al., 2013).  Oseni and colleagues (2013) have begun to 
address this issue by isolating ovine nasal cartilage chondrocytes using 
different pre-digest methods and varying concentrations and 
incubations of collagenase type II (Oseni et al., 2013).  Pre-digestion 
appeared to provide no benefit to cell yield and had a negative effect on 
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cell viability and was therefore deemed unnecessary (Oseni et al., 
2013).  The optimum concentration and incubation of collagenase type 
II was 0.2% and ten hours respectively, which resulted in a cell yield of 
1-1.5x106 cells/gram of tissue (Oseni et al., 2013). 
 
Diaz-Romero et al (2005) also took this into consideration when 
comparing expression of markers in human chondrocytes after 24 hours 
and two weeks of culture.  Firstly they assessed the effect of 
collagenase and pronase on marker expression 24 hours after isolation 
(24 hours plus time for enzyme treatment (collagenase incubation: 
overnight; pronase incubation: one hour)).  CD63 and CD82 expression 
was not affected by either enzyme and only CD105 expression altered 
in response to collagenase (Diaz-Romero et al., 2005).  The expression 
of nine markers (CD14, CD49e, CD49f, CD44, CD54, CD81, CD105, 
CD106 and CD151) was affected by pronase (Diaz-Romero et al., 
2005).  Out of the 31 markers looked at 16 markers were found to be 
differentially expressed in chondrocytes cultured for 24 hours and two 
weeks (Diaz-Romero et al., 2005).  The authors do acknowledge that 
this expression pattern may change as chondrocytes are cultured for 
longer (Diaz-Romero et al., 2005).  They also mention the difficulty in 
obtaining samples, like Hamada and colleagues.  Their approach to this 
problem was to cryopreserve chondrocytes but the concern is that 
cryopreservation can further affect the phenotype of the cells.  However 
the authors showed, in this case, the expression profiles of 
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cryopreserved and freshly isolated chondrocytes were very similar 
(Diaz-Romero et al., 2005). 
 
Most studies involve populations of chondrocytes isolated from all 
cartilage zones.  Grogan and colleagues (2013) questioned whether 
there are markers specific to chondrocytes from each zone.  They found 
higher expression of ten genes in the superficial zone compared to the 
deep zone in both human and bovine cartilage (Grogan et al., 2013).  
Such genes included chitinase 3-like 1 (CH13L1), endothelial growth 
factor±containing fibulin-like extracellular matrix protein 1 (EFEMP1), 
THBS4, proteoglycan 4 (PRG4) and  tenascin C (TNC) (Grogan et al., 
2013).  Only four genes were found to be more highly expressed in the 
superficial zone compared to the middle zone, whereas for the genes 
C-type lectin domain family 3, member A (CLEC3A), vav-3 guanine 
nucleotide exchange factor (VAV3) and leukocyte cell±derived 
chemotaxin 1 (LECT1), the opposite was the case (Grogan et al., 2013).  
The deep zone was found to have much higher levels of integrin-
binding sialoprotein (IBSP) and secreted phosphoprotein 1 (SPP1) than 
the superficial zone (Grogan et al., 2013).  Variation in chondrocyte 
monolayer expansion techniques including seeding densities and 
passage numbers are discussed in further detail in Chapter Three, 
section 3.1.  
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It is clear that some research groups are going beyond looking at the 
production of key matrix markers to understand the phenotype of 
chondrocytes both in vivo and in vitro.  This thesis will examine the 
expression of four proteins (in addition to looking at cell morphology and 
GAG production).  These are the matrix proteins collagen types I and II, 
the transmembrane protein CD44 and the transcription factor Sox9. 
 
Collagen type I is a fibrillar collagen like collagen type II (Jensen and 
Host, 1997, Gelse et al., 2003), with its triple helix being a heterotrimer 
RIWZRLGHQWLFDOĮ>,@FKDLQVDQGRQHĮ>,@FKDLQ(Gelse et al., 2003).  It 
is the most abundant collagen and is present in many tissues including 
bone, tendon, ligament, skin and cornea (Jensen and Host, 1997, Gelse 
et al., 2003).  In fact, it represents 90% of the organic mass of bone 
(Gelse et al., 2003).  It is not found in hyaline articular cartilage (Gelse 
et al., 2003) and is frequently found to be upregulated in 
dedifferentiating chondrocytes (Table 1.4).  Collagen type II is specific 
to cartilage and is usually downregulated in dedifferentiating 
chondrocytes (Table 1.5).  The structure and function of collagen type II 
is covered in section 1.4.4.1. 
 
Sox9 was chosen as it is a non-collagenous protein which has been 
used in multiple studies to assess the chondrocyte phenotype, with it 
often being found to be downregulated in monolayer-expanded 
chondrocytes (Table 1.5).  The sox family of proteins are transcription 
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factors which are part of high mobility group (HMG) superfamily; they 
are characterised by a HMG-box DNA binding domain (de 
Crombrugghe et al., 2001, Kiefer, 2007, Wegner, 2010).  Sox9 is 
important for skeletal development as mutations in this protein can lead 
to campomelic dysplasia, a skeletal malformation syndrome (McDowall 
et al., 1999, de Crombrugghe et al., 2001).  This transcription factor is 
expressed during chondrogenesis (Wright et al., 1995) and has a 
similar pattern of expression to collagen type II during foetal 
development (Ng et al., 1997).  It is frequently used as a marker for 
chondrogenic differentiation of mesenchymal stem cells (MSCs) (Reed 
and Johnson, 2008, Vieira et al., 2009, Lettry et al., 2010).  Although 
Sox9 is a major regulator of chondrogenesis there are two other Sox 
proteins involved; Sox5 and Sox6 (Ikeda et al., 2004, Wegner, 2010).  
Together these proteins are known as the SoxTrio (Ikeda et al., 2004, 
Wegner, 2010). This trio has been shown to induce the chondrocyte 
phenotype in a range of cells including pluripotent embryonic stem cells, 
multipotent MSCs and terminally differentiated dermal fibroblasts (Ikeda 
et al., 2004). 
 
Membrane proteins are not frequently studied when assessing the 
phenotype of cultured chondrocytes.  CD44 has appeared in the 
literature, with regards to chondrocyte dedifferentiation, slightly more 
frequently than other membrane proteins (Diaz-Romero et al., 2005, 
Albrecht et al., 2009, Hamada et al., 2013). It also has a key role in 
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pericellular matrix organisation and assembly (Knudson and Loeser, 
2002, Knudson, 2003, Goldring, 2005).  For these reasons, it was 
selected as the fourth protein of interest.  The µ&'¶ LQ WKH QDPHV RI
these membrane proteins stands for cluster of differentiation (Zola et al., 
2005).  This nomenclature was created during Human Leukocyte 
Differentiation Antigen workshops (Zola et al., 2005, Zola et al., 2007).  
During the early 1980s, immunologists were developing a large number 
of monoclonal antibodies targeted against various leukocyte cell surface 
molecules, all with different names (Zola et al., 2005, Zola et al., 2007).  
The workshops aimed to standardise the nomenclature by coding 
antibodies and sending them to laboratories for testing against different 
cell types (Zola et al., 2005).  Clusters of antibodies with similar binding 
SDWWHUQV ZHUH LGHQWLILHG JLYLQJ ULVH WR WKH WHUPLQRORJ\ µFOXVWHU RI
GLIIHUHQWLDWLRQ¶(Zola et al., 2005). 
 
CD44 is a transmembrane protein that was originally identified on 
lymphocytes and was reported to be involved in cell adhesion and 
homing (Sneath and Mangham, 1998, Knudson and Loeser, 2002, 
Goldring, 2005).  As well as chondrocytes, cells in many different 
tissues including the lung, skin, stomach and spleen express it (Sneath 
and Mangham, 1998, Knudson and Loeser, 2002).  The major role of 
CD44 in articular cartilage is to act as a receptor for hyaluronan 
(Knudson and Loeser, 2002, Knudson, 2003).  Hyaluronan is rarely 
present in isolation in articular cartilage; aggrecan monomers bind to a 
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hyaluronan filament via a link protein (Knudson and Loeser, 2002, 
Knudson, 2003).  The number of aggrecan monomers that bind to one 
filament can be over 100 (Knudson, 2003).  Therefore the interaction of 
CD44 with hyaluronan enables these large, hydrated protein 
aggregates to be retained in the pericellular matrix, immediately 
surrounding the chondrocyte (Knudson and Loeser, 2002, Knudson, 
2003).  It has been reported that CD44 expression is high in 
proliferating cells (Sneath and Mangham, 1998), suggesting that as 
chondrocytes have a more proliferative role in monolayer culture, the 
expression of CD44 may be higher in these cells than native cells. 
 
1.5.4 Three-dimensional (3D) Culture of Chondrocytes 
 
One way of maintaining the chondrocyte phenotype in vitro is to culture 
the cells three-dimensionally.   A range of 3D culture techniques have 
been used to maintain or induce the chondrocytic phenotype.  A 
common 3D culture technique used is high density pellet culture (Abbott 
and Holtzer, 1966, Manning and Bonner, 1967, Kato et al., 1988, 
Solursh, 1991, Ballock and Reddi, 1994, Tallheden et al., 2003, Malda 
et al., 2004, Zhang et al., 2004, Dehne et al., 2009).  Abbott and Holtzer 
(1966), found that chondrocytes from 10-day chick embryos cultured in 
pellets had similar properties to those cultured in intact vertebrae.  
Other studies have also shown that chondrocytes cultured in high 
density pellets retain their spherical morphology (Manning and Bonner, 
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1967, Kato et al., 1988).  Ballock and colleagues (1994) found that cells 
cultured in pellets expressed collagen type II mRNA irrespective of the 
culture medium used.  They also found that expression of this gene 
increased with decreasing levels of FBS in the medium.  In fact 
expression was highest when FBS was absent and insulin was added 
to the culture medium.  The authors also found that gene expression of 
collagen type X increased with increasing culture length, with 
expression similar in cultures with or without serum.  (Ballock and Reddi, 
1994).  Stewart and colleagues (2000) compared the phenotype of 
equine chondrocytes cultured in monolayer, pellets, aggregates and 
explants in addition to observing the effects of FBS and bone 
morphogenetic protein two (BMP-2). Procollagen type II gene 
expression was higher in pellet and aggregate cultures compared to 
monolayer and explant cultures.  Expression of this gene was 
significantly increased in BMP-2 treated cells cultured in monolayer and 
aggregates.  Gene expression of procollagen type II was lower in all 
cells incubated with FBS, regardless of culture system; however the 
only significant difference reported was in monolayer culture.  Aggrecan 
expression was highest in the control group in pellet cultures; however 
incubation with BMP-2 enhanced expression in monolayer cells to a 
similar level.  Collagen type I gene expression was detected in all 
culture systems apart from explant culture, although expression in 
aggregate and pellet cultures was lower compared to monolayer 
(Stewart et al., 2000). 
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Another group set out to determine the plasticity of human 
chondrocytes (Tallheden et al., 2003).  For the chondrogenic 
differentiation component of the study, cells were pelleted and cultured 
in chondrogenic medium (DMEM-HG with ITS premix, 1mM pyruvate, 
10ng/ml TGF-ȕ -7M dexamethasone and 80µM ascorbate-2-
phosphate) .  In fact, the pellet culture method is often used to induce 
chondrogenesis in mesenchymal stem cells (Johnstone et al., 1998, 
Csaki et al., 2007, Stewart et al., 2007, Stewart et al., 2008, Vidal et al., 
2008, Lettry et al., 2010).  This method is used as it mimics the 
condensation of MSCs during the early stages of chondrogenesis 
(Cancedda et al., 2000, Goldring et al., 2006, Chen and Tuan, 2008, 
Pelttari et al., 2008). 
 
In another study, researchers used pellet culture to generate articular 
cartilage from chondrocytes isolated from day 16 chick embryos (Zhang 
et al., 2004). The authors chose pellet culture believing it would stabilise 
the phenotype of the chondrocytes in addition to having the advantage 
of not having additional material such as a supporting scaffold.  The 
tissue generated after two weeks had a hyaline-like appearance and 
staining for collagen type II was similar to that seen in explants.  
Staining for aggrecan within the pellets was pericellular and less intense 
than that shown in the explants.  Type IX collagen staining was shown 
to be stronger in pellets compared to explants.  Both pellets and 
explants were negative for type X collagen.  By day 14, pellets were 
shown to have a matrix with a similar fibrillar density to that in the 
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explants however matrix was more organised in the latter (Zhang et al., 
2004).  
 
Other 3D culture methods for culturing chondrocytes have involved 
seeding chondrocytes into a supporting scaffold material.  One material 
commonly used is alginate (Bonaventure et al., 1994, Hauselmann et 
al., 1994, Hauselmann et al., 1996, Loty et al., 1998, van Osch et al., 
1998, Chubinskaya et al., 2001, Domm et al., 2002, Schulze-Tanzil et 
al., 2002, Lee et al., 2003, Stoddart et al., 2006, Rai et al., 2009, Brand 
et al., 2012, Caron et al., 2012).  One group used alginate as an 
intermediary step to produce cartilage-like implants from bovine 
chondrocytes (Stoddart et al., 2006). The authors of this paper claim 
that implants generated without the alginate culture step shrunk in the 
silicon mould and consisted mainly of cellular material (Stoddart et al., 
2006).  However, with the alginate culture process, implants looked 
similar to that of the transitional zone in native bovine articular cartilage 
(Stoddart et al., 2006).  Another study investigated genes which are 
differentially regulated in chondrocytes cultured in monolayer and 
alginate (Haudenschild et al., 2001).  This group discovered that all the 
matrix formation cDNAs were enriched in monolayer cultures, whereas 
matrix remodelling factors were enriched in alginate cultures.  More 
specifically, mRNA expression for collagen types I and II, aggrecan and 
connective tissue growth factor was evident in both culture systems.  
However, expression of collagen type II and aggrecan seemed to be 
lower in monolayer cultures, suggesting that the 3D culture encouraged 
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retention of the chondrocytic phenotype (Haudenschild et al., 2001).   In 
a more recent study, researchers looked at the effect of cell density in 
alginate beads on the expression of collagen types I, II and X and the 
transcription factor Sox9 (Bernstein et al., 2009b).  High density alginate 
beads had an initial seeding density of 7x107 cells/ml of alginate, 
whereas low density beads had an initial seeding density of 4x106 
cells/ml.  The authors found Sox9 expression to be significantly higher 
in the low density beads but expression of both collagen types I and II 
were higher in the high density beads.  This difference in collagen gene 
expression was only significant in the early stages of the culture.   
Collagen type X expression fluctuated throughout the cultured period 
but was significantly higher in the low density beads at weeks one and 
four (Bernstein et al., 2009b). 
 
A more recent study used a novel surface expansion system in an 
attempt to prevent chondrocyte dedifferentiation (Rosenzweig et al., 
2012).  This research group compared bovine chondrocytes cultured on 
three different surfaces, high extension silicone rubber (HESR) which 
was continually expanded (CE cultures), standard tissue culture 
polystyrene (SD cultures) and polystyrene culture dishes coated with 
approximately 1mm of silicone rubber (SS cultures).  Cell morphology 
and gene expression of collagen types I and II, aggrecan, COMP and 
Sox9 were similar in SD and SS cultures from passages one to five.  
The morphology of the cells in the CE cultures more closely resembled 
that of a native chondrocyte.  Expression of collagen type I, Sox9, 
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COMP and aggrecan was upregulated in these cells whereas 
expression of collagen type I was downregulated when compared to SD 
cultures.  Following monolayer culture, cells from each of the three 
conditions were cultured three dimensionally in pellets.  Staining for 
collagen type II and GAGs was more intense in pellets containing CE 
cultured cells compared to those containing SD and SS cells.  These 
findings suggest that culturing chondrocytes on a continually expanding 
surface helps retain the chondrocytic phenotype during in vitro 
expansion (Rosenzweig et al., 2012). 
 
In addition to alginate, some other materials have been used to culture 
chondrocytes three-dimensionally in order to encourage redifferentiation 
(Table 1.7).  This includes synthetic polymers such as polyglycolic acid 
(PGA) (Homicz et al., 2003), poly(DL-lactic-co-glycolic acid (PLGA) 
(Chen et al., 2003) and polycaprolactone (PCL) (Garcia-Giralt et al., 
2008). 
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Scaffold Material References 
Alginate (Bonaventure et al., 1994, 
Hauselmann et al., 1994, 
Hauselmann et al., 1996, Loty et al., 
1998, van Osch et al., 1998, 
Chubinskaya et al., 2001, Domm et 
al., 2002, Schulze-Tanzil et al., 2002, 
Lee et al., 2003, Stoddart et al., 
2006, Rai et al., 2009, Brand et al., 
2012, Caron et al., 2012) 
Atelocollagen Solution Khoshfetrat 2008 
Type I collagen gel (Lee et al., 2007) 
Gelatin (Brochhausen et al., 2013) 
Silk (Das et al., 2013) 
Silk-gelatin (Das et al., 2013) 
Polyglycolic Acid (PGA) (Homicz et al., 2003) 
Poly(DL-lactic-co-glycolic acid (PLGA) (Chen et al., 2003) 
Polycaprolactone (PCL) (Garcia-Giralt et al., 2008) 
Methoxypolyethyleneglycol-block-co-
poly(lactide-co-glycolide) (MPEG-
PLGA) 
(Foldager et al., 2011) 
 
Table 1.7: Various scaffold materials used for the 3D culture of chondrocytes. 
 
Three-dimensional culture alone is often not enough to completely 
reverse or prevent chondrocyte dedifferentiation.  Therefore, there are 
additional changes to the culture system that can be made in order to 
enhance redifferentiation. 
 
Some research groups have altered monolayer expansion conditions in 
an effort to maintain the chondrocyte phenotype or enhance 
redifferentiation (de Haart et al., 1999, Lee et al., 2005), whilst others 
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have adjusted 3D culture conditions to maximise redifferentiation 
(Domm et al., 2002, Murphy and Polak, 2004, Duval et al., 2009, Babur 
et al., 2013).  Some researchers have attempted to optimise both 
stages of chondrocyte culture to successfully maintain the chondrogenic 
phenotype (Egli et al., 2008). 
 
Aspects of the culture system that can be altered include changing the 
physical conditions surrounding the 3D construct and adding soluble 
factors to the culture medium. 
 
The media used to culture chondrocytes both in monolayer and in 3D 
varies in the literature.  Mandl and colleagues (2002) expanded human 
chondrocytes in four different media preparations (DMEM+10% FCS, 
DMEM+ITS+, DMEM+ITS+5ng/ml FGF2 and DMEM+100ng/ml FGF2) 
before seeding the cells into alginate.  Alginate cultures were again 
incubated in two different solutions (DMEM+10% FCS+25ȝJPO
ascorbic acid and DMEM+IGF-1 and TGF-ȕȝJPO DVFRUELF DFLG
Collagen type I expression  was significantly lower in the group 
expanded in DMEM+100ng/ml FGF2 followed by culture in DMEM+IGF-
1 and TGF-ȕȝJPO DVFRUELF DFLG FRPSDUHG WR FHOOV H[SDnded in 
media containing serum, followed by the same conditions.  Collagen 
type II expression was significantly higher in the beads seeded with 
cells cultured in media containing serum or, followed by DMEM+IGF-1 
and TGF-ȕȝJPO DVFRUELF DFLG (Mandl et al., 2002).   In a more 
recent study, human chondrocytes were expanded in monolayer in two 
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GLIIHUHQW PHGLD FRPSRVLWLRQV '0(0+DP¶V ) )&6 DQG
DMEM+DP¶V ) )&6QJPO )*)ȝJPO LQVXOLQ EHIRUH
being seeded into collagen sponges (Claus et al., 2012).  Once seeded 
into the sponges the cells were again cultured in two different media, 
'0(0+DP¶V ) )&6ȝJ -phospho-L-ascorbic 
acid+200ng/ml BMP-Į  ȝJPO LQVXOLQ DQG Q0 WK\UR[LQ 7 RU
'0(0+DP¶V ) )&6ȝJ -phospho-L-ascorbic acid.  The 
authors found that collagen type II was only expressed in the sponges 
cultured in supplemented media; however the genes Sox9 and 
aggrecan were expressed in all groups.  However Sox9 protein was not 
expressed by cells in sponges cultured in non-supplemented media, 
regardless of the monolayer expansion conditions (Claus et al., 2012). 
 
Yang and colleagues (2006a), cultured human chondrocytes in two 
different media preparations in monolayer, followed by another two 
solutions in 3D culture.  The authors also used two 3D culture systems, 
pellets and collagen coated filters.  Interestingly, as well as having 
different media, different seeding densities were used.  The exact 
culture conditions used in this study is summarised in Table 1.8.  The 
authors showed that pellets seeded with chondrocytes expanded in 
basic media (BEC) were negative for collagen type II whereas those 
seeded with chondrocytes expanded with growth factor supplemented 
media (GFSEC) contained regions positive for this collagen type II.  
BEC filters also had regions positive for collagen type II whereas 
GFSEC filters were positive throughout.  GAG content was found to be 
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significantly higher in filters compared to pellets; however the content 
was significantly higher in both GFSEC cultures compared to BEC 
cultures (Yang et al., 2006a). 
 
Ascorbate is a common feature in these media designed to help 
maintain the chondrocyte phenotype in in vitro culture.  Therefore, this 
vitamin will be used in the latter stages of this thesis in an attempt to 
enhance any redifferentiation observed in the 3D cultures.  Ascorbate is 
discussed in greater detail in Section 5.1, Chapter Five. 
 
Monolayer culture 
DMEM containing L-glutamine, 10% 
FBS, 1 x non-essential amino acids, 
10mM HEPES, 0.2mM ascorbic acid, 
0.4mM proline (BEC). 
DMEM containing L-glutamine, 4.5mg/ml 
glucose, 25mM HEPES, 10% FBS.  After 
the first three days 10ng/ml bFGF was 
added (GFSEC). 
3D culture 
Pellet Collagen coated filters 
DMEM containing Glutamax, 0.1% 
human serum albumin, 0.2mM ascorbic 
acid, 1xITS+10ng/ml IGF-1 and 
10ng/ml TGF-ȕ 
DMEM containing L-glutamine, 2% 
human serum albumin, 1xITS, 5ng/ml 
TGF-ȕDQGP0DVFRUELFDFLG 
 
Table 1.8:  Different culture media used in a study by Yang et al (2006a) for the 
culture of chondrocytes. 
 
As well as adding soluble factors to culture media, researchers have 
also varied the physical environment surrounding the chondrocytes to 
encourage and enhance redifferentiation.  One group investigated how 
adhesion sites within agarose gels and the stiffness of the agarose itself 
impacted chondrocyte redifferentiation (Schuh et al., 2012).  The 
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authors found that increasing adhesion sites and stiffness had a 
negative impact on chondrocyte redifferentiation.   Another way of 
altering the in vitro environment is to lower the oxygen tension to closer 
to what is experienced in the joint.  This is the second mechanism that 
will be used later in the thesis to enhance redifferentiation and is 
discussed in greater detail in Section 5.1, Chapter Five. 
 
Up to this point, only healthy cartilage has been reviewed.  Articular 
cartilage can be damaged through injury, osteoarthritis (OA) or 
spontaneously as a consequence of the condition osteochondritis 
dissecans (Clar et al., 2005).  The following sections will deal with 
cartilage damage and the treatment of cartilage lesions with a particular 
look at cellular therapies and regenerative medicine. 
 
 
1.6 Cartilage Damage 
 
Articular cartilage can be damaged in three main ways, through 
osteoarthritis, a sudden accidental injury or osteochondritis dissecans 
(NHS, 2014).  Another way in which cartilage can be damaged is 
through infection (NHS, 2014).  It is difficult to ascertain the frequency 
of cartilage damage as those with mild damage may not always seek 
medical assistance (NHS, 2014).  Although it is known that around 
10000 people a year in the UK seek treatment for cartilage damage 
(NHS, 2014).  In some cases, traumatic injuries to cartilage can lead to 
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the development of OA; out of 46 million people in America diagnosed 
with OA, 12% of cases were associated with trauma (Waters et al., 
2014).  It is not clear whether all cartilage injuries lead to OA or whether 
there is a critical size or depth of injury which results in the development 
of OA (Loken et al., 2010). 
 
There are two key elements to cartilage injury resulting from acute 
trauma; the structure of the collagen matrix and the loading rate of the 
tissue (Gallo and Mosher, 2013).  When a blunt injury occurs during a 
traffic accident, there is a high rate of loading.  This energy is dispersed 
across the superficial layer of the articular cartilage and can cause 
superficial cracks in the tissue (Gallo and Mosher, 2013).  Oblique 
surface-layer tears can occur if excessive shear force is applied to 
cartilage (Gallo and Mosher, 2013).  In a paper studying 993 knee 
arthroscopies, 20% of the patients had localized lesions without 
degeneration (Aroen et al., 2004).  Out of this 20%, 44% were partial 
thickness lesions, 47% were localized full thickness lesions and 9% 
were categorised as osteochondritis dissecans.  Across the total 
number of patients (993), 59% reported an acute onset of symptoms 
whereas the remaining 41% experienced a more gradual onset.  This 
group also reported the causes of injury in these patients; sport was the 
majority at 49% with the next highest being unknown at 23%.  Traffic 
accounted for only 4% of the injuries seen.  Interestingly, this group 
found that soccer and team handball contributed to most of the sporting 
injuries at 30% and 13% respectively (Aroen et al., 2004).  Another 
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paper looking at 1000 knee arthroscopies found chondral or 
osteochondral lesions in 61% of the patients studied (Hjelle et al., 2002).  
The majority of these lesions were OA lesions (44%).  The remaining 
lesions were categorised as follows, focal chondral lesions (28%), 
chondromalacia patellae (23%), osteochondritis dissecans (2%) and 
other (3%) (Hjelle et al., 2002).  Chondromalacia patella is a condition 
which involves softening or breakdown of articular cartilage on the 
medial and odd facet of the patella and fibrillation of the patellar bone 
(Macmull et al., 2012, Pak et al., 2013).  The exact cause of this 
condition remains to be confirmed and there is currently no cure for it 
(Macmull et al., 2012, Pak et al., 2013). 
 
The exact pathophysiology of osteochondritis dissecans is unknown 
and there is some debate as to whether the term osteochondrosis 
would be more accurate due to the lack of inflammation observed in this 
condition (Edmonds and Polousky, 2013, McCoy et al., 2013).  In this 
disease there is damage to the subchondral bone and articular cartilage 
(McCoy et al., 2013, Shea et al., 2013).  Features of the disease can 
include softening, swelling, early separation, partial detachment or 
complete separation resulting in the formation of a loose body (Shea et 
al., 2013). The most common region to be affected is the femoral 
condyles of the knee (Eismann et al., 2014), although this disease can 
also affect ankle and elbow joints (Paterno et al., 2014).  
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1.6.1 Osteoarthritis 
 
Osteoarthritis (OA) is an extremely common arthritic disease in humans 
(Chen and Tuan, 2008, Felson, 2009, Penny et al., 2012).  It is 
progressive and degenerative and as such can also be called 
degenerative joint disease (Miljkovic et al., 2008, Mobasheri et al., 2009, 
Buhrmann et al., 2010, Richardson et al., 2010, Penny et al., 2012).  
There a numerous risk factors for OA, including age, sex, obesity, 
trauma and overuse (Chen and Tuan, 2008, Felson, 2009, Penny et al., 
2012).  Degradation of cartilage, inflammation and the formation of 
osteophytes are the major events in OA (Abramson and Attur, 2009, 
Felson, 2009, Mobasheri et al., 2009, Penny et al., 2012) (Figure 1.8). 
There are two major proteinases involved in matrix degradation in OA, 
matrix metalloproteinases and aggrecanases (Martel-Pelletier et al., 
2008, Umlauf et al., 2010)  In the early stages of OA, patients 
experience acute pain which later becomes chronic (Felson, 2009, 
Penny et al., 2012).  Current treatments for OA are unable to stop 
progression of the disease and focus more on alleviating pain (Felson, 
2009, Penny et al., 2012). 
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Figure 1.8:  Comparison of the features of a healthy and osteoarthritic joint. The 
cartilage is severely worn and subchondral bone remodelling is seen in the diseased 
joint.  Figure is adapted from (Aigner and Stove, 2003, Aigner et al., 2006). 
 
It is not only humans that are affected by OA.  Spontaneous OA is 
common in athletic and older horses (Goodrich and Nixon, 2006, Penny 
et al., 2012).  Other species including dogs (Liu et al., 2003, Cook et al., 
2010, Rychel, 2010), guinea pigs and mice (Bendele, 2002) also suffer 
from OA. 
 
OA can be a primary or secondary complaint and in dogs it is commonly 
secondary to other musculoskeletal disorders (Henrotin et al., 2005).  
Such disorders include hip and elbow dysplasias (Clements et al., 2010, 
Cook et al., 2010) and osteochondrosis (Bari et al., 1989, Arican et al., 
1994).  All breeds of dogs can develop OA regardless of their shape 
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and size (Rychel, 2010); however some breeds are more predisposed 
to it than others.  Labrador Retrievers have a much higher risk of 
developing OA (Liu et al., 2003, Todhunter et al., 2003, Clements et al., 
2010), whereas Greyhounds are rarely affected by OA (Todhunter et al., 
2003).  Male dogs are also more susceptible to developing OA 
(Clements et al., 2010).  OA is said to affect up to 20% of dogs over one 
year old (Clements et al., 2010) and accounts for 37% of all lameness 
in the dog (Arican et al., 1994). 
 
The dog has been extensively used as a model for OA. The most 
common model used is transection of the anterior cruciate ligament 
(Altman et al., 1984, Fife, 1986, Pelletier et al., 1988, Pelletier et al., 
1992, Matyas et al., 1999, Liu et al., 2003, Matyas et al., 2004, 
Rogachefsky et al., 2004, Kuroki et al., 2011, Gharbi et al., 2013).  The 
dog is a very useful model because the anatomy of the knee is very 
similar to humans and many features including the articular cartilage, 
synovium and joint capsule are histologically and biochemically highly 
conserved between species (Cook et al., 2010). 
 
1.7 Treatments for OA 
 
Most of the treatments for OA focus on alleviating symptoms rather than 
preventing the progression of the disease.  One problem is that OA is 
often present for a long time before a patient experiences any 
noticeable discomfort (Matyas et al., 2004).  There is current research 
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which aims to identify biomarkers of early OA, with the hope that these 
will help identify cases of OA in the early stages of disease or identify 
predisposing factors.  Recent progress in this area of OA research is 
reviewed in (Mobasheri, 2012). 
 
1.7.1 Pharmaceuticals and Nutraceuticals 
 
There is a hierarchy of treatment for OA in humans, which has been 
described as a treatment pyramid (Lohmander and Roos, 2007, Roos 
and Juhl, 2012).  All treatment begins with educating the patient about 
their lifestyle and advising them about weight loss and exercise regimes 
(Lohmander and Roos, 2007, Roos and Juhl, 2012).  The next level of 
treatment, which can be combined with the information and advice in 
the first line of treatment or can be a second line of treatment, is non-
surgical intervention (Lohmander and Roos, 2007, Roos and Juhl, 
2012).  This can include pharmacological pain relief, physiotherapy, 
occupational therapy and acupuncture (Lohmander and Roos, 2007, 
Roos and Juhl, 2012). 
 
Pharmacological relief includes paracetamol, non-steroidal anti-
inflammatory drugs (NSAIDs) and opiods (Lohmander and Roos, 2007, 
Swift, 2012).  Paracetamol is opted for first due to the fact that it is 
relatively effective at relieving pain and has fewer side effects than 
NSAIDs (Dougados, 2007, Swift, 2012).  This is in contrast to treatment 
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of OA in veterinary species where NSAIDs are chosen first (Rychel, 
2010). NSAIDs work by inhibiting the enzyme cyclooxygenase (COX) 
which is involved in the production of prostaglandins and thromboxanes 
(Henrotin et al., 2005).  There are two isoforms of COX, COX-1 and 
COX-2 (Henrotin et al., 2005, Solomon and Goodson, 2007).  The first 
is constitutively expressed whereas the latter is inducible and 
expressed in cells involved in inflammation in diseased tissue (Henrotin 
et al., 2005, Solomon and Goodson, 2007).  Prostaglandin E2 has been 
found in the synovial fluid of OA patients and seems to contribute to 
pain, inflammatory erythema and fever (Solomon and Goodson, 2007).  
Therefore inhibiting the COX enzymes reduces the production of such 
compounds and subsequently the pain and fever they cause.   
Carprofen, Meloxicam and aspirin are examples of NSAIDs (Henrotin et 
al., 2005, Solomon and Goodson, 2007).  Over 40 NSAIDs have been 
developed but a quarter of those have since been removed from the 
market due to their toxicity (Solomon and Goodson, 2007).  There are 
also NSAIDs which specifically inhibit COX-2 (Henrotin et al., 2005, 
Solomon and Goodson, 2007).  However a few of these have been 
withdrawn from the market due to severe side effects (Solomon and 
Goodson, 2007).  In addition to NSAIDs, opioids can be used to 
manage pain but they have many side effects including nausea, 
dizziness and constipation (Swift, 2012). 
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Another class of treatments for OA are nutracueticals.  Glucosamine is 
one of the popular products in the UK but limited evidence is available 
for its affectivity (Swift, 2012).  In fact, in veterinary species, 
glucosamine with chondroitin is a highly recommended treatment for 
OA (Rychel, 2010).   
 
These treatments are effective at reducing pain and increasing mobility 
but they do not act against the underlying problem of damaged cartilage.   
 
1.7.2 Surgical Treatments 
 
The top level of the treatment pyramid is surgical intervention.  Some 
surgery just replaces the entire joint or alleviates pain whereas other 
surgical options aim to repair the damaged cartilage, either by 
prompting spontaneous repair or inserting newly formed cartilage. 
 
Debridement is one such surgical technique which aims to temporarily 
relieve OA patients of the pain they are suffering (Hunziker, 2002).  
Osteotomy is also used to reduce pain and improvement alignment of 
the joint; however it is only recommended for OA patients who also 
have deformities (Hunziker, 2002). 
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Microfracture, on the other hand is a technique used to initiate 
spontaneous repair of the damaged articular cartilage (Hunziker, 2002).  
This involves drilling small holes in the joint, throughout the cartilage 
lesion, down to the subchondral bone (Hunziker, 2002).  This 
encourages the spontaneous repair response and a blot clot consisting 
of a fibrin matrix forms and fills the defect (Hunziker, 2002).  
Subsequently mesenchymal cells penetrate the matrix and the clot is 
converted to a vascularised scar-like tissue (Hunziker, 2002).  The 
disadvantage with this repair is that the tissue formed is more like 
fibrocartilage and as such is mechanically inferior (Hunziker, 2002).  It 
also begins to degenerate after a few weeks (Hunziker, 2002). 
 
Autologous chondrocyte implantation (ACI) is an established treatment 
for cartilage lesions that are larger than 4cm2 (Schulze-Tanzil, 2009, 
Oldershaw, 2012, Steinert et al., 2012). It is also used as a secondary 
treatment where microfracture has failed (Steinert et al., 2012).  This 
technique involves harvesting cartilage from a non-loading bearing 
surface and isolating chondrocytes from it (Richardson et al., 2010, 
Steinert et al., 2012).  These chondrocytes are then expanded in 
monolayer before injecting the cells back into the patient (Brittberg, 
2008, Brittberg, 2010, Zeifang et al., 2010, Oldershaw, 2012, Steinert et 
al., 2012).  The major problems with this technique include 
dedifferentiation of the cells during monolayer culture, calcification and 
cell leakage (Steinert et al., 2012).  The first version of ACI was ACI 
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with a periosteal flap (ACI-P) (Zeifang et al., 2010).  This involved 
covering the defect (once filled with chondrocytes) with a periosteal flap 
and sealing it with fibrin glue (Zeifang et al., 2010).  There were many 
disadvantages to this technique, including the requirement of a second 
surgical procedure to obtain the periosteal flap and sutures to secure it 
(Zeifang et al., 2010).  The chondrocytes in the defect were also 
unequally distributed using this method (Zeifang et al., 2010).  ACI-P 
was subsequently modified to use a flap made of porcine type I/III 
collagen (ACI-C) (Zeifang et al., 2010).  The latest ACI modification is 
matrix-induced autologous chondrocyte implantation (MACI) (Zeifang et 
al., 2010).  With this technique chondrocytes are embedded in a 
biological scaffold and implanted and secured into the defect with fibrin 
glue (Zeifang et al., 2010).  Bartlett and colleagues (2005) compared 
the outcomes of ACI-C and MACI used to treat osteochondral defects in 
the knee.  All patients complained of pain and limited function prior to 
the operation.  The average defect size was 6.0cm2 in the ACI-C group 
and 6.1cm2 in the MACI group.  The majority of patients had good 
repair tissue one year after the procedure in both treatment groups; 
however the most of the tissues contained fibrocartilage (Figure 1.9) 
(Bartlett et al., 2005). 
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Figure 1.9: Comparison of ACI-C and MACI treatments for osteochondral 
defects in the knee. (a) Charts indicating the grade of the repair tissue, 24 patients 
and 18 patients were assessed in the ACI-C and MACI groups respectively. (b) Charts 
indicating the type of repair tissue, data represents 14 patients in the ACI-C group and 
10 patients in the MACI group. Charts were generated based on the data given by 
(Bartlett et al., 2005).  The reason behind differing patients for each assessment is not 
clear. ACI-C (autologous chondrocyte implantation with a collagen flap) and MACI 
(matrix-induced autologous chondrocyte implantation). 
 
Another research group compared the outcomes of knee defects 
treated with ACI-P or MACI (Zeifang et al., 2010).  Inclusion criteria for 
the study were patients aged between 16 and 50 years with defects 
between 2.5cm2 and 6.0cm2.  At six months after the operation, defect 
repair and filling was more extensive in the MACI treated patients.  
However at 12 months, knee function was significantly improved in both 
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treatment groups and similar knee function was also seen at 24 months.  
Hypertrophy was observed more frequently in ACI-P treated patients 
but more MACI treated patients required revisions after the initial 
operation (Zeifang et al., 2010).  These results seem to suggest that, 
although MACI is perceived to be an improvement on the original ACI 
technique, the restoration of the function of the affected joint is actually 
similar between the two treatments.  Another paper details the 
histological quality of MACI repair tissue in the knee (Enea et al., 2012).  
For this study lesion size was 2cm2 or greater and follow-up biopsies 
were taken six months after the MACI procedure.  Authors report that 
when biopsies were taken, 14 out of 33 biopsies were taken from 
asymptomatic patients, whereas the remaining 19 were taken from 
patients experiencing a recurrence in or persistence of their original 
symptoms.  Out of these biopsies, 30.3% were classified as normal, 
51.5% as nearly normal, 12.2% as abnormal and 6.1% as severely 
abnormal.  The authors also state that 21% of biopsies contained 
mostly hyaline matrix, 6% were mostly a fibrous matrix and another 6% 
were a mixture of the two, with fibrocartilage often on top of a layer of 
hyaline cartilage (Enea et al., 2012).  This again indicates that although 
improvement was seen in some patients, MACI does not repair 
damaged cartilage back to its native form in many cases.  Although ACI 
has undergone several modifications since it was introduced in 1987, 
repair of damaged cartilage is still a major challenge for orthopaedic 
surgeons (Filardo et al., 2013). 
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The final surgical option is joint replacement.  In fact, total hip 
replacement is frequently used to treat end-stage OA (Mellon et al., 
2013).  This procedure is now very common, with 71 672 total hip 
replacements being undertaken in 2011 in England and Wales alone 
(Mellon et al., 2013).  Although the survival of the replacements are 
very good (90% - 95% last for up to ten years and approximately 85% 
last for up to 20 years), they can still fail (Mellon et al., 2013).  Failure 
can be for a variety of reasons, including infection, dislocation and 
aseptic loosening, with the latter being the most common (Mellon et al., 
2013).  Total knee replacement is also a common treatment for OA 
affected joints (Liddle et al., 2013).  In the USA, 676 000 total knee 
replacements were carried out in 2009 and this figure is expected to 
increase to 3.5 million by 2030 (Liddle et al., 2013).  This procedure is 
well-established and can be considered to be the gold standard 
treatment for knee OA but it may not be appropriate for every patient 
(Liddle et al., 2013).  A recent study followed patients that had 
undergone total ankle replacement for end stage ankle OA (Rosello 
Anon et al., 2014).  At the final follow-up (this varied between patients 
but averaged at 37 months after surgery), 15 patients were satisfied 
with the outcome of the surgery, 1 patient was satisfied with 
reservations and 2 patients were dissatisfied (Rosello Anon et al., 2014).  
In another study 114 out of 225 patients were found to be dissatisfied 
with their knee replacement (Ali et al., 2014).  Those dissatisfied were 
found to have a lower range of motion and higher levels of pain, anxiety 
and depression (Ali et al., 2014).  These studies suggest that total 
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replacement of a joint affected by severe cartilage damage and / or OA 
can be very effective for some patients but they are not the best 
solution for everybody. 
 
(YHQ FXUUHQW VXUJLFDO WUHDWPHQWV GRQ¶W VXFFHVVIXOO\ UHVWRUH WKH MRLQW
back to its native state and in some cases the repair tissue is of poor 
quality (Stoddart et al., 2009).  Therefore current research is looking 
into other ways of repairing cartilage, mainly tissue engineering and 
regenerative medicine. 
 
1.7.3 Tissue Engineering and Regenerative Medicine 
 
Tissue engineering essentially involves the reconstruction of 
mammalian tissues which have structural and functional properties 
which closely mimic those of the native tissue (Hunziker, 2002).  This 
process can either be done exclusively in vitro or it can be started in 
vitro and then finished off in vivo (Hunziker, 2002).  There are three 
major elements to a tissue engineered construct; a matrix scaffold, cells 
and signalling molecules (Hunziker, 2002).  Cartilage tissue engineering 
has been intensively researched for the past two decades; however 
there are still only a few treatment options which have reached the clinic 
(Johnstone et al., 2013). 
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During the past two decades many different cells (the optimum source 
is yet to be identified) and scaffolds have been evaluated for the 
regeneration of articular cartilage each with their own benefits and 
disadvantages (Stoddart et al., 2009, Johnstone et al., 2013, Bhardwaj 
et al., 2014).  Successful regenerative medicine depends on cell 
biologists working together with tissue engineers and surgeons to repair 
or regenerate damaged tissues and organs (Krampera et al., 2006, 
Helder et al., 2007, Penny et al., 2012). 
 
The first cell option for cartilage repair and regeneration is autologous 
chondrocytes and these are already approved for clinical use 
(Johnstone et al., 2013, Wright et al., 2013, Kwak et al., 2014).  A 
recent paper studied patients following autologous chondrocyte 
implantation for osteochondral lesions of the talus (Kwak et al., 2014).  
Before the operation, 26 patients rated their ankles as poor and three 
rated them as fair.  After the procedure, nine ankles were given an 
excellent rating, 14 good, five fair and one poor.  Although most patients 
observed an improvement, one procedure failed and out of the 23 
patients actively involved in sport before the procedure only ten 
returned to the same level of activity after the operation (Kwak et al., 
2014). This suggests that ACI is not the best solution to treat cartilage 
damage for every patient.  Another study aimed to characterise the cells 
contained in repair tissue following ACI (Wright et al., 2013). When 
compared with adjacent macroscopically normal cartilage, ACI repair 
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tissue was found to contain fewer GAGs and less collagen type II.  This 
group isolated cells from the repair tissue, chondrocytes from normal 
cartilage and MSCs from subchondral bone.  They found all cells to be 
positive for CD73, CD90 and CD105 and negative for CD19, CD31, 
CD34, CD45 and HLA-DR. Expression of CD14 in repair tissue cells 
and chondrocytes varied, whereas MSCs were negative for CD14 
(Wright et al., 2013). This would suggest that repair cells are similar to 
chondrocytes but are not as effective as native cells in producing 
cartilage ECM.   
 
Chondrocytes have the advantage of a low risk of immunological 
reaction and they possess the native phenotype (Johnstone et al., 2013, 
Roelofs et al., 2013).  However large numbers of chondrocytes are 
needed for larger cartilage defects and a consequence of expansion is 
a loss of phenotype (see Section 1.5.3).  Another research group have 
investigated the potential of chondrons (a chondron consists of the 
chondrocyte itself and its surrounding pericellular matrix) for 
regenerating articular cartilage (Vonk et al., 2010, Vonk et al., 2014).  In 
their 2010 paper they demonstrated that chondrons encapsulated in 
alginate beads expressed greater levels of aggrecan and collagen type 
II than those containing chondrocytes alone (Vonk et al., 2010).  Beads 
containing chondrons were also shown to contain more GAGs (Vonk et 
al., 2010).  In a more recent paper using damaged cartilage, the same 
group showed similar results with respect to chondrons exhibiting a 
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more chondrocyte-like phenotype in vitro compared to chondrocytes 
alone (Vonk et al., 2014).  Allogeneic chondrocytes could be another 
option offering a potential off-the-shelf solution (Johnstone et al., 2013).  
Almqvist and colleagues (2009) investigated whether implanting 
alginate beads containing human mature allogenic chondrocytes were a 
safe and feasible option for the treatment of symptomatic cartilage 
lesions in the knee.  Patients had an average defect size of 2.6cm2.  
Twelve patients had suffered from a traumatic injury and nine had non-
traumatic injuries (e.g. focal OA).  Alginate beads containing 20x106 
cells/ml were cultured for two weeks prior to implantation.  Patients 
follow-up was carried out for a maximum of 24 months after the 
operation.  The level of pain experienced by patients significantly 
decreased post-operatively and decreased over time.  There were no 
adverse effects from the implantation.  Of those patients who consented 
to 12 month biopsy, two contained hyaline-like repair tissue, six 
contained a mixture of hyaline-like and fibrocartilaginous tissue, four 
consisted of fibrocartilaginous tissue.  In addition to this, there was one 
biopsy that was categorised as fibrous vascularised tissue.  In terms of 
actually filling the defect, two were completely filled, four were 
hypertrophic and seven were underfilled (Almqvist et al., 2009).  This 
data would seem to suggest that the success of  particular cellular 
treatment will vary greatly depending on the patient and the size and 
cause of the defect.   
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Over the past few years interest in the use of mesenchymal stem cells 
(MSCs) in regenerative medicine has grown substantially.  MSCs are 
multipotent rather than totipotent because they can differentiate into a 
restricted range of cells (Smith and Webbon, 2005, Taylor et al., 2007).  
These cells have been isolated from a range of species including dogs, 
humans, horses, rodents and rabbits (Javazon et al., 2004, Penny et al., 
2012).  They are also extracted from a number of different tissues, 
including bone marrow, adipose tissue, umbilical cord (blood and matrix) 
and placental chorionic villi (Penny et al., 2012).  The two major 
advantages of these cells is that they can  be expanded in vitro without 
worrying about a loss of phenotype and there are multiple sources 
available (Johnstone et al., 2013).  However, the major problem with 
this cell type is the lack of consistency with isolation procedures and 
their specific phenotypic identity.  The International Society for Cellular 
Therapy have tried to address this by publishing criteria that should be 
used to characterise human mesenchymal stromal cells (Dominici et al., 
2006).  There are three components to this criteria; firstly the cells 
should be adherent to plastic (Dominici et al., 2006). Secondly 95% of 
cells should express the surface markers CD73, CD90 and CD105 and 
2% or less should express CD11b, CD19 CD34, CD45 and HLA-DR 
(Dominici et al., 2006).  Finally, the cells must be multipotent and have 
the ability to undergo chondrogenic, adipogenic and osteogenic 
differentiation (Dominici et al., 2006). 
 
 112 
 
Despite the fact that isolation, characterisation and chondrogenic 
differentiation techniques of MSCs vary in the literature and controversy 
surrounds their exact identity (Johnstone et al., 2013); one research 
group is hopefully that a one-step surgical procedure involving MSCs 
will one day be available (Helder et al., 2007).  Whilst the surgeon 
operates on the patient a tissue engineer isolates MSCs from adipose 
tissue and seeds them onto a graft (Helder et al., 2007).  When the graft 
is ready the surgeon implants it all in the same operation (Helder et al., 
2007).  The authors state that the whole process would take around two 
and a half hours (Helder et al., 2007). 
 
Although these cells hold much promise for use in treating cartilage 
lesions, another problem with inducing chondrogenesis in MSCs is 
premature hypertrophic differentiation (Chen and Tuan, 2008).  This 
generates cartilage similar to the growth plate rather than articular 
cartilage (Chen and Tuan, 2008). 
 
Another cell type that can be used is the induced pluripotent stem cell 
(iPS).  These cells would create a large source of patient specific cells 
capable of regenerating articular cartilage, which can be generated from 
a starting cell population that is harvested via a minimally invasive 
technique (Diekman et al., 2012, Johnstone et al., 2013).  A skin 
sample can be harvested from a patient with an articular defect and 
fibroblasts can be isolated via enzymatic digestion (Tsumaki et al., 
2014).  These cells can then be reprogrammed into iPS cells using 
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transfection (Tsumaki et al., 2014).  The resultant iPS cells can either 
be differentiated into chondrocytes and then implanted into a defect or 
they can be used generate cartilage in vitro (Tsumaki et al., 2014).  It is 
important to note that iPS derived chondrocytes will dedifferentiate in 
culture like chondrocytes isolated directly from articular cartilage 
(Tsumaki et al., 2014).  Therefore, it is imperative that expansion of iPS 
cells is carried out before differentiation.  One research group aimed to 
generate tissue engineered cartilage from murine iPS cells from a 
starting population predifferentiated down the chondrogenic lineage 
(Diekman et al., 2012).  Fibroblasts were isolated from the tails of eight 
to ten week old mice and were shown to express the stem cell markers 
Nanog, Oct4 and SSEA1.  These undifferentiated iPS cells were also 
shown to form teratomas when injected into murine kidneys and testes.  
The authors cultured these iPS cells in chondrogenic media and sorted 
for cells expressing collagen type II.  This sorted population expressed 
significantly higher levels of collagen type II and aggrecan than the 
unsorted cells.  They also produced more GAGs but also expressed 
higher levels of collagen type X.  When implanted into an in vitro defect, 
both cell populations generated cartilage like matrix, however tissue 
generated by the sorted population had a significantly higher shear 
strength (Diekman et al., 2012).  In another paper, iPS cells from 
different sources were shown to have different effects (Uto et al., 2013).  
Nanog green fluorescent protein (GFP) iPS cells (the GFP protein was 
knocked in to the Nanog locus) were shown to produce teratomas.  
Green mouse iPS cells developed from the bone marrow of EGFP-
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transgenic mice, when embedded into a collagen hydrogel, filled a 
cartilage defect with cartilage-like tissue in the patellar groove of the left 
femur in eight week old mice (Uto et al., 2013).  Research into these 
cells is still in the early stages and issues surrounding efficiency, 
reproducibility and control of differentiation need to be refined before 
they are introduced into the clinic (Johnstone et al., 2013).   
 
The final cell option available is embryonic stem cells (Johnstone et al., 
2013).  These cells have the capability to differentiate into any cell type 
within the body and could offer and off-the-shelf treatment option 
(Johnstone et al., 2013).  One paper has shown a three step method of 
differentiating human embryonic stem cells (hESCs) into chondrocytes 
(Oldershaw et al., 2010).  The first stage is differentiating the hESCs 
into the primitive streak mesendoderm.  At the end of this stage, the 
cells have a large, prominent nuclei and express NANOG, OCT4, CDH1, 
GSC2, T and GATA4.  The second stage involves differentiation to the 
mesoderm.  Cells at the end of this stage form densely packed clusters 
in culture and express MIXL1, KDR, SOX9 and ACAN.  The final stage 
is chondrogenic differentiation.  These cells form 3D aggregates in 
culture and express PDFGRB, COL2A1, SOX9, SOX6, CD44 and 
ACAN (Oldershaw et al., 2010).  For the functions of the proteins these 
genes encode, see Table 1.9.   
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Table 1.9: Genes expressed by human embryonic stem cells during a three step 
directed differentiation protocol.  a Functional information for each gene was 
obtained from Genecards - http://www.genecards.org/ 
Gene Functiona 
ACAN Encodes for the protein aggrecan.  Aggrecan is an essential 
component of cartilage ECM, contributing to compression 
resistance. 
CD44 Encodes for a cell surface glycoprotein which has roles in cell 
adhesion, migration and cell-cell interactions. 
CDH1 Encodes for the calcium dependent cell-cell adhesion 
glycoprotein, cadherin 1. 
COL2A1 Encodes the alpha-1 chain of collagen type II.  Collagen type two 
is a major component of cartilage ECM and has a crucial role in 
providing compressive resistance in this tissue. 
GATA4 Encodes a zinc-finger transcription factor which is thought to be 
involved in the regulation of genes with roles in embryogenesis 
and myocardial function and differentiation. 
GSC2 Encodes a protein thought to have a role in development. 
KDR Encodes a tyrosine-protein kinase receptor.  It is a cell surface 
receptor for vascular endothelial growth factors A, C and D. 
MIXL1 Encodes a transcription factor which has multiple roles during 
development.  These include cellular differentiation from the 
primitive streak to blood and morphogenesis of the heart and gut 
during embryogenesis. 
NANOG Encodes a transcription regulator involved in the proliferation and 
self-renewal of embryonic stem cells and the inner cell mass. 
OCT4 Encodes a transcription factor that has major roles in embryonic 
development and stem cell pluripotency. 
PDGFRB Encodes a cell surface tyrosine kinase receptor for platelet 
derived growth factor homodimers (B and D) and heterodimers (A 
and B).  It is involved in many processes including cell 
proliferation, differentiation and survival. 
SOX6 Encodes a transcription factor which has roles in many 
developmental processes including formation of the skeleton and 
neurogenesis. 
SOX9 Encodes a transcription factor involved in skeletal development. It 
is important in chondrogenesis. 
T Encodes an embryonic nuclear transcription factor which is 
important in the formation and differentiation of mesoderm. 
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In another study sheep embryonic stem-like cells were transplanted into 
cartilage defects and compared with empty and glued-only defects 
(Dattena et al., 2009).  Defects treated with the embryonic stem-like 
cells were shown to be filled with hyaline cartilage and joints appeared 
to be macroscopically healthy (Dattena et al., 2009).  In a more recent 
paper, researchers looked at the ability of chondroprogenitors derived 
from hESCs to repair damaged cartilage (Cheng et al., 2014).  During 
chondrogenic differentiation, hESCs were shown to express typical 
chondrogenic gene markers, Sox5, Sox6, Sox9, Collagen type II and 
Aggrecan.  Following differentiation into chondrocytes, cells were 
encapsulated into fibrin gels and implanted into osteochondral defects 
(2mm wide and 2mm deep) in the trochlear grooves of the distal femurs 
of athymic rats.  At four weeks after implantation, the defects treated 
with fibrin containing cells were partially repaired, mostly with flat, shiny 
and translucent tissue.  Defects treated with fibrin alone contained 
minimal, rough and irregular repair tissue.  The same difference was 
seen 12 weeks after implantation; fibrin only treated defects were poorly 
repaired, whereas joints treated with cells appeared to be fully repaired. 
The cells derived from hESCs formed hyaline-like repair tissue and 
there were still some of these cells remaining in the tissue at 12 weeks, 
suggesting that these cells contributed to the formation of the cartilage-
like repair tissue (Cheng et al., 2014).  
 
Although these cells are a promising alternative to chondrocytes, they 
do have their own disadvantages.  The major problem with these cells 
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is the ethical considerations and regulations.  Also, like with iPS cells 
there is a risk of teratoma formation (Johnstone et al., 2013). 
 
The other important component of a tissue engineered construct is the 
matrix or scaffold that surrounds the cells (Hunziker, 2002, Kolacna et 
al., 2007, Stoddart et al., 2009, Johnstone et al., 2013).  The ideal 
scaffold must possess several qualities (Stoddart et al., 2009, 
Johnstone et al., 2013).  Firstly the scaffold must be made of a 
substance that will not evoke an immune reaction in the patient 
(Stoddart et al., 2009, Johnstone et al., 2013).  Secondly it should be 
biodegradable and any fragments created during degradation should 
also not cause an immune response (Stoddart et al., 2009, Johnstone 
et al., 2013).  In addition to this, the material should be engineered in a 
way that optimises cell-material interactions (Stoddart et al., 2009).  The 
scaffold should be large enough to fit inside the defect it is designed for 
(Stoddart et al., 2009).  Tissue engineered scaffolds must also be able 
to withstand high levels of mechanical loading (Stoddart et al., 2009).  
Finally an ideal scaffold or matrix should be porous to enable seeded 
cells to migrate or native cells to infiltrate and growth factors and 
signalling molecules to filter through (Hunziker, 2002). 
 
Many different scaffolds have been tested, including protein- and 
carbohydrate-based polymers and artificial polymers (Table 1.10) 
(Hunziker, 2002).  However only a few biodegradable scaffolds have 
been commercialised for the use of cartilage repair (Stoddart et al., 
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2009).  One such product is CaRes, which is a collagen type I gel 
(Stoddart et al., 2009). Chondrocytes are directly seeded into the gel 
without prior monolayer expansion but are further cultured in the 
scaffold prior to implantation (Stoddart et al., 2009). Scaffolds are also 
discussed in Chapter 6. 
 
Protein-based scaffolds Carbohydrate-based 
scaffolds 
Artificial polymer 
scaffolds 
Fibrin Polylactic acid Dacron 
Type I collagen Polyglycolic acid Teflon 
Type II collagen Hyaluronan Carbon fibres 
Gelatine Agarose Polyesterurethane 
Silk Alginate Polybuturic acid 
 Chitosan Polymethylmethacrylate 
  Hydroxyapatite 
 Polyethylene glycol 
 
Table 1.10: Different scaffolds investigated for cartilage tissue engineering.  
Adapted from (Hunziker, 2002). 
 
1.8 Summary, Hypotheses and Aims/Objectives of the Project 
 
Articular cartilage can be damaged through injury or OA.  OA is a 
debilitating and painful disease in humans and other species including 
dogs and horses.  Most of the current treatment focuses on alleviating 
pain and there is no treatment which can stop the progression of the 
disease.  Articular cartilage is extremely poor at regenerating itself and 
there is currently no completely successful treatment which repairs 
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cartilage back to its native state.  Therefore, extensive research into 
regenerating cartilage either entirely in vitro or partially in vivo is 
currently being undertaken.  Cells are an integral part of cartilage repair 
and although chondrocytes are used for ACI, their major disadvantage 
is their limited availability.  The consequence of this is the requirement 
for in vitro expansion, which ultimately leads to a loss in the 
chondrocyte phenotype.  Other cell types including MSCs are also 
being investigated for their regenerative capacity, however as of yet no 
optimum cell source has been identified.  Other research into cellular 
strategies for cartilage repair have involved a variety of scaffolds but 
again no  ideal scaffold and cell combination has been identified.     
 
The overall aim of this thesis was to develop a greater understanding of 
chondrocyte dedifferentiation and redifferentiation in vitro using canine 
chondrocytes.  Not only do dogs suffer with OA, but they have also 
been used as models for this disease.  This thesis contains three 
experimental chapters, each with individual aims and objectives.  These 
are as follows: 
 
Chapter 3: Chondrocyte Dedifferentiation in Monolayer Culture 
 
Aim: To examine the phenotype of canine articular chondrocytes 
expanded to P5 in monolayer and confirm dedifferentiation. 
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Hypothesis One: Canine chondrocytes will alter in morphology with 
increasing passage, adopting a more fibroblastic 
phenotype. 
 
Hypothesis Two:   Expression of collagen type II and Sox9 will decrease 
with increasing passage whereas collagen type I and 
CD44 will increase. 
 
Chapter 4: Establishment of Chondrocyte 3D culture 
 
Aim: To establish a 3D culture of canine chondrocytes and assess the 
phenotype of monolayer-expanded cells within this system. 
 
Hypothesis One: Chondrocytes previously expanded in monolayer will 
begin to adopt a more native phenotype 
(redifferentiate) in 3D culture.  Expression of collagen 
type II and Sox9 will increase whereas expression of 
collagen type I and CD44 will decrease. Synthesis of 
GAGs should also be detected in the 3D culture 
system. 
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Chapter 5: Enhancement of Chondrocyte Redifferentiation in 3D culture 
 
Aim: To identify factors that will enhance chondrocyte redifferentiation in 
3D culture. 
 
Hypothesis One:    Addition of ascorbic acid ȝJPO to the cell culture 
medium will enhance the redifferentiation of canine 
chondrocytes cultured three dimensionally following 
expansion in monolayer culture. 
 
Hypothesis Two:     Culturing chondrocytes in a 3D system in an oxygen 
concentration of 2.4% will enhance the 
redifferentiation of monolayer expanded canine 
chondrocytes. 
 
Hypothesis Three:  Addition of IL-ȕ (10ng/ml) to the cell culture 
medium will inhibit the redifferentiation of canine 
chondrocytes cultured three dimensionally following 
expansion in monolayer. 
 
 122 
 
2. Materials and Methods 
 
2.1 Tissue and Cell Sources 
 
Cartilage tissue and positive control tissues were obtained from animals 
euthanized for reasons other than research, where possible the history 
of the animals were obtained to check for joint problems.  As the tissue 
was taken from dogs euthanized for unrelated clinical reasons, this 
project does not fall under the Animals (Scientific Procedures) Act 1986 
or the Veterinary Surgeons Act 1966.  Approval for the use of clinical 
material was obtained from the local Ethical Review Committee.  
Various dog breeds were used and animals were aged between 2 years 
and 11 years old. For more information on the animal material used for 
the work detailed in this thesis, see Appendix A. 
 
2.2 Antibodies 
 
All the antibodies used in this project are detailed in tables 2.1 (primary 
antibodies) and 2.2 (secondary antibodies).  All antibodies from Aviva 
Systems Biology came as a lyophilized powder.  All vials were 
centrifuged at 12 000xg for 20 seconds.  Powder was resuspended in 
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phosphate buffered saline (PBS) (Invitrogen, Paisley, UK) containing 
0.02% sodium azide (Sigma).  Vials were vortexed briefly to distribute 
the liquid before being centrifuged as before.  Antibodies were 
aliquotted and stored at -20oC.  All antibodies from the Developmental 
Studies Hybridoma Bank (DSHB) were aliquotted on arrival and stored 
at 4oC.  All other antibodies were either kept at 4oC or -20oC according 
WR PDQXIDFWXUHU¶V LQVWUXFWLRQV
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Antibody Supplier Catalogue 
Number 
Specificity Application 
COL1A1 Aviva Systems Biology ARP59998 Rabbit polyclonal against C terminal region of collagen 
type I 
IF, WB 
COL1A1 Aviva Systems Biology ARP59999 Rabbit polyclonal against C terminal region of collagen 
type I 
IF, WB 
CD44 Aviva Systems Biology ARP61023 Rabbit polyclonal against C terminal region of CD44 IF, WB 
SOX9 Aviva Systems Biology ARP37986 Rabbit polyclonal against C terminal region of Sox9 IF, WB 
SOX9 Aviva Systems Biology P100797 Rabbit polyclonal against N terminal of Sox9 IF, WB 
COL1A2 Aviva Systems Biology ARP58441 Rabbit polyclonal against middle region of collagen type 
I 
IF, IHC, WB 
Hermes-1 DSHB N/A Rat anti-CD44 WB 
H4C4 DSHB N/A Mouse anti-CD44 WB 
P1G12 DSHB N/A Mouse anti-CD44 WB 
CIIC1 DSHB N/A Mouse anti-collagen type II WB 
II-II6B3 DSHB N/A Mouse anti-collagen type II WB 
M-38 DSHB N/A Mouse anti-collagen type I WB 
Anti-Collagen 
II 
Abcam ab34712 Rabbit polyclonal against collagen type II IHC, WB 
Rabbit 
polyclonal 
IgG 
Abcam ab27478 Isotype control IHC, WB 
Mouse IgG 
isotype 
control 
Vector Labs I-2000 Isotype control IHC 
ȕ-actin Sigma A5136 Mouse anti-KXPDQȕ-actin WB 
Table 2.1: Primary antibodies used in this project.  For each antibody the supplier, specificity and application are given and where appropriate 
the catalogue number is also provided. 
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Antibody Supplier Catalogue 
Number 
Specificity Application 
Goat pAb to Rb 
IgG (DyLight® 
488) 
 
Excitation: 
493nm, Emission: 
518nm 
Abcam ab98462 Fluorescent 
conjugated 
secondary 
antibody 
IF 
Fluorescein anti-
mouse IgG (H&L) 
 
Excitation: 490-
500nm, 
Emission: 510-
520nm 
Vector 
Laboratories 
FI-2000 Fluorescent 
conjugated 
secondary 
antibody 
IF 
Anti-rabbit IgG, 
HRP-linked 
Antibody 
 
Cell 
signalling 
technology 
#7074 HRP 
conjugated 
secondary 
antibody 
WB 
Polyclonal Rabbit 
Anti-Rat 
Immunoglobulins/
HRP 
DAKO P0450 HRP 
conjugated 
secondary 
antibody 
WB 
Biotinylated 
universal (anti-
mouse IgG / 
rabbit IgG) 
antibody 
Vector 
Laboratories 
PK6200 Biotinylated 
secondary 
antibody 
IHC 
 
Table 2.2 Secondary antibodies used in this project.  For each antibody the 
supplier, catalogue number, specificity and application are given. 
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2.3 Cartilage Harvest and Chondrocyte Isolation 
 
2.3.1 Canine Forelimb and Hindlimb Dissection and Cartilage 
Harvest 
 
Articular cartilage was harvested either from the canine elbow joint in 
the forelimb or the stifle joint in the hindlimb (Figure 2.1).  All limbs were 
shaved before being washed with cold water and washing up liquid.  
These were then scrubbed in cold water and 10% trigene.  The limbs 
were then left to soak in 2% bleach for 30 minutes. Once taken out of 
the bleach each limb was sprayed with 70% ethanol (Fisher Scientific, 
Loughborough, UK) before the skin was removed. The cartilage was 
checked to see if it appeared macroscopically healthy (Figure 2.2). 
Healthy cartilage should be smooth and white as shown in  by 
Marijnissen and colleagues (2002). If deemed healthy, the opened 
joints were flooded with sterile PBS.  Cartilage was harvested using a 
sterile scalpel (Swann Morton, Sheffield, England) and forceps. 
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Figure 2.1: Location of the canine elbow and stifle joints. (a) Location of the elbow 
and stifle joints in a dog (image taken from (Johnstone and Biery, 2003)) (b) a 
dissected and washed elbow joint (c) a dissected and washed stifle joint.  The 
photographs in (b) and (c) were taken immediately prior to cartilage harvest. 
Photographs were taken using a Sony Cyber-shot DSC-W30 digital camera. 
 
Thin shavings were taken in order to increase the efficiency of the 
tissue matrix digestion and therefore cell release.  These shavings were 
placed into a falcon tube (Greiner Bio-One, Gloucestershire, UK) 
FRQWDLQLQJ FROOHFWLRQ PHGLD /RZ *OXFRVH 'XOEHFFR¶V 0RGLILHG (DJOH
Medium (DMEM) containing 4mM L-glutamine, 1000mg/L glucose and 
110mg/L sodium pyruvate (Fisher Scientific) supplemented with 2% 
antibiotics (10,000Units/ml penicillin and 10,000µg/ml streptomycin) 
(Invitrogen)).    
a
b c
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2.3.2 Chondrocyte Isolation from Articular Cartilage  
 
In order to isolate chondrocytes from cartilage shavings, the cartilage 
tissue was digested using the enzyme collagenase.  Firstly, the 
shavings were tipped into a sterile petri dish (Thermo Scientific, 
Roskilde, Denmark) with a small volume of the collection media and cut 
into smaller chips using a sterile scalpel.  This was done to increase the 
surface area available for the enzyme to digest.  These chips were then 
placed in a falcon tube containing sterile PBS supplemented with 10% 
antibiotics on a roller for 20 minutes.  The PBS was removed and the 
sterile filtered 0.1% Collagenase Type I (Invitrogen) solution 
(Collagenase Type I dissolved in DMEM supplemented with 2% 
a b
Figure 2.2: Macroscopically healthy and degenerate articular cartilage.  
Throughout this study healthy cartilage was harvested to isolate chondrocytes.  
Healthy cartilage is smooth and shiny as shown in (a).  The cartilage in (b) is not 
smooth or shiny and is significantly worn.  No cartilage was harvested from the 
joint in (b). Photographs were taken using a Sony Cyber-shot DSC-W30 digital 
camera. 
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antibiotics) was added.  The cartilage shavings and collagenase 
solution were then poured into a T25 flask (Thermo Scientific, Germany) 
and placed in a 37oC, 5% CO2 incubator overnight for 16-18 hours.  
Subsequently, the flasks were placed on a shaker for two hours at room 
temperature.  Once the cartilage had been digested, the cellular 
solution was sterile filtered, using a 70µm cell strainer (BD Biosciences, 
Erembodegem, Belgium) into a falcon tube.  This solution was then 
centrifuged at 200xg for ten minutes at 20oC.  The cell pellet was 
washed with sterile PBS using the same centrifuge conditions as before. 
After the second wash, collection media was added to the cell pellet 
and a cell count was performed using the Trypan Blue dye exclusion 
assay (see section 2.5.1). Once counted, the cells were washed for a 
final time in PBS and centrifuged as before.  After the final wash the 
pellet was resuspended in culture medium (DMEM supplemented with 
2% antibiotics and 10% foetal calf serum (FCS) (Invitrogen)) and the 
cellular suspension was split into three flasks (where possible, see 
Chapter Three, section 3.2.1), already containing culture medium.  
These flasks were kept in a 37oC, 5% CO2 incubator with media being 
changed at least twice a week. 
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2.4 Expansion of Chondrocytes in Monolayer 
 
Once seeded into T25 flasks the cells were monitored under the 
inverted light microscope, Leica DM IL and images were captured using 
the DFC490 camera and Leica Application Suite (Leica, Milton Keynes, 
UK) and media was changed every two to three days. When the cells 
were 90-100% confluent, they were passaged.  The culture medium 
was removed and the cells were washed with sterile PBS.  The cells 
were then incubated with 1ml 1x TrypLE express (Invitrogen) (5ml for 
T75 flasks and 10ml for T175 flasks) at 37oC and 5% CO2.  Flasks were 
observed under a light microscope at five-minute intervals for cell 
detachment.  Once a suitable level of cell detachment had occurred, the 
cell suspension was dispensed into a sterile falcon tube.  The surface of 
each flask was washed with a small volume of 1x TrypLE express (1ml 
for T25 flasks, 2ml for T75 flasks and 3ml for T175 flasks) to maximise 
the cell removal.  This cell solution was added to the sterile falcon tube.  
Sterile PBS was added and the whole solution was centrifuged at 200xg 
for ten minutes at 20oC.  The wash with sterile PBS and centrifugation 
was repeated once, before the cell pellet was resuspended in collection 
medium and the cells were counted using the Trypan Blue dye 
exclusion assay (section 2.5.1).  After the cell count, the cells were 
washed with sterile PBS and centrifuged as before.  The cell pellet was 
resuspended in cell culture medium and the resulting cell suspension 
was split into three flasks already containing culture medium.   This 
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whole process was repeated for every passage.  Depending on the 
downstream applications, cells were split into T25s, T75s or T175s 
(Thermo Scientific). 
 
2.5. Cell Viability Assays 
 
2.5.1 Trypan Blue 
 
Cell pellets were resuspended in a volume of media (DMEM with 2% 
antibiotics) appropriate for the size of the particular cell pellet.  An 
aliquot of the cell suspension was removed and dispensed into a sterile 
eppendorf to which Trypan Blue (Fisher Scientific) was then added.  
10µl of this solution was then dispensed into each side of a 
haemocytometer (Sigma, St. Lois, USA), which was viewed under a 
light microscope at x10 objective.  The number of viable cells (appear 
as bright cells) and non-viable cells (stained blue) were counted and the 
concentration and percentage of viable cells were calculated (Figure 
2.3).  Five squares on each side of the haemocytometer (ten squares in 
total) were counted and an average count was taken.  To get the 
concentration of cells/ml, the average number of cells per square was 
multiplied by the dilution factor and then by 10000. 
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Figure 2.3: Cell counting using a haemocytometer.  (a) Diagram of a 
haemocytometer. (b) The grid used to count the cells.  Only cells in the four corner 
squares and central squares were counted (indicated by red squares). Dead cells 
stained blue whereas live cells appeared bright. 
 
 2.5.2 Cyquant  
 
The Cyquant NF assay (Invitrogen) uses a fluorescent dye to measure 
cellular DNA content within a sample.  This will indicate the cell number 
in the sample as DNA content within cells is highly regulated, making 
the values closely proportional.  Cells were seeded into 96 well plates 
(Corning black plates with clear bottoms, supplied by Fisher Scientific) 
and left to adhere for a minimum of four hours. Plates were kept at 37oC, 
5% CO2 during this time.  When appropriate, cells were seeded at a 
known density; to determine the cell density Trypan Blue was used.  
After the cells had adhered, culWXUHPHGLXPZDVDVSLUDWHGDQGȝORI
Cyquant NF dye reagent diluted in Hanks Balanced Salts Solution 
(HBSS) (Invitrogen) buffer was added to each well.  Following 
a b 
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optimisation (Figure 2.4) cells were incubated with the dye for 10mins, 
at 37oC, 5% CO2. This optimisation also identified the maximum cell 
density that could be used for this assay is 10000 cells/well.  The 
fluorescence was measured at room temperature in fluorescence 
microplate reader (Fluostar Optima, BMG Labtech GmbH, Ortenberg, 
Germany) with the excitation filter set at 485nm and the emission filter 
set at 520nm. 
 
Figure 2.4: Cyquant Assay optimisation.  Cells were seeded into a 96 well plate at 
different densities and were incubated with the Cyquant NF dye for different lengths of 
time.  The fluorescence started to plateau after a density of 10000 cells/well and the 
level of fluorescence detected began to dip after 10 minutes particularly at higher 
densities.  Therefore a 10 minute incubation was selected for all further assays and 
the maximum number of cells seeded per well was 10000. 
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 2.5.3 Alamar Blue  
 
The Alamar Blue assay measures the metabolic activity of cells through 
a oxidation-reduction (REDOX) reaction.  Alamar Blue has been used to 
assess the viability of cells in vitro since the early nineties (O'Brien et al., 
2000).  2¶%ULHQDQGFROOHDJXHV (2000) identified that Alamar Blue and 
resazurin are in fact the same compound.  One of the first uses of the 
resazurin reduction test was to assess the level of bacteria in milk (John, 
1939, Nixon and Lamb, 1945).  Whilst the cells are growing, the 
surrounding environment is chemically reduced and that reduction 
continues during cell growth.  If cell growth is inhibited the environment 
becomes more oxidised.  In a reduced environment, the Alamar blue 
dye changes from non-fluorescent blue to fluorescent red.  
 
Chondrocytes were counted using Trypan Blue and seeded into 24 well 
plates (Thermo Scientific) at known densities to generate a standard 
curve.   This assay was primarily used to assess the viability of 
chondrocytes seeded into alginate beads.  When this assay was 
performed on alginate beads, individual beads were placed into a well 
in a 24 well plate. Cells were left to adhere to the plastic overnight 
(incubated at 37oC, 5% CO2).  Media was aspirated and all wells were 
washed three times with sterile PBS. The Alamar Blue stock solution 
(AbD Serotec, Oxford, UK) was diluted 1:10 with HBSS.  A volume of 
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1ml of this solution was added to each well; plates were wrapped in 
aluminium foil (SLS, Nottingham, UK) and incubated at 37oC, 5% CO2 
for 90mins.  Alamar blue solution ȝO was transferred to a 96-well 
plate; this was performed in triplicate for each well of the 24-well plate.  
This 96-well plate was wrapped in foil during transport to the fluorescent 
plate reader (Fluostar Optima). The fluorescence was measured at 
room temperature with the excitation filter set at 560nm and the 
emission filter set at 590nm. 
 
2.6 Cryopreservation and Revival of Canine Chondrocytes  
 
Culture medium was removed from the flasks.  The cells were briefly 
rinsed with TrypLE express before being incubated at 37oC, 5% CO2 
with TrypLE express.  The cells were checked for detachment every five 
minutes.  When the cells had lifted, the solution was drawn up and 
dispensed into a sterile falcon tube.  An equal volume of DMEM 
supplemented with 2% antibiotics was added to inactivate the TrypLE 
express.   This solution was then centrifuged at 1000xg for five minutes 
at 20oC.  After the supernatant was removed the cells were 
resuspended in 1ml of freeze medium (90% 50:50 DMEM 
supplemented with 2% antibiotics: FCS and 10% Dimethyl Sulphoxide 
(DMSO) (Fisher Scientific).  A cell count was then performed, using the 
Trypan Blue Dye exclusion assay (section 2.5.1).  The required volume 
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of freeze media was added in order to obtain a cell concentration of 1-
2x106 cells/ml.  Aliquots of 1ml of this solution were dispensed into 
cryoprotective vials, which were then placed in a Nalgene Mr Frosty (a 
passive freezer).  The Mr Frosty was kept in a -20oC freezer for one 
hour before being transferred to a -80oC freezer overnight.  The vials 
were then removed from the Mr Frosty and placed into liquid nitrogen 
storage. 
 
Cell revival has to be carried out quickly in order to maximise cell 
survival.  After the vial was removed from liquid nitrogen storage the cell 
solution was rapidly thawed in a 37oC water bath. Once thawed, the 
contents of the vial were transferred to a falcon tube and 10ml of culture 
medium was added (drop-wise at first).  The cells were then centrifuged 
at 200xg for five minutes at 20oC and the supernatant discarded.   The 
pellet was resuspended in culture medium and the whole cell solution 
was pipetted into a T25 flask.  The flask was placed in a 37oC, 5% CO2 
incubator and left for two days for the cells to settle.  When the cells 
were between 90% and 100% confluent, they were passaged using the 
method previously described. 
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2.7. 3D Culture of Canine Articular Chondrocytes 
 
 2.7.1 High Density Pellet Culture 
 
Articular cartilage was harvested and chondrocytes were isolated and 
expanded as described in sections 2.3.1 and 2.3.2.  When the cells 
were 90-100% confluent, pellet culture was attempted.  Firstly, the 
culture medium was removed and the cells were washed with sterile 
PBS.  The cells were then incubated with TrypLE express at 37oC and 
5% CO2.  Flasks were checked at five-minute intervals for cell 
detachment.   The lifted cells were dispensed into a sterile falcon tube 
and an equal volume of DMEM supplemented with 2% antibiotics was 
added.  The cell solution was centrifuged at 1000xg for five minutes at 
20oC.  After the supernatant was removed the cell pellet was 
resuspended in 1ml of culture medium.  A small aliquot of this cell 
suspension was taken for cell counting as described earlier.  The 
required volume of culture medium was then added to obtain a cell 
concentration between 1x106 and 2x106 cells/ml.  Aliquots (1ml) of the 
cell suspension were then pipetted into 1.5ml sterile eppendorfs.  These 
eppendorfs had holes in the lid, made using a hypodermic needle, to 
assist with gaseous exchange.  The cells were then centrifuged at 
400xg for five minutes at 20oC.  All pellets were incubated at 37oC and 
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5% CO2 for 21 and 35 days.  The media was changed every two to 
three days. 
 
 2.7.2 Alginate Bead Culture  
 
The method used to seed the cells into alginate was adapted from 
(Liebman and Goldberg, 2001).  When the cells were between 90% and 
100% confluent, culture medium was removed and the cells were 
washed with sterile PBS.  TrypLE was then added to the flask, which 
was placed in back in the 37oC, 5% CO2 incubator and checked every 
five minutes for cell detachment.  Once a significant proportion of the 
cells had lifted, the whole solution was drawn up and dispensed into a 
sterile falcon tube.  A further volume of TrypLE express was added to 
the flask to further enhance the number of cells lifted from the flask.  An 
equal volume of DMEM supplemented with 2% antibiotics was added to 
this solution which was then centrifuged at 1000xg for five minutes at 
20oC.  The supernatant was discarded and the cell pellet was 
resuspended in 1ml of DMEM with 2% antibiotics.  A cell count was 
then performed as previously described.  The cells were centrifuged for 
a second time at 250xg for ten minutes at 20oC.  Whilst centrifuging, 
102mM CaCl2 (Fisher Scientific) was added to each well of a six well 
plate (Thermo Scientific).  Once the supernatant had been removed, the 
cells were resuspended in 1.2% (low viscosity) alginate to get a cell 
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concentration of 2x106 cells/ml.  The 1.2% alginate solution was made 
by dissolving 1.2g of alginic acid from brown algae (Sigma) in 100ml of 
0.155M NaCl.  This solution was then autoclaved prior to its use in cell 
culture. 1.2% alginate has been used for chondrocyte culture by many 
research groups (Hauselmann et al., 1994, Beekman et al., 1997, van 
Osch et al., 1998, Chubinskaya et al., 2001, Domm et al., 2002, 
Stoddart et al., 2006, Brand et al., 2012, Caron et al., 2012) The cells 
were mixed thoroughly with the alginate using a sterile pipette.  This 
cellular suspension was then drawn up through a 18G needle (Terumo 
Europe, Leuven, Belgium) into a sterile 10ml syringe (Terumo Europe).  
The suspended chondrocytes were expressed dropwise through the 
18G needle into the CaCl2 in the six well plate.  Each well contained 20 
drops.  The instantly formed beads were left to polymerize for a further 
ten minutes in the CaCl2 solution.  The beads were then washed three 
times with 0.155M NaCl (Fisher Scientific).  After the final wash, culture 
medium was added to each well and the plate was placed in a 37oC, 
5% CO2 incubator.  Media was changed every two to three days. 
 
The size of the needle used to generate the beads and the chondrocyte 
seeding density were selected based on experimental work which is 
discussed in Chapter Four, section 4.2.2.1. 
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 2.7.3 Varying the Culture Conditions of the Alginate Beads 
 
Beads were set up as before and were left to settle in culture medium 
(DMEM supplemented with 2% antibiotics and 10% FCS) for four days 
at 37oC and 5% CO2.  On the fourth day media was removed and 
treatments were added or beads were placed in different environmental 
conditions (Figure 2.5).  Media was changed every three days and 
treated media was made fresh immediately before it was changed.  
Cultures were terminated after 35 days.  The exact changes in culture 
conditions are detailed in the following two sections. 
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Figure 2.5: Timeline of alginate bead experiments involving changes in culture 
conditions. Canine articular chondrocytes were isolated and expanded in monolayer 
for two passages before being seeded into alginate beads.  The beads were cultured 
in normal culture conditions (DMEM+10%FBS+2% antibiotics, 21% oxygen, 5% CO2 
and 37oC) to allow the cells to settle into the new culture environment.  On the third 
day, a selection of beads was kept in normal culture conditions and two treatment 
groups were created.  Some beads had ascorbate added to the culture medium 
whereas another selection of beads were incubated in reduced oxygen conditions. P2: 
passage two. 
  
  2.7.3.1 Ascorbate 
 
A stock of 1mg/ml ascorbic acid (Sigma) was made in nanopure water 
and aliquots were stored at -20oC.   Aliquots were thawed on ice prior to 
media change.  Ascorbic acid was added to culture medium to a final 
concentration of 25µg/ml.  Media was removed from the wells and 
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media containing ascorbate was added.  Beads were cultured as before 
and media was changed every three days. 
 
  2.7.3.2 Environmental Conditions  
 
Culture media was aliquotted into a sterile falcon tube and placed into 
an incubator set at 2.4% oxygen overnight.  This enabled the media to 
adjust to the reduced oxygen conditions.  Plates were briefly taken out 
of the incubator, along with the prepared media and media was 
changed.  Plates were immediately placed back in the reduced oxygen 
incubator after media change.  All other conditions (37oC and 5% CO2) 
remained the same. 
 
  2.7.3.3 Inflammatory Mediator  
 
The inflammatory mediator IL-ȕ 5HFRPELQDQW (TXLQH IL-ȕ,/-IF2, 
R&D Systems, Minneapolis, USA) was reconstituted in PBS at a 
concentration of 10µg/ml.  This stock was aliquotted and stored at -
20oC.  Aliquots were thawed on ice prior to media change.  IL-ȕZDV
added to culture media to a final concentration of 10ng/ml.  Beads were 
cultured as before and media was changed every three days.  
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2.8 Histological Staining 
 
Fixation and processing of high density pellets and alginate beads had 
to be altered in order to maintain the integrity of the samples.  This is 
discussed in detail in sections 4.2.1 (high density pellets) and 4.2.2.2 
(alginate beads) in Chapter Four. 
 
 2.8.1 Haematoxylin and Eosin  
 
Slides were placed in Histoclear (National Diagnostics, Hull, UK) for ten 
minutes before being placed in graded alcohol baths (100%, 95% and 
70%) (Ethanol Absolute, Fisher Scientific) for two minutes each.  After 
being washed with tap water the slides were left in Haematoxylin (BDH, 
VWR International, Poole, UK) for three minutes.  The slides were 
washed again before being dipped in 1% acidic industrial methylated 
spirit (IMS) (IMS (Fisher Scientific) with Hydrochloric Acid (Acros 
Organics, Geel, Belgium) for two to four seconds.  After another wash, 
the slides were dipped in ammoniated water (ammonia solution (35%): 
Fisher Scientific).  The slides were then left in Eosin (MERCK, 
Darmstadt, Germany) for five minutes after being washed. The slides 
were washed for a final time before being dipped in graded alcohol 
solutions (70%, 95% and 100%).  Before being transferred to xylene 
(Fisher Scientific) for five minutes, the slides were left in Histoclear for 
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five minutes.  The slides were dipped in a second xylene bath before 
they were mounted with DPX mounting medium (BDH).  The slides 
were left in the fume cupboard at room temperature for 24 hours for the 
mountant to set.  Slides were observed under a light microscope, 
DM5000B fitted with digital camera DCF350FX (Leica) at x5 x10 and 
x20 objectives.   
 
 2.8.2 Alcian Blue  
 
Slides were placed in Histoclear for ten minutes followed by graded 
alcohol baths (100%, 95% and 70%) for two minutes each.  The slides 
were then washed under running water for two minutes before being 
placed in Alcian Blue (pH2.5) (Alcian Blue 8GX (Sigma) in 3% glacial 
acetic acid (Fisher Scientific)).  Following incubation in the stain, slides 
were washed in water and dipped in graded alcohol baths (70%, 95% 
and 100%).  Various concentrations and incubation times of Alcian Blue 
and washing times were trialled to achieve optimal staining.  This work 
is discussed in detail in Chapter Four, section 4.2.2.3.   The slides were 
then placed in Histoclear for five minutes and then xylene for five 
minutes before being mounted with DPX mounting medium. The slides 
were left in the fume cupboard at room temperature for 24 hours for the 
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DM5000B fitted with digital camera DCF350FX (Leica) at x5, x10 and 
x20 objectives.   
 
 2.8.3 Safranin O  
 
The following method was obtained from Professor Susan 
&KXELQVND\D¶V JURXS EDVHG DW 5XVK 8QLYHUVLW\ LQ &KLFDJR  7KLV
method had been adapted specifically for alginate from (Rosenberg, 
1971). Slides were placed in Xylene for 15 minutes (three separate 
baths for five minutes each) followed by a series of alcohol baths, 100% 
ethanol for six minutes (three baths; two minutes each), 95% ethanol for 
four minutes (two baths; two minutes each), 70% ethanol for two 
minutes and 50% ethanol for two minutes.  The slides were then 
washed in RO water for 15 minutes.  Following deparaffinization, the 
slides were placed in 0.1% fast green (Raymond A Lamb Ltd, 
Eastbourne, UK) for three minutes.  After two dips in 1% acetic acid 
water, the slides were left in 0.1% Safranin O (Raymond A Lamb Ltd) 
for four minutes.  After staining, the slides were dehydrated by placing 
them in graded alcohol baths (70% ethanol, one dip; 95%, three dips 
and 100% ethanol (two baths, two minutes each)).  The slides were 
then placed into 50:50 ethanol : xylene for two minutes before being put 
in xylene for nine minutes (three separate baths, three minutes each). 
The slides were mounted with DPX mounting medium and left in the 
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fume cupboard at room temperature for 24 hours for the mountant to 
set.  The slides were observed under a light microscope DM5000B 
fitted with digital camera DCF350FX (Leica) at x5, x10, x20 and x40 
objectives.   
 
2.9 1,9-dimethylmethylene blue (DMMB) Assay  
 
2.9.1. Papain Digestion 
 
In order to evaluate glycosaminoglycan (GAG) production in a test 
sample, that sample must first be digested with the enzyme papain.  
Papain is a cysteine protease found in papaya that cleaves peptide 
bonds in basic amino acids (histidine, lysine and arginine), leucine and 
glycine.   
 
Alginate beads were removed from culture, placed in a six well plate 
and washed with PBS.  Individual beads were placed into pre-weighed 
eppendorfs, which were re-weighed in order to calculate the wet weight 
of the bead.  The eppendorfs were left open and parafilm (Fisher 
Scientific) was used to cover the top.  A few holes were pierced into the 
parafilm and the beads were snap frozen in liquid nitrogen.  The 
eppendorfs were then placed in the freeze drier (Alpha 1-2 LD plus, 
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SLS) overnight.  Then the eppendorfs were re-weighed to obtain the dry 
weights of the beads.  These samples were then stored at -80oC until 
required. 
 
Preparing individual beads resulted in very low quantities of sample.  
After a further literature search the preparation of beads for the GAG 
assay was altered.  The following method was adapted from 
(Uitterlinden et al., 2007).   After washing with PBS, five beads were 
placed in sterile eppendorfs and 1ml of 1x dissolving buffer (55mM 
sodium citrate (Sigma), 150mM NaCl and 30mM EDTA (BDH)) was 
added.  Samples were vortexed for one minute.  After vortexing 1ml of 
papain solution (papain from papaya latex, Sigma) was added and 
tubes were placed in a waterbath set at 60oC overnight.  In order to 
prevent evaporation, lids were closed tightly and wrapped in parafilm.  
Any solution not used immediately was stored at -80oC.  Stocks of 
papain solution were made in advance, aliquotted and kept at -80oC.  
To make the papain solution (concentration: 1.06mg/ml), 0.0264g of 
papain was dissolved in 25ml of papain buffer (0.1M dibasic sodium 
phosphate (Sigma)), 0.005M cysteine hydrochloride (Sigma) and 
0.005M EDTA (Sigma), pH6.5). For papain buffer preparation see 
Appendix B. 
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2.9.2 DMMB Assay 
 
Firstly the DMMB solution (pH1.5) was prepared (see Appendix B for 
recipe).  This solution was stored at room temperature in a foil-wrapped 
bottle.  Then the standards were prepared.  A stock solution of 
chondroitin-4-sulphate (chondroitin sulphate sodium salt from shark 
cartilage, Sigma) was prepared by dissolving 100mg in RO water to 
give a concentration of 1mg/ml.  This was then diluted 1:10 with blank 
papain solution to create a working solution with a concentration of 
100µg/ml.  The working solution was further diluted with blank papain 
solution to generate a range of concentrations for the standard curve (0, 
5, 10, 15, 20, 25, 30, 40, 50 and 75 µg/ml).  Blank papain solution was 
added to a 96 well plate, followed by the standards and then the test 
samples (the volume of all solutions added to the 96 well plate was 
ȝO.  All solutions were loaded in triplicate.  DMMB solution was 
added to all wells ȝO and the plate was read in a LT-4000 
Microplate Reader at 540nm within ten minutes of adding the DMMB 
solution. 
 
2.10 Immunofluorescence  
 
Cells were seeded into 96 well plates (Corning, supplied by Fisher 
Scientific) at a density of 10000 cells/well and were left to adhere 
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overnight in a 37oC / 5% CO2 incubator.  Once adhered, media was 
removed from the wells and each well was rinsed with PBS.  Cells were 
then fixed with ice-cold methanol (Fisher Scientific) for ten minutes.  In 
the initial run, 4% paraformaldehyde (Sigma) fixation was compared 
with methanol fixation.  Following this experiment, methanol was used 
for fixation as it enabled more defined staining (see Figure 2.6).  After 
fixation cells were washed twice with PBS.  After the final wash, fresh 
PBS was added to each well and plates were stored in the fridge (at 
4oC) until required. Plates were sealed with parafilm to help prevent 
them drying out. 
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Figure 2.6: Comparison of methanol and paraformaldehyde fixation.  
Chondrocytes were seeded into 96 well plates and after being left to adhere were 
fixed with ice-cold methanol (a) and (b) or 4% paraformaldehyde (c) and (d) for ten 
minutes. (a) and (c) Cells were evaluated for the expression of collagen type I using 
the Aviva antibody COL1A2 at a concentration of 1µg/ml. (b) and (d) are the 
corresponding isotype controls.  The staining appears to be masked in the cells fixed 
with paraformaldehyde. Magnification: x100, scale bar 100µm. 
 
When ready for staining, plates were taken out the fridge and the PBS 
was removed.  Cells were then incubated with 0.1% Triton X-100 
(Sigma) in PBS for ten minutes at room temperature, which 
permeabilizes the cells.  The cells were then washed three times with 
PBS (five minutes each time).  In order to block non-specific binding of 
the primary antibody, cells were incubated with 3% bovine serum 
albumin (BSA) (Fisher Scientific) for one hour at room temperature.  
Following this, the blocking solution was removed and the appropriate 
primary antibody (diluted in 3% BSA) was added to each well.  Cells 
a b
c d
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were incubated with the primary antibody overnight at 4oC.  The primary 
antibody was removed and cells were washed three times with PBS 
(five minutes each time).  Cells were then incubated with the secondary 
antibody (also diluted in 3% BSA) for one hour at room temperature, in 
the dark.  The secondary antibody was removed and cells were washed 
three times with PBS (five minutes each time).  Plates were wrapped in 
aluminium foil and placed in the fridge until imaging.  Plates were 
imaged using the Axiovert 200 Inverted Fluorescence Microscope 
System at the Waltham Centre for Pet Nutrition. 
 
2.11 Immunohistochemistry 
 
2.11.1 Preparation of Positive Control Tissues and Test 
Samples 
 
Canine articular cartilage was used as a positive control tissue for the 
antigen collagen type II as it is a major component of the extracellular 
matrix in this tissue.  It was also used as a positive control for CD44. 
Articular cartilage shavings were harvested as described in section 
2.3.1 and placed immediately in 10% neutral buffered formalin (NBF) 
(Neutral Buffered Formaldehyde Concentrate, Surgipath Ltd, 
Peterborough, UK) for 24 hours at room temperature.  Following fixation, 
the shavings were stored in 70% ethanol until processing. Shavings 
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were then placed in cassettes in the tissue processor and were 
processed for 17 hours (see Appendix C). 
 
After the tissue was processed, it was embedded in paraffin wax.  The 
embedded tissue was kept at room temperature until sectioning.  The 
tissue was cut into 5µm sections using a microtome.  Sections were 
straightened using 30% ethanol followed by floating in a water bath 
heated to 42oC.  Sections were then placed on polysine slides (Fisher 
Scientific) which were left to dry on a hotplate for one hour at 40oC.  To 
fully bake the sections onto the slides, slides were left in an oven set to 
50oC overnight.  Slides were stored at room temperature until staining. 
 
Canine tendon tissue was used as a positive control for collagen type I 
detection as it is an abundant extracellular matrix protein in this tissue.  
Canine forelimbs were prepared for cartilage harvest as described 
previously.  Before cutting into the joint, tendons were removed and 
placed in collection media.  Following this, tendons were washed with 
sterile PBS.  Tendons were cut into small sections and placed in 1.5ml 
eppendorf tubes.  Tubes containing tendon tissue were immersed into 
liquid nitrogen to snap freeze the tissue.  Snap frozen tissue was stored 
at -80oC until required. 
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In order to prepare the tissue for sectioning, an eppendorf containing 
tendon segments was placed on the cryobar of the cryotome (set to        
-60oC).  Plastic moulds were coated with Vaseline before being lined 
with a small volume of OCT mounting medium (Raymond A Lamb Ltd).  
Moulds were placed in the cryotome and as the OCT began to set 
tendon sections were inserted vertically into the mounting medium.  The 
moulds were left in the cryotome until the OCT had completely frozen.  
Following this, the remaining exposed tendon was covered with OCT 
and blocks were left in the cryotome until the OCT had completely 
frozen.  The blocks were removed from the plastic mould and stored at -
20oC until sectioning.  The tissue was cut into 5µm sections using a 
cryotome and placed on polysine slides.  Slides were stored at -20oC 
until staining. 
 
The processing of the alginate bead test samples had to be optimised; 
this optimisation is discussed in Chapter Four, section 4.2.2.2.  Briefly, 
beads were processed manually before being embedded in paraffin 
wax.  Bead samples were sectioned as described for the cartilage 
tissue sections. 
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2.11.2 Detecting Collagen Types I and II and CD44 Expression 
 
For samples embedded in paraffin wax, the slides need to be dewaxed 
and rehydrated before any staining protocol can be applied.  Slides 
were placed in xylene twice for five minutes each before being placed in 
graded alcohol baths (100%, 95% and 70%) for five minutes each.  
Slides were washed in PBS for five minutes, following a five minute 
wash in RO water. 
 
Tissue embedded in OCT requires fixation after sectioning.  Slides were 
placed in ice cold methanol for ten minutes before being washed twice 
with PBS for five minutes each time.  These slides do not require 
dewaxing and rehydration, so after the final PBS wash the same 
staining protocol as used for the wax embedded sections was followed.  
 
Slides were blotted dry and a circle was drawn around each tissue or 
bead section with a paraffin pen (liquid blocker super PAP pen, Sigma).  
This helps retain any solutions on the slide and also limits the total 
volume of each solution used as only enough to cover the section is 
required.  It is at this point that the slides are transferred to a humidity 
chamber.  This helps to keep the slides moist and prevent them from 
drying out.  Slides were then incubated for ten minutes at room 
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temperature with 3% H2O2 (Fisher Scientific) to block endogenous 
peroxidase activity.  After being washed with PBS twice (five minutes 
each time) sections were incubated with avidin solution (Avidin and 
Biotin Blocking Kit, Vector Laboratories, California, USA) for 15 minutes 
at room temperature.  All washing steps were performed in troughs as 
opposed to pipetting PBS over the slides in the humidity chamber.  This 
was done to further reduce any potential background staining.   Slides 
were briefly washed with PBS before being incubated with biotin 
solution (Avidin and Biotin Blocking Kit, Vector Laboratories) for 15 
minutes at room temperature.  The avidin and biotin solutions are 
added to block any endogenous biotin, biotin receptors and avidin 
binding sites present in the tissue.  Following another brief wash with 
PBS slides were incubated with 2.5% normal horse serum (diluted in 
PBS) (Vectastain ABC Kit Universal, Vector Laboratories, Peterborough, 
UK) for 20 minutes at room temperature.  The serum is used to block 
non-specific binding of the primary antibody.  Excess serum was blotted 
off the slide and the appropriate primary antibody, diluted in 2.5% horse 
serum, was added to each section.  Slides were incubated with the 
primary antibody inside the humidity chamber at 4oC overnight. 
 
Following the overnight incubation, slides were washed three times (ten 
minutes each time) with PBS containing 0.1% Tween20 (Tween20, 
Fisher Scientific).  After the final wash slides were placed back in the 
humidity chamber and incubated with biotinylated universal (anti-mouse 
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IgG / rabbit IgG) secondary antibody (Vectastain ABC Kit Universal, 
Vector Laboratories) for 30 minutes at room temperature.  Whilst 
incubating, the AB complex (Vectastain ABC Kit Standard, Vector 
Laboratories, California, USA) was prepared as it has to be left at least 
30 minutes before use.  After incubating with the secondary antibody, 
the slides were washed for ten minutes with PBS containing 0.1% 
Tween20 and for a further ten minutes in PBS alone.  The AB complex 
was then added to the sections and slides were incubated with this 
solution for 30 minutes at room temperature inside the humidity 
chamber.  Slides were then washed two times with PBS (five minutes 
each time).  After washing, diaminobenzidine (DAB) substrate 
(Peroxidase Substrate Kit, Vector Laboratories, California, USA) was 
added to the sections.  With each different sample DAB was added to 
the slide and the change in colour was monitored under a light 
microscope.  The incubation times varied from three minutes to ten 
minutes for different samples.  Incubation times for negative controls 
were matched to the time required for the corresponding test section.   
Slides were then washed in running tap water for five minutes, before 
being counterstained with haematoxylin.  Slides were placed in 
haematoxylin for 15-30 seconds before being rinsed in tap water until 
the water ran clear.  Slides were then dipped twice in 1% acidified IMS, 
rinsed in water, dipped twice in ammoniated water and rinsed again in 
water. 
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The standard protocol following this final rinse in water is to dip the 
slides in graded alcohol baths (70%, 95% and 100%)  before placing 
them in two xylene baths (five minutes each).  This prepares the slides 
for mounting with DPX mountant.  However, this process caused 
sections to lift off of the slides.  An alternative method for preparing 
slides for mounting is to let them dry out completely.  Therefore, after 
the final rinsing step, slides were placed in an oven set to 30oC for a 
minimum period of one day to allow the slides to dry out.  Once 
completely dry, slides were mounted with DPX mountant.  Before 
observing the slides under the microscope they were left overnight (in 
the fume hood at room temperature) to allow the mountant to set.  
Slides were observed under a light microscope Nikon 50i at x10, x20 
and x40 objectives and images were captured using the DS-2M/5M/Fi1 
camera with DS-U2/L2 controller and the EclipseNet software.  For 
each tissue and sample three sections were tested.  Multiple images 
were captured at several objectives for each tissue and sample and 
representative images are presented in this thesis. 
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2.12 Western Blotting 
 
 2.12.1 Selection and Preparation of Positive Controls  
 
For the antigens collagen type II and I the positive control tissues 
selected were canine articular cartilage and canine tendon respectively.  
These tissues were harvested as previously described.  After harvest, 
cartilage shavings were washed in PBS and weighed.  Pre-weighed 
cartilage was placed in a mortar which was pre-cooled using liquid 
nitrogen and crushed using a pre-cooled pestle.  Crushed cartilage was 
placed in an eppendorf and sample buffer containing protease inhibitors 
(Protease Inhibitor Cocktail, Sigma-Aldrich) was added (111mg 
cartilage, 100ȝO VDPSOH EXIIHU DQG ȝO SURWHDVH LQKLELWRUV SHU
eppendorf).  The recipe for sample buffer is given in Appendix B.  This 
solution was boiled for five minutes before being centrifuged at 10000xg 
for ten minutes.  The supernatant was split into aliquots which were 
subsequently stored at -80oC. 
 
Tendon tissue was harvested and washed as previously described.  
After washing tendons were cut into chunks and weighed (110mg of 
tendon tissue was placed in each eppendorf).  Tendon sections were 
placed in eppendorfs and snap frozen in liquid nitrogen. Pre-weighed 
tendon tissue was placed in a mortar which was pre-cooled using liquid 
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nitrogen and crushed using a pre-cooled pestle. Crushed tendon was 
placed in an eppendorf containing sample buffer (1ml) and protease 
inhibitors ȝO.   Samples were heated to 95oC for five minutes before 
being centrifuged at 10 000xg for ten minutes.  The supernatant was 
aliquotted into eppendorfs and stored at -80oC. 
 
For the antigens CD44 and Sox9, canine spleen and canine testis 
tissue lysates were used respectively.  Canine spleen and testis tissue 
was removed from a cadaver during post-mortem and placed in a -80oC 
freezer until collection.  Tissue was collected from the Veterinary 
Laboratories Agency, Sutton Bonington, transported on ice and placed 
immediately in the -80oC freezer until processing. 
 
To generate tissue lysates, testis and spleen tissue were homogenised 
in a TissueLyser II (Qiagen GmbH, Hilden, Germany).  For the 
homogeniser to work effectively, a maximum of 25mg of tissue should 
be placed in an eppendorf along with a ball bearing.  This is reduced to 
10mg for spleen tissue due to its high cell density.  Each tissue was 
weighed before being placed in an eppendorf containing a ball bearing.  
RIPA buffer (see Appendix B for recipe) containing protease inhibitors 
was also added to the tube (625ȝO 5,3$ EXIIHU  25ȝO SURWHDVH
inhibitors per 25mg of testis and 250ȝO 5,3$ EXIIHU  10ȝO SURWHDVH
inhibitors per 10mg of spleen tissue).  Samples were placed in the 
 160 
 
homogeniser for two runs (three minutes each) before being put on ice 
for 30 minutes.  Lysates were then centrifuged at 10000xg at 4oC until 
all the tissue fragments had sedimented into the bottom of the tube.  
The supernatant was split into sterile eppendorfs and stored at -80oC. 
 
 2.12.2 Preparation of Cellular Samples  
 
For cell monolayer lysates, all media was removed from the flasks and 
flasks were rinsed three times with sterile PBS.  Flasks were washed 
thoroughly to remove as many serum proteins as possible.  RIPA buffer 
containing protease inhibitors was added to the flasks (0.5ml RIPA 
bXIIHU  ȝO SURWHDVH LQKLELWRUV IRU D 7 PO 5,3$ EXIIHU  ȝO
SURWHDVH LQKLELWRUV IRU D 7 DQG PO 5,3$ EXIIHU  ȝO SURWHDVH
inhibitors for a T175), which were incubated with this solution, on ice, 
for 30 minutes.  All further procedures except centrifugation were 
performed on ice.  Cells were scraped off of the flask and the cell 
suspension was pipetted into a dounce glass homogeniser.  Cells were 
manually sheared 30 times using this homogeniser.  The solution 
containing the lysed cells was then transferred to eppendorfs and 
centrifuged at 10000xg at 4oC.  The supernatant was removed, placed 
in a sterile eppendorf and stored at   -80oC.  Samples were aliquotted 
after the protein concentration was determined (see section 2.12.3).  
Each tube contained DYROXPHHTXDWLQJ WRȝJRISURWHLQ 7KLVZDV
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done to minimise the number of freeze-thawing steps prior to using the 
sample on a western blot. 
 
Alginate beads were removed from six well plates and placed in a 
sterile petri dish.  Beads were washed briefly with sterile PBS to remove 
any remaining media.  Five beads were placed in each eppendorf 
containing dissolving buffer (55mM sodium citrate, 150mM NaCl and 
30mM EDTA).  Samples were vortexed for one minute.  All aliquots 
were then placed in a falcon tube and centrifuged at 200xg for ten 
minutes.  The supernatant was pipetted into a fresh falcon tube and 
stored at -80oC.  The cell pellet was resuspended in 0.5ml RIPA buffer 
and 20ȝOprotease inhibitors and incubated on ice for 30 minutes.  The 
cell solution was then transferred to a dounce homogeniser and cells 
were manually sheared, on ice, 30 times. The solution containing the 
lysed cells was then transferred to an eppendorf and centrifuged at 
10000xg at 4oC.  The supernatant was removed, placed in a sterile 
eppendorf and stored at -80oC.  Samples were aliquotted following 
determination of the protein concentration; each aliquot represented 
ȝJRISURWHLQ 
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 2.12.3 Determining Protein Concentration 
 
The Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Scientific) 
was used to determine the protein concentration of all samples, except 
the cartilage and tendon lysates, which were loaded onto gels 
volumetrically.  These latter two samples were prepared in sample 
buffer which would interfere with the protein assay. 
 
This assay works by detecting the reduction of Cu2+ to Cu1+ by protein.   
In particular, the macromolecular structure of the protein, the amino 
acids, cysteine, tryptophan and tyrosine and the number of peptide 
bonds are said to be involved in the reaction being detected by this 
assay.  The change in colour from green to purple is caused by BCA 
molecules binding to cuprous cations (Cu1+) at a ratio of 2:1. 
 
For the standard curve, BSA was diluted in RO water at a range of 
concentrations, 1500µg/ml, 1000µg/ml, 750µg/ml, 500µg/ml and 
250µg/ml.  Protein assays were performed in 96 well plates (Thermo 
Scientific) and each sample was loaded in triplicate.  Blank wells 
containing RO water only and RIPA buffer only were loaded first, 
followed by the BSA standards and then each sample.  10µl of blanks, 
standards and test samples were loaded.  200µl of working solution was 
then added to each well.  Working solution was prepared by mixing 50 
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parts of Reagent A (contains sodium carbonate, sodium bicarbonate, 
BCA and sodium tartrate in 0.1M sodium hydroxide) to 1 part Reagent 
B (contains 4% cupric sulphate).  Plates were then wrapped in 
aluminium foil and placed in a 37oC incubator for 30 minutes.  
Absorbance was measured at 540nm and protein concentration was 
calculated using the Multiskan Ascent V1.24 Plate reader and software. 
 
Occasionally the original sample was either too concentrated or dilute to 
be measured.  If the sample was too concentrated, it was further diluted 
in RO water and retested as above.  Samples that were too dilute were 
placed back the -80oC freezer to re-freeze.  Once frozen, samples were 
placed in a freeze drier (Alpha 1-2 LD plus, SLS) until completely dry 
(this varied depending on the starting volume of the sample).  The 
protein lysate was then resuspended in a smaller volume of RO water 
and the concentration was measured again following the same method 
as before. 
 
 2.12.4 Preparation of SDS-PAGE Gels  
 
Glass plates were wiped with weak HCl before being sprayed with 70% 
IMS to clean them.  Spacers were also cleaned with 70% IMS prior to 
use.  Pairs of plates and spacers were slid into the plate holder and 
screwed into place.  The bottoms of the plates were then wiped with 
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Vaseline, in order to prevent leakage.  The sealed plates were clipped 
into the gel casting stand and water was pipetted between the plates to 
check for leakage.  The water was removed and resolving gel (10%) 
was added (see table 2.3 for the components of the gel).  50% 
isopropanol was then pipetted on to the top of the gel to straighten it.  
Gels were left for 15 minutes to set at room temperature. Once set, the 
isopropanol was removed and the top of the gel was rinsed with RO 
water.  Stacking gel (4%) (see table 2.3 for gel components) was then 
pipetted on top of the resolving gel and a comb inserted.  This was left 
to set at room temperature for 45 minutes.  Once the gel had set, the 
plate holder was unclipped from the gel casting stand and clicked into 
the gel cassette, which was then placed in the tank.  The tank was then 
filled with running buffer (for the recipe, see Appendix B).  If gels were 
made in advance, the tank containing the gels were wrapped in cling 
film and kept in the fridge for a maximum of 48 hours. 
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Resolving Gel Stacking Gel Supplier 
Tris pH8.8 1.5M Tris pH6.8 0.625M Tris Base ± Fisher 
Scientific 
30% Acrylamide 30% Acrylamide Geneflow, 
Staffordshire, UK 
Sodium Dodecyl 
Sulphate 
Sodium Dodecyl 
Sulphate 
Sigma 
RO water RO water N/A 
TEMED TEMED Sigma 
Ammonium 
Persulphate 
Ammonium Persulphate Sigma 
 
Table 2.3: The components of an SDS-PAGE gel.  Where appropriate the supplier 
information has been given.  Exact quantities of each chemical are given in Appendix 
B. 
 
 2.12.5 Gel Electrophoresis  
 
Samples were removed from the -80oC freezer and thawed on ice.  
Gels were taken out of the fridge (if made in advance) and the combs 
were removed.  Sample buffer (for recipe see Appendix B) was 
prepared as a 5x stock and aliquots were kept at -20oC.  Sample buffer 
was thawed at room temperature.  Once samples had thawed, aliquots 
corresponding to 25µg of protein were pipetted into sterile eppendorfs 
and sample buffer was added (the final concentration of sample buffer 
in each tube was 1x).  Volumetrically loaded samples (already 
containing sample buffer) were aliquotted into sterile eppendorfs.  All 
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samples were heated to 95oC for five minutes in a heat block before 
being centrifuged at 295xg for two minutes.  This centrifugation aimed 
to draw all of the sample back down into the bottom of the tube.  Before 
loading samples onto the gel 3µl of a molecular weight marker 
(Precision Plus Protein Standards Kaleidoscope, Bio-Rad) was loaded 
into the first lane.  This was followed by the positive control and then the 
test samples.  The gel was routinely run for 1 hour at 150V, however 
the molecular weight marker was monitored during this time and on 
some occasions the gel need slightly longer to run. 
 
 2.12.6 Blotting  
 
Whilst gels were running, the PVDF membrane (Bio-Rad, Hertfordshire, 
UK) and filter paper (Fisher Scientific) were cut to size and the 
membrane activated.  In order for the proteins on the gel to bind to the 
membrane during transfer, the membrane needs to be activated.  
Membranes were activated by being placed in 100% methanol on a 
shaker for ten minutes at room temperature.  Following activation, 
membranes were washed in RO water and then placed in transfer 
buffer until needed.  Once cut to size, filter paper was soaked in transfer 
buffer; sponges in the transfer cassette were also soaked in transfer 
buffer. 
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Once the gels had stopped running, running buffer was removed and 
the tank containing the gels was rinsed twice with RO water.  Each gel 
was left in the cassette until the transfer cassette was prepared.  Firstly, 
the transfer cassette was placed with the black plate at the bottom.  A 
soaked sponge was placed on top, followed by three sheets of soaked 
filter paper.  The gel was then removed from the cassette and the 
stacking gel was cut off.  The remaining gel was rinsed in transfer buffer 
before being reversed and placed on the filter paper.  It is important to 
keep everything in the transfer cassette moist, so transfer buffer was 
added when necessary.  The activated membrane was then placed on 
top of the gel, followed by three sheets of pre-soaked filter paper.  
Finally, a second piece of soaked sponge was placed on top.  Any air 
bubbles were rolled out using a pipette.  Cassettes were then clipped 
shut and placed inside the transfer tank.  Once all cassettes were 
prepared (maximum of four in one tank), the tank was filled with transfer 
buffer.  Transfer was set to 100V for two hours at room temperature. 
 
After transfer, membranes were placed in 5% milk (Marvel, Dublin, 
Ireland) in TBS-Tween (the recipe for TBS-Tween is in the Appendix B) 
for two hours at room temperature on a shaker.  This was to block non-
specific binding of the primary antibodies. 
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 2.12.7 Coomassie Blue and Ponceau S 
 
After transfer, gels were placed in Coomassie Blue stain (see Appendix 
B for full recipe) on a rocker overnight.  Gels were then placed in 
destaining buffer (see Appendix B for recipe) overnight.  Following 
destaining, gels were rinsed with RO water and then stored in RO water 
at room temperature until imaging.  Gels were scanned using the 
ImageQuant 300 machine.  This was to check the transfer of the 
proteins from the gel to the membrane.  Some gels were also stained 
prior to transfer, (see figure 2.7 to see the difference before and after 
transfer). 
 
Figure 2.7: SDS-PAGE gels stained with Coomassie Blue before and after 
transfer. (a) Before transfer (b) After transfer.  Some of the higher molecular 
weight proteins and more abundant proteins are left on in the gel after transfer. 
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Another way to assess transfer is to stain the membrane with Ponceau 
S.  Membranes were incubated with Ponceau S stain (0.1% Ponceau S 
(Sigma) in 5% acetic acid) for ten minutes at room temperature on a 
shaker.  After staining, membranes were washed in RO water until the 
background was clear.  Membranes were photographed using a Sony 
Cyber-shot DSC-W30 digital camera. 
 
 2.12.8 Primary and Secondary Antibody Incubation  
 
Following incubation with block, membranes were incubated with 
primary antibody, diluted in 5% milk in TBS-Tween, overnight at 4oC on 
a roller.  Membranes were then washed five times with TBS-Tween (five 
minutes each) before being incubated with the secondary antibody 
(diluted in 5% milk in TBS-Tween) for one hour at room temperature on 
a roller.   After this incubation, membranes were washed as stated 
before. 
 
 2.12.9 Detection  
 
Following the final wash, membranes were incubated with 
chemiluminescence solution (Biological Industries, Haemek, Israel) for 
five minutes at room temperature.  Excess chemiluminescence solution 
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was removed and the membranes were placed in a plastic wallet in an 
x-ray cassette.  The plastic sheets were wiped to further remove any 
excess chemiluminescence solution.  All further steps were performed 
in the dark.  X-ray films (CL-Xposure Film, Thermo-Scientific and 
Amersham Hyperfilm ECL, SLS) were placed on top of the membranes 
and the cassette was closed.  Membranes were exposed to films 
between one second and ten minutes.  After the appropriate exposure 
time had elapsed, films were removed from the cassette and placed into 
the X2 auto-red film developer.  Films were scanned using the 
ImageQuant 300 machine.  Films to which densitometric analysis was 
applied were scanned using a GS-800 Calibrated Densitometer.  
Densitometric analysis was performed using ImageJ and proteins of 
interest were normalised to expression of the housekeeping gene ȕ-
actin.  
 
2.13 Statistical Analysis 
 
Statistical analysis was performed using the software GraphPad Prism 
5.  One way ANOVA with 7XNH\¶V PXOWLSOH FRPSDULVRQ post-test was 
applied to data with a p value of <0.05 being significant.
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3. Chondrocyte Dedifferentiation in Monolayer 
Culture 
 
3.1 Background 
 
In chondrocyte biology, dedifferentiation usually refers to loss of the 
chondrocytic phenotype and adoption of a more fibroblastic phenotype. 
An early study into the loss of the chondrocyte phenotype in vitro was 
conducted by Holtzer and colleagues (Holtzer et al., 1960).  The 
authors sought to determine whether the differentiated state of a cell 
would be retained after several divisions in vitro (Holtzer et al., 1960).    
The authors claim that cells isolated from ten-day chick embryos had a 
reduced ability to retain the differentiated phenotype in pellet culture 
with increased monolayer culture (Holtzer et al., 1960). 
 
Articular cartilage is very poor at repairing itself and as such cell and 
tissue engineering strategies are being extensively explored to repair 
damaged cartilage.  Autologous Chondrocyte Implantation (ACI) is a 
technique favoured forrepairing articular cartilage defects larger than 
4cm2 (Schulze-Tanzil, 2009, Oldershaw, 2012).  ACI has undergone 
several modifications since its inception in 1987   (Ringe and Sittinger, 
2009, Schulze-Tanzil, 2009, Brittberg, 2010, Zeifang et al., 2010, 
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Oldershaw, 2012), but  all forms of the ACI method involve isolation and 
expansion of chondrocytes in monolayer culture before being placed 
into the defect (Brittberg, 2008, Brittberg, 2010, Zeifang et al., 2010, 
Oldershaw, 2012).    A major problem with the large cell requirements 
for these techniques is that the cells begin to lose their phenotype 
during in vitro expansion.    Despite the advances in ACI technology, 
treatment of cartilage lesions are still a major challenge for orthopaedic 
surgeons, particularly when there are added complications, such as 
osteoarthritis (Filardo et al., 2013).  
 
Loss of the chondrocyte phenotype whilst undergoing in vitro expansion 
has been reported in many species including, humans (Archer et al., 
1990, Schnabel et al., 2002, Goessler et al., 2006, Yang et al., 2006b, 
Tew et al., 2008), goats (Darling and Athanasiou, 2005), cows (Brodkin 
et al., 2004, Shao et al., 2013), pigs (Watt, 1988) and rabbits (Malemud 
and Papay, 1984, Baici et al., 1988).  However, all these studies have 
differed in their approach to chondrocyte expansion, their assessment 
of dedifferentiation and how this is information is reported.     
 
One difference is the age of the animals used in the studies.  In the 
human studies for example, the average age ranges from 29.4 years 
(Hamada et al., 2013) to 84 years (Schnabel et al., 2002).  Both of 
these papers aimed to study the phenotypes of chondrocytes in culture 
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with the latter looking to identify markers to distinguish dedifferentiated 
cells.  Some studies have investigated differences in chondrocytes with 
age.  Guerne et al (1995) demonstrated that DNA synthesis in human 
chondrocytes decrease with age (samples taken from humans aged 
between late twenties and early eighties; the exact ages are not given).   
A more recent study investigated how ageing affects human 
chondrocyte yield, proliferation, chondrogenic capacity following 
expansion and response to growth factors during culture (Barbero et al., 
2004).  The authors claim that cell viability was unaffected by age but 
the cell yield did decrease with age.  Proliferation of chondrocytes was 
similar across all age groups (twenties, thirties, forties, fifties, sixties, 
over seventy).  Proliferation was enhanced in all groups cultured with 
JURZWK IDFWRUV 7*)ȕ )*)-2 and PDGF-BB).  GAG synthesis was 
similar across all ages although a reduction with age was seen in 
cultures with growth factors (Barbero et al., 2004).  Another research 
group states that the population doublings of rabbit chondrocytes 
decrease with age, quoting 11-12 doublings for four week old rabbits, 8-
10 for six month old rabbits and 3-4 doublings for three and a half year 
old rabbits (Evans and Georgescu, 1983).  This group also made the 
observation that canine chondrocytes are smaller than those from 
human and rabbit cartilage and that they maintain their morphology in 
culture longer than rabbit chondrocytes (Evans and Georgescu, 1983).  
A different group showed that the number of cells present in cartilage 
was higher in younger rabbits (1-2 months) compared to older rabbits 
(four years) (Adolphe et al., 1983).  They also found that chondrocytes 
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in the latter group had a larger volume.  Cell population growth was 
shown to be faster with younger chondrocytes (Adolphe et al., 1983).  A 
more recent paper looked at the transcriptome of equine chondrocytes 
from young (four years) and old (>15 years) horses (Peffers et al., 
2013).  A variety of genes were shown to be differentially expressed in 
the two groups with collagen type II alpha 1, biglycan and hyaluronan 
synthase 3 expression lower in older chondrocytes (Peffers et al., 2013).  
In some literature, the ages of the animals from which the cartilage is 
harvested is not given (Watt, 1988, Goessler et al., 2006, Tew et al., 
2008, Shao et al., 2013).  Although it must be acknowledged that in 
some cases, particularly when working with non-human species, it is 
not possible to obtain accurate background information about samples.  
For example, the pig tissue used by Watt and colleagues (1988) was 
obtained from a butcher.  Taking all this into consideration, there may 
be differences in chondrocyte phenotype which are attributable to age 
of the animal from which tissue was harvested; however it is not always 
possible for accurate ages to be obtained.  This was sometimes the 
case with the canine material used in this thesis (see Appendix A for 
animal details). 
 
In addition to this, the information provided in terms of seeding 
chondrocytes into a culture vessel differs considerably between 
SXEOLFDWLRQV  6RPHSDSHUVGRQ¶W OLVW DQ\ FHOO QXPEHUV (Malemud and 
Papay, 1984, Hamada et al., 2013, Shao et al., 2013), some give cell 
 175 
 
densities (Schnabel et al., 2002, Darling and Athanasiou, 2005, Yang et 
al., 2006b, Tew et al., 2008, Nadzir et al., 2011) and others state the 
total number of cells per vessel (Baici et al., 1988, Watt, 1988, Archer et 
al., 1990).  The exact cell seeding information given in a range of 
papers, covering a range of species is given in Table 3.1.  One of the 
papers listed in Table 3.1 gives two cell densities (Watt, 1988).  This is 
because the purpose of the work was to assess the affect of cell density 
on the phenotype of the cultured chondrocytes (Watt, 1988).  Collagen 
type I and II expression was detected in cultures at both densities but 
staining was stronger and more widespread in high density cultures 
particularly with collagen type II (Watt, 1988).  This would suggest that 
seeding density has an impact on chondrocyte phenotype and therefore 
should be a consideration when expanding chondrocytes in monolayer 
culture.  Another paper detailing a protocol for culturing immature 
murine articular chondrocytes provides recommended seeding densities 
for various tissue culture plates in order to limit dedifferentiation (Gosset 
et al., 2008).  This again suggests seeding density plays an important 
role in the phenotype of chondrocytes in culture and should therefore be 
documented. 
 
Another aspect of the chondrocyte expansion process that differs in the 
literature is passaging.  In some publications, culture time is only 
reported in terms of the numbers of days or hours with no indication of 
the numbers of passages undertaken during that time.  One research 
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group refer to low, medium and high density cultures but this only refers 
to the number of days, rather than cell or passage number (Malemud 
and Papay, 1984).  When passage details are given, there is a 
considerable difference between the number of passages observed.  
Some groups have expanded the cells to passage two (P2) (Schnabel 
et al., 2002, Yang et al., 2006b) or  passage three (P3) (Munirah et al., 
2010); others have left the culture for slightly longer up to  passage four 
(P4)  (Baici et al., 1988, Darling and Athanasiou, 2005, Hamada et al., 
2013) and  passage five (P5) (Shao et al., 2013).  One group looked at 
human chondrocytes expanded in monolayer up to passage 17 (P17) 
(Tew et al., 2008).  The authors of this paper state that confluence took 
ten days but provide no further information on the exact level of 
confluence at each passage.  Other researchers do give more detailed 
information in terms of confluence at passage; two papers quote 80% 
confluence at passage for rabbit (Nadzir et al., 2011) and human 
(Hamada et al., 2013) chondrocytes, whereas in another paper the cell 
density prior to passage is given (5x104 cells/cm2) (Darling and 
Athanasiou, 2005).  It should also be acknowledged that passage is a 
subjective term and that some researchers believe population doublings 
are a more accurate way of monitoring cells in culture (Greenwood et 
al., 2004).  One group aiming to identify a measurable parameter for 
chondrogenic capacity of monolayer-expanded chondrocytes provided 
an initial seeding density (20000 cells/cm2), subsequent densities 
(10000 cells/cm2), confluence at passage (80-90%) and population 
doublings (Giovannini et al., 2010).  Another research group assessed 
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population doubling limit of human chondrocytes cultured in 5% and 
21% oxygen (Moussavi-Harami et al., 2004).  They showed that the 
limit was enhanced in the lower oxygen group (60-70 doublings) 
compared to the 21% oxygen group (30-40) (Moussavi-Harami et al., 
2004).  Considering chondrocytes in vivo are exposed to relatively low 
oxygen tensions and do not proliferate, it is perhaps surprising that a 
higher population doubling limit was observed at the lower oxygen 
tension. 
 
 
Table 3.1: Seeding details given in different studies for chondrocytes from 
various species. How chondrocyte seeding is described varies between papers and 
the numbers of cells also differs between studies.  * and ** classified as low density 
and high density respectively in (Watt, 1988). 
 
Species Seeding Information Reference 
Human 7.9x104 cells/cm2 (Archer et al., 1990) 
1.5x104 cells/cm2 (Schnabel et al., 2002) 
5.0x103 cells/cm2 (Yang et al., 2006b) 
2.0x104 cells/cm2 (Tew et al., 2008) 
Goat 1.6x104 cells/cm2 (Darling and Athanasiou, 
2005) 
Pig 1.04x104 cells/cm2* (Watt, 1988) 
1.04x102 cells/cm2** 
Rabbit 5.24x104 cells/cm2 (Baici et al., 1988) 
1.0x104 cells/cm2 (Nadzir et al., 2011) 
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In addition to differences in culture technique, there are also differences 
in the proteins studied to determine the phenotype of chondrocytes 
cultured in vitro. Tables 1.4 and 1.5, Chapter 1, show various markers 
which have been shown to be upregulated (1.4) and downregulated (1.5) 
in monolayer-expanded chondrocytes.  
 
Out of the proteins listed in the Tables 1.4 and 1.5, four (collagen types 
I and II, Sox9 and CD44) were chosen to assess the phenotype of 
canine chondrocytes expanded in monolayer.  The reasons behind the 
selection of these proteins are given in section 1.5.3, Chapter 1.   
 
Although it is known that chondrocytes dedifferentiate during monolayer 
expansion, the nature of how this change in phenotype is observed 
varies considerably in the literature.  The aim and subsequent 
hypotheses of this chapter were as follows: 
 
Aim: To examine the phenotype of canine articular chondrocytes 
expanded to P5 in monolayer and confirm dedifferentiation. 
 
Hypothesis One: Canine chondrocytes will alter in morphology with 
increasing passage, adopting a more fibroblastic 
phenotype. 
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Hypothesis Two:   Expression of collagen type II and Sox9 will decrease 
with increasing passage whereas collagen type I and 
CD44 will increase. 
 
 In addition to this, due to the limited number of antibodies available that 
are already known to cross-react with canine antigens, antibody 
evaluation and validation was also expected to be conducted. 
 
3.2 Results 
 
3.2.1 Change in Chondrocyte Morphology with Increasing   
Passage 
 
To assess the change in morphology of freshly isolated chondrocytes, 
the cells were expanded in monolayer until P5.  The original plan was to 
seed cells into flasks at a known density of 8,000 cells/cm2 (200,000 
cells in total per flask) for P0 and 20,000 cells/cm2 (500,000 cells in total 
per flask) for later passages (Figure 3.1).  These figures were based on 
previous cell counts obtained.  From two previous canine samples 
600,000 and 604,000 chondrocytes were freshly isolated from cartilage 
shavings.  On both occasions, these cells were split into three T25 
flasks, at densities of 8,000 cells/cm2 and 8,053 cells/cm2 respectively.  
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For these same cells, flasks were pooled at P1 to be seeded into larger 
(T75) flasks.  The three T25 flasks seeded at a density of 8,000 
cells/cm2 generated a total of 13.95x106 cells and two flasks seeded at 
a density of 8,053 cells/cm2 generated a total of 3.54x106 cells.  Taking 
into consideration the difference in cell numbers obtained and the 
smaller flask size in the plan a seeding density of 20,000 cells/cm2 was 
deemed appropriate. 
 
Another part of the monolayer expansion plan was to keep the time of 
passage consistent, some groups have controlled passage by time 
point (cells were passaged every seven days (Lee et al., 2003)).  
However it was deemed more appropriate to assess the level of 
confluence prior to passaging.  It was decided that cells should be 
passaged once they had reached 90-95% confluence; this would 
generate a relatively high cell yield without the cells becoming over-
confluent. 
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Figure 3.1 Monolayer cell culture plan.  Chondrocytes were closely monitored 
throughout the culture process and passaged once they had reached 90-95% 
confluence.  Diagram is representative of all passages, with the cell density used at 
P1 planned to be used at all subsequent passages.  The dashed arrow indicates a 
flask that was used to generate samples for western blotting.  In subsequent passages 
three flasks from each passage were used. 
 
Elements of the cell culture plan had to be adapted based on the tissue 
available.  For example, the first tissue to become available after the 
cell culture plan was devised was cartilage shavings sent from Dr 
Rebecca Lewis, University of Liverpool.  The initial yield of 
chondrocytes isolated from this tissue was too low to be counted 
accurately and the entire population was seeded into one T25 flask.  
The cell culture plan was followed as closely as possible with these 
Harvest articular cartilage and 
isolate chondrocytes using 
collagenase
Perform cell count and seed 
cells into 3 T25s at a minimum 
density of 8000 cells/cm2 (total 
of 200, 000 cells)
Monitor the cells every day, taking 
images of each flask and changing 
media every 2-3 days. Split when 
90-95% confluent.
Split each T25 into three further T25s for P1.  
Seeding at a minimum density of 20, 000 cells/cm2
(500, 000 cells in total)
Monitor the cells every day, taking 
images of each flask and changing 
media every 2-3 days. Split when 
90-95% confluent.
Use for 
downstream 
assays
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cells however, cell densities were far lower (between 7,000-8,500 
cells/cm2) at each passage.  At P5 the seeding density was just under 
3,400 cells/cm2).  Due to the lack of an initial cell count and low seeding 
densities, the phenotypic analysis of these cells is not shown, as it 
would not truly represent typical canine chondrocyte culture. 
 
The next tissue to become available was cartilage was harvested from 
the forelimbs of a four year old Rottweiler. After enzyme treatment there 
were enough cells to seed into three T25 flasks at a density of 13,200 
cells/cm2 (330,000 cells in total per flask).  Cells were expanded in 
monolayer up to P5.  In another change to the plan, it was decided that 
the cell density should be kept as consistent as possible throughout all 
passages, including P0. The seeding densities at each passage are 
listed in Figure 3.2b.  Each passage took between eight and nine days 
to reach 90-95% confluence, except passage five which took eleven 
days.  At each passage the viability of the cells was assessed. It ranged 
from 98.0% to 95.0%.  The cumulative population doublings were also 
calculated during the monolayer expansion of these cells.  Cell doubling 
was relatively slow during initial expansion and then was in exponential 
phase until day 25.  After this point cell growth slowed down and after 
34 days began to decline. 
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Figure 3.2: Monolayer expansion of canine chondrocytes. (a) Cumulative 
population doublings of chondrocytes expanded in monolayer (b) passage, seeding 
density and length of culture for the same cells as in (a).  Cells were isolated from 
cartilage harvested from a four year old Rottweiler.  Population doublings were 
calculated using the formula: PD = [log(N/Xo)] / log(2), where PD = population 
doubling, N = final cell count, Xo = starting (baseline) cell count. 
 
The morphology of the cells was closely monitored throughout the 
culture process.  Before attaching to the cell culture plastic, freshly 
isolated chondrocytes appeared spherical in shape (Figure 3.3a). Once 
attached, chondrocytes were flatter and more ovoid in shape (Figure 
3.3b).  At P0 at 90-95% confluence, the majority of the cells had an 
ovoid morphology but a few had already begun to stretch out and adopt 
a more fibroblastic morphology (Figure 3.3c).  The stretching and 
flattening out became more pronounced from P0 to P5 (Figure 3.3).  
Cells also increased in size with increasing passage and by passage 
five, cells began to grow in clusters rather than a continuous monolayer 
(Figure 3.3). 
0 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5
0
1
2
3
4
5
6
7
L e n g th  o f C u ltu re  (d a y s )
C
u
m
u
la
tiv
e
 
P
o
pu
la
tio
n
 
D
o
u
bl
in
gs Passage Seeding density 
(cells/T25 flask)
Length 
of 
culture 
(days)
0 330000 9
1 356000 8
2 361875 8
3 335714 9
4 371428 8
5 307333 11
ba
 184 
 
 
 
 
 
a b
c d
e f
g h
 185 
 
Figure 3.3: Morphology of canine chondrocytes expanded in monolayer.  
Primary canine chondrocytes (isolated from cartilage from a four year old Rottweiler) 
at various stages of monolayer culture. (a) one day after seeding, (b) four days after 
seeding (c) P0 at 90-95% confluence, (d) P1 at 90-95% confluence, (e) P2 at 90-95% 
confluence, (f) P3 at 90-95% confluence, (g) P4 at 90-95% confluence, (h) P5 at 90-
95% confluence.  Magnification: x100, scale bar: 50µm.  Cells appear spherical before 
attachment.  Once attached the cells adopt a polygonal morphology and become 
increasingly elongated with increasing passage. 
 
3.2.2 Antibody Evaluation and Western Blotting 
Optimisation 
 
To assess the dedifferentiation and redifferentiation of canine 
chondrocytes when expanded in monolayer and cultured three-
dimensionally, the expression of collagen types I and II, CD44 and Sox9 
was going to be assessed.   In order to do this, the cross-reactivity of 
antibodies for these antigens in canine tissue was evaluated. 
 
First, a panel of antibodies from Aviva Systems Biology was applied to 
canine chondrocytes fixed in 96-well plates. All of the antibodies were 
selected based upon the broad cross-reactivity stated in the datasheets.  
Three of the antibodies (ARP37986, ARP61023 and P100797) listed 
dog as one of the species they react with.  Each antibody was tested at 
a range of concentrations (5µg/ml, 2µg/ml, 1µg/ml and 0.5µg/ml).  Out 
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of the two antibodies targeted against the C-terminus of collagen type I, 
the second antibody tested (ARP59999), appeared to have a more 
intense and specific staining (Figure 3.4 a-d).  One of the SOX9 
antibodies (ARP37986) and a collagen type I antibody targeted against 
the N-terminus had strong and specific staining when compared to the 
isotype control (Figure 3.4 g-h and k-l).  The other antibody targeted 
against Sox9 (P100797) and the antibody targeted against CD44 
appeared to have the same pattern of staining as the isotype control, 
indicating non-specific binding (Figure 3.4 e-f and i-j). 
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a b c d
e f g h
i j k l
Figure 3.4:  Evaluation of Aviva antibodies for cross-reactivity with canine antigens. Canine chondrocytes were seeded into 96-well plates and 
fixed using ice-cold methanol.  (a) COL1A1 (ARP59998), (c) COL1A1 (ARP59999), (e) CD44 (ARP61023), (g) SOX9 (ARP37986), (i) SOX (P100797), 
(k) COL1A2 (ARP58441); (b, d, f, h, j and l) Isotype control (rabbit polyclonal IgG-ChIP grade, ab27478).  Concentration of all antibodies: 1µg/ml. 
Secondary antibody: goat polyclonal to rabbit IgG DyLight 488 (ab98462): 1:300 dilution.  Magnification: x100, scale bar: 100µm.  The antibodies used in 
(c), (g) and (k) appear to stain specifically whereas the staining in (a), (e) and (i) looks to be non-specific. 
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Alongside the Aviva antibodies, a DSHB antibody targeted against 
collagen type II was tested for its cross reactivity with canine antigens.  
The CIIC1 antibody had a range of species listed under cross-reactivity 
including human, bovine, ovine and mouse and was selected for this 
reason.  This antibody was applied to cells that had been grown and 
fixed on sterile coverslips.  It was tested at a range of dilutions from 
undiluted to 1:100 (Figure 3.5).  There was no difference in staining 
between any of the dilutions indicating non-specific binding.  However it 
should be noted that an isotype control was not included with this 
experiment and therefore limited conclusions can be drawn.  Therefore, 
this test was repeated (along with an isotype control) using cells seeded 
and fixed in 96-well plates and all concentrations were completely 
negative. 
 
 
 
 
 
 
 
 
  
189 
 
 
Figure 3.5:  Evaluation of the DSHB antibody CIIC1 for cross-reactivity with 
canine antigens.  Cells were seeded onto coverslips and fixed with ice-cold methanol.  
The primary antibody was tested at the following dilutions (a) neat, (b) 1:1, (c) 1:5, (d) 
1:10, (e) 1:50 and (f) 1:100.  Secondary antibody: Fluorescein anti-mouse IgG (H+L) 
(FI-2000): 1:100 dilution. Magnifcation: x100, scale bar: 50µm.  Staining was similar at 
all concentrations, indicating non-specific binding. 
 
To confirm the cross-reactivity with canine antigens, western blotting 
was carried out. Throughout the antibody validation process the 
a
c
b
d
e f
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western blotting protocol was deconstructed to identify the optimum 
method for each step.  This optimisation is described in section 3.2.2.1 
before moving on to the validation of specific antibodies for individual 
antigens; collagen type I (section 3.2.2.2), collagen type II (section 
3.2.2.3), Sox9 (section 3.2.2.4) and CD44 (section 3.2.2.5). 
 
3.2.2.1 Western Blotting Protocol Optimisation 
 
First, the protein profiles of all samples were checked. Samples were 
loaded onto and ran on an SDS-PAGE gel.  Gels were then 
immediately placed in Coomassie Blue rather than proceeding to 
transfer (Figure 3.6).  This generated a reference for all samples which 
could be checked against if problems were encountered further 
downstream.  It also enabled the assessment of appropriate loading for 
each sample, particularly for the canine positive control lysates. For 
canine cartilage, spleen and testis lysates a clearer banding pattern 
was observed with the higher load (Figure 3.6a).  The equine cartilage 
lane (lysate kindly given by Adam Williams, University of Nottingham) 
was completely blank.  This may have been due to the sample being 
too dilute.  For the canine testis lysate, 10µg seemed an optimal volume 
for loading as the gel began to become overloaded when 20µg was 
loaded.  For the dedifferentiation samples (canine chondrocyte lysate 
samples from P0 to P5), the protein banding was similar across all 
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samples, with bands throughout the length of the gel (Figure 3.6b and 
c).  In the second gel containing canine chondrocyte lysates, the lanes 
spread a little, this may be due to there being spaces between the lanes 
(Figure 3.6c). 
Figure 3.6: SDS-PAGE gels of positive control tissues and chondrocyte cell 
lysates stained with Coomassie Blue.  This was done to generate a protein profile 
reference for all samples.  (a) gel containing canine and equine positive control tissue 
lysates.  Gel was scanned in reverse to show the bands more clearly (b) and (c) gels 
containing canine chondrocyte lysates.  MW: molecular weight marker, C1: canine 
cartilage lysate ȝO & FDQLQH FKRQGURF\WH O\VDWH ȝO ( HTXLQH FKRQGURF\WH
O\VDWH ȝO6 FDQLQHVSOHHQ O\VDWH ȝJ6 FDQLQHVSOHHQ O\VDWH ȝJ7
FDQLQH WHVWLV O\VDWHȝJ7FDQLQH WHVWLV O\VDWHȝJ7QFDQLQH WHQGRQ O\VDWH
ȝO7QFDQLQHWHQGRQO\VDWH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.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The next stage of the western blotting process to be optimised was the 
transfer time and conditions.  Canine and equine samples were tested 
alongside porcine diaphragm cell lysate (kindly provided by Dr Zoe 
Redshaw, University of Nottingham).  Two identical gels were either 
transferred at 100V for two hours at room temperature (short-term) or at 
30V overnight at 4oC.  The blots were probed with an antibody targeted 
against the housekeeping gene histone H3.  An aliquot of this rabbit 
polyclonal anti-histone H3 antibody (ab1791) was kindly given by Dr 
Zoe Redshaw, University of Nottingham. This antibody had previously 
been shown to work in the porcine sample, consistently detecting a 
single band at 20kDa; therefore this was included as a positive control.  
The predicted molecular weight of this antigen is 15kDa but the 
datasheet advises that the antibody will detect a band at 17kDa. There 
was a band at 15kDa in the porcine sample and at around 17kDa in the 
canine cartilage, spleen and testis samples (Figure 3.7c and d).  No 
band was detected at the predicted molecular weight in the equine 
sample (equine chondrocyte lysate kindly provided by Ismail Hdud, 
University of Nottingham). In terms of transfer time, there seemed to be 
little difference in the bands detected on the blot between the short and 
long transfer; however the gels stained with Coomassie Blue post-
transfer indicate that the short-term transfer was more efficient (Figure 
3.7a and b).  Therefore short-term transfer was routinely adopted as 
part of the protocol. 
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Figure 3.7: Detection of histone H3 in porcine, canine and equine samples, 
comparing short-term and long-term transfer. (a) and (b) SDS-PAGE gels stained 
with Coomassie Blue after two hours of transfer at 100V at room temperature (a) and 
overnight transfer at 30V at 4oC (b). (c) and (d) western blots for histone H3, exposure: 
one second.  (c) short-term transfer and (d) long-term transfer.  MW: molecular weight 
marker, P: porcine diaphragm satellite cell l\VDWH ȝJ & FDQLQH FDUWLODJH O\VDWH
ȝO 6 FDQLQH VSOHHQ O\VDWH ȝJ 7 FDQLQH WHQGRQ O\VDWH ȝO ( HTXLQH
FKRQGURF\WHO\VDWHȝJ Transfer time had little effect on the protein bands detected 
on the blot but the stained gels indicate the shorter transfer was more efficient. 
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A frequent problem encountered during antibody validation was the 
detection of multiple non-specific bands.  Therefore, the next part of the 
western blotting process to be optimised was blocking times and 
solutions.  Blocking with 5% milk in TBS-Tween for two hours at room 
temperature was compared with using 3% BSA in TBS-Tween for two 
hours at room temperature.  It was also decided to test whether diluting 
the primary antibody in TBS-Tween alone or in blocking solution made 
a difference to the bands detected.  H4C4, a DSHB antibody targeted 
against CD44, was selected for this test and three different 
concentrations of the antibody were used for each condition.  The 
conditions are summarised in Table 3.2.  The highest concentration 
used was 0.5µg/ml, which was the same as was used previously.  As 
there were non-specific bands detected by this antibody in a previous 
blot, the other two concentrations were lower to try and further reduce 
non-specific binding.  Secondary antibody conditions were matched to 
that of the primary. 
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Antibody 
Dilution 
(Concentration 
in µg/ml) 
Blocking and Primary Antibody Conditions 
 Milk 
Block 
BSA 
block 
1oAb 
(TBS) 
1oAb 
(TBS+Milk) 
1oAb 
(TBS+BSA) 
1:1144 
(0.5) 
9   9    
9    9   
 9  9    
 9    9  
1:1500 
(0.38) 
9   9    
9    9   
 9  9    
 9    9  
1:2000 
(0.29) 
9   9    
9    9   
 9  9    
 9    9  
 
Table 3.2: Optimisation of blocking and primary antibody conditions using H4C4.  
H4C4 was used at three different concentrations. Milk block: 5% milk in TBS-Tween, 
BSA: 3% BSA in TBS-Tween, TBS: TBS-Tween only.  When the primary antibody 
contained blocking solution, a stock solution of the block was made and part of this 
was used to dilute the primary antibody.  Secondary antibody conditions were 
matched to that of the primary. 
 
Three bands were detected in the majority of the blots, even in the 
negative controls where the primary antibody was omitted (Figure 3.8).    
The multiple bands could indicate non-specific binding of the primary 
antibody; however as some of these bands were also present in the 
negative control, this may suggest cross-reaction with the secondary 
antibody.  Interestingly, the milk block appeared to be more effective 
than BSA at the higher antibody concentrations; however, the opposite 
was the case at the lowest antibody concentration.  Out of all the 
combinations, blocking with 5% milk and diluting the primary antibody in 
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milk appeared to be the most efficient at reducing non-specific binding.  
Even after ten minutes exposure, most of the bands were quite faint.  
Therefore, four blots (two blocked with milk and two blocked with BSA) 
were selected to be re-probed with more concentrated primary antibody.  
Two concentrations were tested, 1.1ȝJ/ml (1:500) and 2.ȝJ/ml (1:200).  
There were no clear bands detected on any of the four blots; only 
background staining was observed.  The background staining was 
weaker on the blots blocked with milk, further indicating milk to be the 
optimum blocking solution.  To confirm whether milk was more efficient 
at blocking non-specific binding, new gels were run with different 
samples and a different antibody was selected for testing.  This time the 
Aviva anti-Sox9 antibody (ARP37986) was chosen and used at two 
different concentrations, 1.44ȝJ/ml (1:700) and 1.0ȝJ/ml (1:1000).  
There was a considerable difference between the two blocking solutions; 
there were multiple bands in all samples in the blots blocked with 3% 
BSA (Figure 3.9).  The binding appeared to be much more specific in 
the blots blocked with 5% milk (Figure 3.9a and b).  However a band at 
the predicted molecular weight of 56kDa only appears in the blots 
blocked with 3% BSA (Figure 3.9c and d). 
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Figure 3.8: Optimisation of blocking for western blotting using H4C4. The DSHB 
anti-CD44 antibody, H4C4, was selected to assess the affect of blocking material on 
WKHEDQGVGHWHFWHG+&ZDVWHVWHGDW WKUHHGLIIHUHQWFRQFHQWUDWLRQVȝJPOD
ȝJPOcDQGȝJPOd). (b) Blots incubated with secondary antibody only. 1: 
Block: 5% Milk; Primary Antibody: TBS-Tween only, 2: Block: 5% Milk; Primary 
Antibody: 5% Milk, 3: Block: 3% BSA; Primary Antibody: TBS-Tween only, 4: Block: 
3% BSA; Primary Antibody: 3% BSA.  For each of these conditions, the secondary 
antibody conditions matched the primary. 5: Block: 5% Milk, Secondary Antibody: 
TBS-Tween only, 6: Block: 5% Milk, Secondary Antibody: 5% Milk.  Milk and BSA 
were diluted in TBS-Tween and the secondary antibody was used at 1:5000. MW: 
molecular weight marker, S: canine spleen l\VDWHȝJ([SRVXUHWHQPLQXWHV  5% 
Milk was more effective at blocking than non-specific binding that 3% BSA, except at 
the lowest concentration where 3% BSA appeared to be more effective. 
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Figure 3.9: Optimisation of blocking for western blotting using an anti-Sox9 
antibody (ARP37986).  The primary antibody was tested at two concentrations, 
ȝJPO(a) and (c) and ȝJPO(b) and (d).  Blots were either blocked with 5% milk 
(a) and (b) or 3% BSA (c) and (d).  Exposure: 30 seconds. T: canine testis lysate (10 
ȝJ), C: canine cartilage lysate (5ȝl), Ch: P2 canine chondrocyte lysate (25ȝJ).  5% 
milk was clearly more effective at blocking non-specific binding; however a band at the 
predicted molecular weight of 56kDa was only detected in the blot blocked with 3% 
BSA.  The red box indicates the band of interest. 
 
After the general optimisation of the western blotting process, the 
following steps were incorporated into the standard protocol, which was 
used for all test samples.  Firstly, all gels were transferred for two hours 
at 100V at room temperature (short-term transfer).  Secondly, 
membranes were blocked in 5% milk in TBS-Tween for two hours at 
room temperature and finally, all antibodies were prepared in 5% milk in 
TBS-Tween. 
 
The following sections detail the processes involved in identifying a 
suitable primary antibody for the target canine antigens, collagen types I 
and II, Sox9 and CD44. 
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3.2.2.2 Antibody Evaluation: Collagen Type I 
 
The first step to assess cross reactivity with canine tissue was to test 
the antibody on canine tissue lysates where the antigen of interest is 
abundant. For collagen type I this was canine tendon lysate. Three 
antibodies targeted against collagen type I from Aviva Systems Biology 
were tested for their cross reactivity with canine antigens.  Two of these 
antibodies, ARP59998 and ARP59999, were targeted against the C-
terminus of collagen type I and have a predicted molecular weight of 
137kDa.  The other collagen type I antibody (ARP58441) was targeted 
against the middle region and had a predicted molecular weight of 
150kDa.  The banding pattern observed in the positive control lanes 
was different for each of the three antibodies (Figure 3.10).  For two of 
the antibodies (ARP59999 and ARP58441), there was a strong band 
detected at around 250kDa (Figure 3.10b and c).  The latter antibody 
detected a second strong band at around 110kDa (Figure 3.10c). The 
other antibody targeted against collagen type I (ARP59998) detected 
multiple bands in the tendon lysate, in a different pattern to the other 
two antibodies (Figure 3.10a).  This antibody also detected multiple 
non-specific bands in a canine chondrocyte sample. 
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Figure 3.10 Detection of collagen type I in canine samples.  (a) ARP59998 at 
1.0µg/ml, 30 seconds exposure, (b) ARP59999 T 0.2µg/ml, 15 seconds exposure, (c) 
ARP58441 at 1.0µg/ml, 40 seconds exposure.  MW: molecular weight marker, T: 
canine tendon lysate (20µl in (a) and 10µl in (b) and (c)) and C: P4 canine 
chondrocyte lysate (25µg). The predicted molecular weights were 137kDa for 
ARP59998 and ARP59999 and 150kDa for ARP38441. Red boxes indicate potential 
bands of interest. 
 
Following this ARP59998 was discontinued due to the lack of defined 
bands detected in either of the canine samples.  Both ARP59999 and 
ARP58441 detected specific bands, although the band at 250kDa was 
much higher than the predicted molecular weight.  This may be due to 
insufficient denaturing of the collagen protein.  The second intense 
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bands detected below 75kDa may be degradation products.  In 
subsequent tests ARP58441 consistently detected bands at 250kDa 
and 110kDa so this was selected for use on test samples and 
ARP59999 was discontinued.  
 
3.2.2.3 Antibody Evaluation: Collagen Type II 
 
Like with collagen type I, the first stage of the antibody validation 
process was to test antibodies targeted against collagen type II on a 
canine positive control tissue.  In this case it was canine cartilage lysate. 
Two DSHB antibodies targeted against collagen type II were tested for 
their cross-reactivity with canine antigens.  CIIC1 was tested at three 
dilutions, 1:25, 1:50 and 1:100 and II-II6B3 was tested at 1:25 and 1:50 
on canine cartilage lysates.  Like CIIC1, II-II6B3 was stated to have a 
broad cross-reactivity.  All blots were completely negative.  To check 
that the negative result was not caused by problem with the transfer, all 
PHPEUDQHVZHUHZDVKHGDQGSUREHGIRU WKHKRXVHNHHSLQJSURWHLQȕ-
DFWLQ   ȕ-actin was detected across all blots in all samples.  This 
suggests that the problem was due to the primary antibody itself; either 
a loss of activity due to prolonged storage or lack of cross-reactivity with 
canine antigens.  Fresh aliquots of these two anti-collagen type II 
antibodies were ordered to confirm whether the negative result was due 
to loss of reactivity or a lack of cross-reactivity.  The fresh batch of 
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CIIC1 and II-,,%ZHUHWHVWHGDWDFRQFHQWUDWLRQRIȝJPORQFDQLQH
cartilage lysate and equine cartilage lysate.  There were no bands 
detected in any sample for either of the two antibodies.     This again 
suggests that these antibodies do not work on canine and equine 
samples.  To confirm whether this was the case, the membranes were 
washed and reprobed with a more concentrated secondary antibody 
and exposure was increased to ten minutes.  This only generated light 
background staining with no bands being detected.  
 
These negative results led to a search for a commercial antibody either 
known or predicted to work in dog.  The Abcam anti-collagen type II 
antibody (ab37412) was selected and tested on different volumes of 
canine cartilage lysate (Figure 3.11).  In all samples a strong band was 
seen at about 150kDa (predicted molecular weight: 142kDa).  There 
was also a band detected between 50kDa and 60kDa which could be a 
degradation product.   Three different dilutions of the antibody were 
tested, 1:1000, 1:5000 and 1:10000 with 1:5000 providing optimal 
detection. 
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Figure 3.11: Evaluation of the anti-collagen type II antibody (ab37412) for cross-
reactivity with canine antigens. MW: molecular weight marker and C: canine 
cartilage lysate.  Canine cartilage lysate was loaded volumetrically, from left to right: 
2µl, 5µl, 7µl and 10µl were loaded.  Antibody dilution: 1:5000; exposure: ten seconds. 
Predicted molecular weight: 142kDa. 
 
The two DSHB antibodies targeted against collagen type II (CIIC1 and 
II-II6B3) were discontinued due to a lack of cross-reactivity.  The anti-
collagen type II antibody was carried forward for use on test samples 
due to the specific banding pattern observed in the canine positive 
control. 
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3.2.2.4 Antibody Evaluation: Sox9  
 
The positive control tissue sample used to assess the cross-reactivity of 
the two anti-Sox9 antibodies from Aviva Systems Biology against 
canine antigens was canine testis lysate.  One Sox9 antibody 
(ARP37986) was targeted against the C-terminus, whereas the other 
antibody was targeted against the N-terminus (P100797).  Both 
antibodies are predicted to recognise a protein of 56kDa.  When these 
antibodies were applied to canine testis lysate and P0 canine 
chondrocyte lysate, slightly different banding patterns were observed 
(Figure 3.12).  The first antibody (ARP37986) detected bands at the 
predicted molecular weight of 56kDa in both samples (Figure 3.12a).  
However there were also strong bands detected further up the blot in 
both samples.  This could be due to glycosylation or dimers and trimers 
being present.  The second Sox9 antibody (P100797) detected a faint 
band at 56kDa in the positive control tissue, however there was a 
strong band detected at the same molecular weight in the canine 
chondrocyte lysate (Figure 3.12b).  Unlike the first antibody, the bands 
detected further up the blot in the chondrocyte lysate were much fainter 
than the band at 56kDa (Figure 3.12b).  The negative control blot, 
where the primary antibody was omitted, contained no bands (Figure 
3.12c). 
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Figure 3.12: Detection of Sox9 in canine samples.  (a) Sox9 antibody ARP37986 at 
1.44µg/ml (b) Sox9 antibody P100797 at 1.44µg/ml (c) Negative control (primary 
antibody omitted).  0:0ROHFXODUZHLJKWPDUNHU7FDQLQHWHVWLVO\VDWHȝJDQG&
3 FDQLQH FKRQGURF\WH FHOO O\VDWH ȝJ  ([SRVXUH  VHFRQGV Predicted 
molecular weight: 56kDa.  Red boxes indicate bands of interest. 
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The antibody targeted against the C-terminus (ARP37986) was carried 
forward for further testing as it detected a band at the predicted 
molecular weight in the positive control sample and the canine 
chondrocyte lysate.  However, in further tests this band was absent.  In 
fact when tested on a human sample known to contain Sox9 (K562, 
Human erythromyeloblastoid leukemia cell line, kindly given by Dr 
Freya Shephard, University of Nottingham) alongside the canine 
positive control, the only bands detected were below the predicted 
molecular weight of 56kDa.  Three bands were detected in the K562 
cell lysate and only one band was detected in the canine sample at 
around 17kDa (Figure 3.13).   Due to the inconsistency in the banding 
pattern observed, the use of this antibody was discontinued.  
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Figure 3.13: Detection of Sox9 in human and canine positive control samples.  
Membranes were incubated with the anti-Sox9 antibody (ARP37986) at 1.44µg/ml. 
MW: molecular weight markeU . . FHOO O\VDWH ȝO &7V FDQLQH WHVWLV O\VDWH
ȝJ([SRVXUHWZRPLQXWHVVHFRQGV Predicted molecular weight: 56kDa. 
 
3.2.2.5 Antibody Evaluation: CD44 
 
As with all the other antibodies, the first stage of validation was to test 
the antibodies on a canine positive control tissue, which for CD44 is the 
spleen.  The first antibody to be tested was from Aviva Systems Biology 
(ARP61023), which was predicted to detect a band at 40kDa.  However 
the molecular weight of CD44 can be increased to 80-100kDa due to 
the attachment of glycosaminoglycan side chains (Sneath and 
Mangham, 1998). This antibody detected various bands in different 
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samples (Figure 3.14). In the positive control tissue, the spleen, a single 
band at 50kDa was detected.  In the canine chondrocyte sample, 
multiple bands were detected with the strongest being at around 
110kDa. The banding pattern was different again in freshly isolated 
equine chondrocytes (equine chondrocyte lysate kindly provided by 
Ismail Hdud, University of Nottingham) with two distinct bands at around 
60kDa and 120kDa.   This difference in molecular weights could be due 
to the fact that there are many different isoforms of CD44 as well as the 
different levels of glycosaminoglycan attachment.  The UniProt 
database only has limited information for canine CD44 and that given is 
for a fragment of the protein.  However the entries for murine and 
human CD44 are much more developed with 13 and 19 isoforms being 
listed respectively. 
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Figure 3.14 Detection of CD44 in canine and equine samples.  CD44 (ARP61023) 
was tested for cross-reactivity with canine and equine samples at a concentration of 
1.44µg/ml.  MW: Molecular weight marker, S: canine spleen lysate (ȝJ), C: P0 
canine chondrocyte cell lysate (ȝJ) and E: freshly isolated equine chondrocyte cell 
lysate (ȝJ). The blots was exposed to film for 30 seconds.  The predicted molecular 
weight according to the antibody datasheet was 40kDa.  The strong bands may 
appear at different molecular weights in different samples because of the many 
isoforms of CD44 and different glycosaminoglycan attachments. 
 
Due to the difference in banding patterns seen in the different samples 
tested for CD44, it was decide to test another panel of antibodies 
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against this antigen.  The aim of this was to try and identify a specific 
band for CD44 in the samples of interest.  Three antibodies targeted 
against CD44 were selected from the DSHB catalogue (Hermes-1, 
H4C4, and P1G12).  All of the antibodies were stated to cross-react 
with human samples. Hermes-1 was listed as reacting with other 
species and P1G12 was stated to work in the macaque.  All three CD44 
antibodies (Hermes-1, H4C4, and P1G12) were tested on canine 
VSOHHQ O\VDWHV DW WZR GLIIHUHQW FRQFHQWUDWLRQV ȝJPO DQG ȝJPO
Blots using H4C4 and P1G12 were completely blank, whereas the blots 
probed with Hermes-1 had multiple bands (Figure 3.15).   
Figure 3.15: Evaluation of three DSHB antibodies targeted against CD44 for their 
cross-reactivity with canine antigens.  (a) Layout of the lanes in the gel that 
corresponds to the blank blot in (b), (b) Blot for CD44 using the antibodies H4C4 and 
3* DW ȝJPO DQG ȝJPO exposure: two minutes, (c) and (d) Blot for  CD44 
using Hermes-DWȝJPOFDQGȝJPOGH[SRVXUHVHFRQGV0PROHFXODU
ZHLJKWPDUNHU6FDQLQHVSOHHQO\VDWHȝJ  No bands were detected by H4C4 and 
P1G12, whereas multiple bands were detected by Hermes-1. 
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H4C4 and P1G12 were raised in mouse whereas Hermes-1 was raised 
in rat; therefore a different secondary antibody was applied to the two 
blots with the mouse primary.  This means that the lack of bands 
detected in the blots probed with H4C4 and P1G12 could have been 
due to the secondary antibody.  Another problem could have been that 
the exposure time was too short.  Therefore, the blot probed with H4C4 
and P1G12 was washed and re-probed with a more concentrated 
secondary antibody and the exposure was increased to ten minutes.  
This resulted in only a light background staining across all blots and no 
bands were detected (Figure 3.16).  
 
 
Figure 3.16: Adjustment of secondary antibody conditions for the DSHB primary 
antibodies.  Primary antibodies were as follows: (a) and (b) H4C4 and (c) and (d) 
3* &RQFHQWUDWLRQV RI WKH SULPDU\ DQWLERGLHV ZHUH ȝJPO LQ a) and (c) and 
ȝJPOLQ(b) and (d).  The secondary antibody used was a DAKO anti-mouse / anti-
rabbit antibody and was diluted 1:20000.  Exposure: ten minutes.  Even after the 
addition of a more concentrated secondary antibody and a prolonged exposure, only 
background staining was observed. 
a b c d
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In a final attempt to identify an antibody that detects canine CD44, 
H4C4 was tested again using a different secondary antibody.  Canine 
chondrocyte lysate was added to the gel alongside the positive control 
and Hermes-1 was also re-tested. Hermes-1 was raised in rat so the 
secondary antibody was not changed from previous testing.  A strong 
band was detected in the canine chondrocyte lysate at around 80kDa 
by the Hermes-1 antibody (Figure 3.17b).  No such band was present in 
the negative control (Figure 3.17c), suggesting that this is a specific 
band for CD44.  However, there were no bands present in the positive 
control tissue lysate (Figure 3.17b).  This may be explained by the 
Ponceau Red staining of the membrane post-transfer (Figure 3.17a).  
There appears to be very few bands in the spleen lysate lanes and 
there is no band in the predicted molecular weight range for CD44.  
This could be rectified by loading more of the positive control tissue. 
Only one band was detected in the blot probed with H4C4 and this was 
at around 12kDa (Figure 3.17d).  This band was also present in the 
negative control, indicating non-specific binding.  As there was a band 
detected by Hermes-1 within the predicted molecular weight range of 
80-95kDa, this antibody was carried forward for use on experimental 
samples. 
 
  
213 
 
 
Figure 3.17: Detection of CD44 in canine samples using Hermes-1 and H4C4.  (a) 
In order to check the transfer, membranes were stained with Ponceau Red prior to 
blocking. (b) western blot for CD44 using the Hermes-1 antibody at 0.34µg/ml (1:1000), 
(c) negative control (primary antibody omitted), (d) western blot for CD44 using the 
antibody H4C4 at 0.29µg/ml (1:2000), (e) negative control (primary antibody omitted).  
MW: PROHFXODUZHLJKWPDUNHU6FDQLQHVSOHHQO\VDWHȝJ&FDQLQHFKRQGURF\WH
O\VDWHȝJ([SRVXUHWHQPLQXWHV  A specific band within the expected molecular 
weight range was only detected by Hermes-1 and only in the canine chondrocyte 
lysate sample. Lack of bands in the positive control lysate could be explained by the 
fact that the bands appear faint on the membrane stained with Ponceau Red, 
suggesting that more positive control lysate should have been loaded. 
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For a summary of all the antibodies evaluated and the reasons behind 
discontinuing or continuing them see Table 3.3.
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Antibody Company Status Reason 
COL1A1 
(ARP59998) 
Aviva Systems 
Biology 
Discontinued No specific banding pattern observed in canine samples. 
COL1A1 
(ARP59999) 
Aviva Systems 
Biology 
Discontinued Although a specific band was detected at 250kDa, ARP58441 was observed to be more 
consistent in detecting two distinct bands. 
COL1A2 
(ARP58441) 
Aviva Systems 
Biology 
Continued Specific bands consistently detected at 250kDa and 110kDa in canine positive control 
samples.  
C11C1 DSHB Discontinued Lack of cross-reactivity with canine antigens. 
II-II6B3 DSHB Discontinued Lack of cross reactivity with canine antigens. 
Collagen type II 
(ab37412) 
Abcam Continued Specific band detected in canine positive control samples at 150kDa. 
Sox9 (ARP37986) Aviva Systems 
Biology 
Discontinued Lack of consistency in banding pattern, multiple bands detected. 
Sox9  
(P100797) 
Aviva Systems 
Biology 
Discontinued Multiple non-specific bands detected.  
CD44 (ARP61023) Aviva Systems 
Biology 
Discontinued Multiple non-specifc bands detected. 
Hermes-1 DSHB Continued Specific band detected within the predicted molecular weight range. 
H4C4  DSHB Discontinued Inconsistency in banding pattern ranging from non-specific bands to a complete lack of 
bands. 
P1G12 DSHB Discontinued Lack of cross-reactivity with canine antigens. 
Table 3.3:  Evaluation of antibodies targeted against collagen types I and II, Sox9 and CD44.  The names, catalogue numbers (where appropriate) and 
companies of the antibodies are given.  Reasons for the continuation or termination of antibodies are given.  The rows highlighted in yellow represent the 
antibodies used on the test samples.
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3.2.3 Change in Expression of Collagen Types I and II and CD44 
 
Collagen type I expression was detected in all passages (band at 
around 150kDa); although bands were barely visible in the P0 and P1 
sample (Figure 3.18b).  There was a general trend of an increase in 
collagen type I expression with increasing passage; however there was 
a decrease in expression at P4 (Figure 3.18a).  Despite this general 
trend none of the results were statistically significant when compared to 
P0 data.  In the collagen type II blots, two distinct bands were detected 
at 250kDa and 150kDa (Figure 3.18f). Expression of the larger isoform 
decreases with increasing passage, however there was a small 
increase in expression from P2 to P3.  Expression at every passage 
was significantly lower than that at P0 (all passages P = < 0.001, except 
P4 where P = < 0.0001) (Figure 3.18d).  Expression of the smaller 
isoform was lower in P1, P2 and P4 and higher in P3 and P5 compared 
to P0 (Figure 3.18e).  However none of these differences in expression 
were statistically significant.  CD44 expression increased from P0 to P5, 
although expression remained relatively low in early passages (P1 to 
P3) (Figure 3.18h-i).  Expression at P5 was the only result to be 
statistically significant when compared to the expression at P0 (P= < 
0.05). 
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Figure 3.18: Expression of collagen types I and II and CD44 in canine 
chondrocytes expanded in monolayer up to P5. (a) Densitometry for collagen type 
I blots (n=3), (b) representative western blot for collagen type I, (c) representative 
western blot for beta actin; (d) and (e) densitometry for collagen type II blots (n=3), (d) 
is for the top band and (e) is for the bottom band, (f) representative western blot for 
collagen type II, (g) representative western blot for beta actin; (h) densitometry for 
CD44 blots (n=3), (i) representative western blot for CD44, (j) representative western 
blot for beta actin.  MW: molecular weight marker, T: canine tendon lysate, C: canine 
cartilage lysate, S: canine spleen lysate, P: passage, P0-P5: canine chondrocyte cell 
lysates. Exposures: (b) and (f) two minutes, (i) five minutes, (c), (g) and (j) one second. 
* P = <0.05, *** P = <0.001, **** P = <0.0001.  Collagen type I expression generally 
increased with increasing passage however none of the results were significantly 
different from P0.  Two distinct bands were detected for collagen type II; the higher 
molecular weight form significantly decreased with increasing passage, whereas the 
lower molecular weight form fluctuated throughout the culture period.  CD44 
expression increased with increasing culture but the only significant difference in 
expression occurred at P5. 
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3.3 Discussion 
 
The first issue addressed in the chondrocyte monolayer expansion 
process was the seeding density.  This varied considerably in the 
literature, so a cell culture plan was designed with seeding densities 
incorporated, which were based on previous counts obtained.  However, 
this plan had to be adjusted depending on the availability of samples.  
Tissue availability is not just a limitation with canine samples; other 
groups have also reported difficulties in obtaining samples (Diaz-
Romero et al., 2005, Hamada et al., 2013).    
 
Freshly isolated chondrocytes took between nine and ten days to 
become between 90-95% confluent.  This is similar to the rate observed 
for human chondrocytes seeded at a density of 20 000 cells/cm2 which 
took ten days to become confluent (Tew et al., 2008).  However another 
paper analyses P2 human chondrocytes at 42 days (Schnabel et al., 
2002).  The canine chondrocytes used in this study reached 90-95% 
confluence at P2 after a total of between 23 and 25 days in culture.  
The difference in values between this study and the work done by 
Schnabel et al. (2002) could be attributed to a difference in the size of 
culture vessel used.  This study used T25 flasks whereas the human 
chondrocytes were seeded into T75 flasks. 
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In terms of morphology, freshly isolated chondrocytes appeared 
spherical before attaching to the tissue culture plastic.  Once attached 
the cells adopted a more polygonal shape and became increasingly 
elongated with increasing passage. This change in morphology was 
also observed in ten-day embryonic chick chondrocytes (Abbott and 
Holtzer, 1966).  One hour after seeding 100% of the cells had a 
rounded morphology whereas after 48 hours this was reduced to 2% 
with 98% having a stellate morphology (Abbott and Holtzer, 1966).  
Archer and colleagues (1990) observed the morphology of  human 
surface zone chondrocytes and deep zone cells separately.  They 
showed that the surface zone cells spread in a more bipolar fashion 
compared to the deep zone cells which adopted a more polygonal 
morphology (Archer et al., 1990).  Although the authors do state that 
there were some deep zone cells that also adopted this morphology 
(Archer et al., 1990).  Both cell types were observed to be highly 
fibroblastic after only 14 days of culture (Archer et al., 1990).  This is in 
contrast to the canine chondrocytes in this VWXG\ZKLFKGLGQ¶WXQGHUJR
extensive elongation even after 53 days in monolayer culture.  In 
another paper the morphology of human chondrocytes expanded in 
monolayer in three different media types (F12:DMEM + 10%FBS + 
growth factors, F12:DMEM + 2%FBS + growth factors and F12:DMEM 
+ 10%FBS) was observed (Munirah et al., 2010).  The images shown in 
the paper are for P0 (taken at seven days) and P3 (Munirah et al., 
2010).  No time point is given for the latter passage as the authors 
acknowledge confluence rates for each group were different (Munirah et 
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al., 2010).  Cells exhibited a polygonal morphology in all groups at day 
seven; however this morphology was only retained at P3 by those 
chondrocytes expanded in media containing growth factors (Munirah et 
al., 2010).  The chondrocytes grown in media without growth factors 
had adopted a more fibroblastic morphology by P3 (Munirah et al., 
2010). 
 
In order to determine the phenotype of the canine chondrocytes 
expanded in monolayer, four proteins were chosen for analysis of 
expression.  Once chosen, the next step was to identify suitable 
antibodies for these target antigens and optimise immunohistology and 
western blotting techniques as appropriate.  As there are limited 
antibodies available for these antigens which are known to cross-react 
with canine samples, various antibodies were screened to evaluate their 
cross reactivity.  It has been noted in a recent review that it is not 
always easy to identify the specific materials used in a paper in order to 
exactly replicate the results shown (Vasilevsky et al., 2013).  This paper 
studied 238 manuscripts from 84 journals and looked at the reporting of 
antibodies, model organisms, knockdown reagents, constructs and cell 
lines (Vasilevsky et al., 2013).  The authors found that only 46% of the 
commercial antibodies and 43% of the non-commercial antibodies used 
were identifiable (Vasilevsky et al., 2013).  The authors recognise that 
commercial antibodies do come with datasheets; however they 
acknowledge that the quality of the information provided can vary 
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considerably (Vasilevsky et al., 2013).  They also recognize that 
actually 63% of researchers use journal articles to select appropriate 
antibodies (Vasilevsky et al., 2013). 
 
After an initial screening of a panel of antibodies targeted against the 
chosen antigens using immunofluorescence, it was decided that 
western blotting would provide a clearer picture in terms of antibody 
cross-reactivity.  In fact, some researchers are of the opinion that 
antibody specificity must be determined by western blotting prior to use 
for immunohistochemistry applications (Kurien et al., 2011).  The 
western blotting process undertaken in this chapter required extensive 
optimisation and as there are many steps involved in western blotting 
which can affect the end-result, each step had to be evaluated.  The 
various levels of optimisation that can be undertaken for western 
blotting are reviewed extensively in (Kurien and Scofield, 2003, Kurien 
and Scofield, 2006, Alegria-Schaffer et al., 2009).  
 
Following the optimisation of western blotting and antibody evaluation, 
three antibodies were selected, one targeted against collagen type I, 
one against collagen type II and one against CD44, for testing on 
canine chondrocyte lysates from multiple passages (P0 to P5).  The 
fourth marker had to be withdrawn from the study due to the lack of an 
effective primary antibody.  Overall, collagen type I expression 
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increased from P0 to P5, however there were decreases in expression 
at P1 and P4 and none of the results were significantly different from 
the expression observed at P0.  This general trend of an increase with 
increasing passage or culture is in agreement with results seen in 
published literature (Brodkin et al., 2004, Darling and Athanasiou, 2005, 
Yang et al., 2006b, Munirah et al., 2010, Nadzir et al., 2011, Hamada et 
al., 2013).   It must be noted that many of these groups have looked at 
mRNA expression rather than protein expression.  To get a true sense 
of what the cells are producing, protein expression should also be 
assessed.  One group who studied chondrocytes expanded up to 
passage 17 found that collagen type I gene expression increased from 
P0 to P3 but remained relatively constant after this passage (Tew et al., 
2008). 
 
The opposite pattern, in part, was observed for collagen type II.  Two 
distinct bands were detected in all chondrocyte lysates, compared to 
only one band in the cartilage lysate.  This may be due to the presence 
of different forms of collagen type II. There are two types of procollagen, 
types IIA and IIB (Ryan and Sandell, 1990, Bruckner and van der Rest, 
1994, Nah et al., 2001, Martel-Pelletier et al., 2008).  Although type IIA 
collagen is normally associated with newly formed cartilage (Bruckner 
and van der Rest, 1994) it has been suggested to be a marker of 
dedifferentiated chondrocytes (Gouttenoire et al., 2010).  This group 
found that type IIA procollagen expression increased with increasing 
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passage of embryonic chondrocytes (Gouttenoire et al., 2010).  Another 
possible explanation for the multiple bands is the detection of collagen 
at various stage of processing.  When collagen is first synthesised, it 
contains propeptides at the N- and C- termini which are essential for the 
formation of the triple helix (Martel-Pelletier et al., 2008, Ricard-Blum, 
2011).  The band at the higher molecular weight may represent 
collagen prior to the cleavage of the propeptides.  Also, as the primary 
antibody used was polyclonal; it has the potential to detect multiple 
forms of the target protein.  The expression of the larger molecular 
weight form of collagen type II significantly decreased with increasing 
passage with all values being significantly lower than that at P0.  This 
decrease with increasing culture length is also demonstrated in the 
literature but like with the collagen type I studies, many groups look at 
gene expression rather than protein expression (Brodkin et al., 2004, 
Darling and Athanasiou, 2005, Yang et al., 2006b, Eleswarapu et al., 
2007, Tew et al., 2008, Munirah et al., 2010, Hamada et al., 2013). 
 
CD44 expression was shown to increase from P0 to P5 with only the 
expression at P5 being significantly higher than P0.  Diaz-Romero 
(2005) and colleagues looked at the expression of a range of cell 
surface markers by flow cytometry of monolayer chondrocytes at zero 
hours and 24 hours.  They found that the level of CD44 increased in this 
time, indicating that an increase in CD44 expression occurs early-on in 
the monolayer expansion process.  Another group also looked at CD44 
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expression using flow cytometry, this time studying cells from P0 to P4 
(Hamada et al., 2013).  The authors of this paper found that there was a 
sharp increase in expression from P0 to P2; there was a slight increase 
from P2-P3 but a minimal decrease from P3 to P4 (Hamada et al., 
2013).  This is in contrast to the data presented in this chapter in which 
the greatest increase in expression is demonstrated at the latter 
passages.   This difference could be due to the different isoforms of 
CD44 present.  Another paper studying the gene expression of CD44 in 
monolayer chondrocytes expanded for four weeks showed that 
expression of the standard and long tail forms of CD44 fluctuated 
throughout the culture period (Albrecht et al., 2009).  However 
expression of the short-tail form was higher in the latter stages of the 
culture (from day 18 onwards) (Albrecht et al., 2009). 
 
It must be noted that results in this chapter have been described in 
relation to passage, which is subjective term and may mean different 
things to different researchers.  Therefore, it may be useful to also take 
population doublings into consideration as this may affect the 
phenotype of the cells.  For example, those chondrocytes analysed 
during the lag phase of expansion may more closely resemble native 
chondrocytes compared to those in the exponential phase.  One 
research group observed that the number of round cells decreased with 
increasing population doublings (Nadzir et al., 2011).  This was also 
observed by another group culturing rabbit chondrocytes on collagen 
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substrate and in collagen gel (Kino-Oka et al., 2009).  Nadzir and 
colleagues (2011) also demonstrated that collagen type I expression 
increased with increasing population doublings.  Collagen type II 
expression was slightly more complex with expression being low at low 
and high population doublings but there was also a considerable peak 
at 5.1 population doublings (termed middle age by the authors) (Nadzir 
et al., 2011).  This could indicate variation in phenotype depending on 
the stage of culture.  Another research group described chondrocytes 
as being dedifferentiated at two, five and eight population doublings 
(Rackwitz et al., 2014).  They also claimed that collagen type I 
expression increased and collagen type II expression decreased with 
increasing population doublings but the data is not shown (Rackwitz et 
al., 2014). 
 
3.4 Conclusion 
 
The results in this chapter clearly show that canine chondrocytes 
dedifferentiate in monolayer, although the change in morphology 
appears to be less dramatic than that reported for human chondrocytes.  
This could be due to the differences in initial seeding densities and cell 
culture technique.  Expression of collagen type I and CD44 increased 
with increasing passage, although the only significant difference in 
expression was at P5 for CD44.  Collagen type II significantly 
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decreased in expression from P0 to P5, however there was a lower 
molecular weight isoform detected that fluctuated in expression across 
the passages. 
 
Also highlighted in this chapter was the difficulty in obtaining a regular 
supply of tissue and the problems involved with identifying suitable 
antibodies which specifically detect the antigens of interest. 
 
The next chapter will deal with encouraging the chondrocytes to 
redifferentiate into the chondrocytic phenotype through establishing a 
three dimensional cell culture system.
  
228 
 
4. Establishment of Chondrocyte 3D Culture 
 
4.1 Background 
 
Various 3D culture techniques have been used to maintain or induce 
the chondrocytic phenotype however the one method that is most 
frequently used is high density pellet culture (Abbott and Holtzer, 1966, 
Manning and Bonner, 1967, Kato et al., 1988, Solursh, 1991, Ballock 
and Reddi, 1994, Stewart et al., 2000, Tallheden et al., 2003, Malda et 
al., 2004, Zhang et al., 2004, Dehne et al., 2009).    Multiple research 
groups have shown that chondrocytes cultured in high density pellets 
retain their spherical morphology (Manning and Bonner, 1967, Kato et 
al., 1988).  Expression of collagen type II or its precursor procollagen 
type II has also been shown to expressed by chondrocytes cultured in 
high density pellets (Ballock and Reddi, 1994, Stewart et al., 2000).  
However, evidence of hypertrophy through collagen type X expression 
has been shown in pellet culture (Ballock and Reddi, 1994). Pellet 
culture has also shown to be ineffective at completely preventing 
chondrocyte dedifferentiation in in vitro culture as collagen type I 
expression has also been detected (Stewart et al., 2000). Pellet culture 
has also been used as a mechanism to induce chondrogenesis in 
mesenchymal stem cells (Johnstone et al., 1998, Csaki et al., 2007, 
Stewart et al., 2007, Stewart et al., 2008, Vidal et al., 2008, Lettry et al., 
2010), as it mimics the condensation of MSCs during the early stages of 
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chondrogenesis (Cancedda et al., 2000, Goldring et al., 2006, Chen 
and Tuan, 2008, Pelttari et al., 2008).  
 
 
Another way to culture chondrocytes three dimensionally is to seed 
them into a supporting scaffold material.  One such material is  alginate 
(Bonaventure et al., 1994, Hauselmann et al., 1994, Hauselmann et al., 
1996, Loty et al., 1998, van Osch et al., 1998, Chubinskaya et al., 2001, 
Domm et al., 2002, Schulze-Tanzil et al., 2002, Lee et al., 2003, 
Stoddart et al., 2006, Rai et al., 2009, Brand et al., 2012, Caron et al., 
2012).    Some groups have also used synthetic polymers such as 
polyglycolic acid (PGA) (Homicz et al., 2003), poly(DL-lactic-co-glycolic 
acid (PLGA) (Chen et al., 2003) and polycaprolactone (PCL) (Garcia-
Giralt et al., 2008) for chondrocyte redifferentiation in 3D culture. 
 
As high density pellet culture is commonly used to help maintain the 
chondrocyte phenotype in vitro and has the advantage of no additional 
materials being required, this method will be applied to the canine 
chondrocytes in this study.  The aim and hypothesis of this chapter 
were as follows: 
 
Aim: To establish a 3D culture of canine chondrocytes and assess the 
phenotype of monolayer-expanded cells within this system. 
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Hypothesis One: Chondrocytes previously expanded in monolayer will 
begin to adopt a more native phenotype 
(redifferentiate) in 3D culture.  Expression of collagen 
type II will increase whereas expression of collagen 
type I and CD44 will decrease. Synthesis of GAGs 
should also be detected in the 3D culture system. 
 
4.2 Results 
 
4.2.1 High Density Pellet Culture 
 
Due to limited tissue availability, the initial work with high density pellet 
cultures was carried out with cryopreserved canine chondrocytes (cells 
were at P1 when frozen).  These cells were revived and expanded in 
monolayer culture until 100% confluence was reached.  The 
chondrocytes were lifted off tissue culture plastic and dispensed into 
15ml falcon tubes.  Cells were centrifuged to form pellets with an initial 
density between 1.75x105 and 1.94x105 cells.  The initial cell density 
used for pellet culture ranges in the literature (Table 4.1).  Due to the 
limited availability of cartilage and chondrocytes, relatively low densities 
were trialled first.    After 21 days in culture at 37oC, 5% CO2 the cells 
had formed a very small pellet (Figure 4.1a). Four of the pellets were 
removed from the media at this stage for processing, embedding and 
sectioning.  Due to the small size of the pellets, three were left for a 
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further two weeks to see if a longer culture period would generate 
significantly bigger pellets (Figure 4.1b and 4.1c).  Little change in size 
was observed after 14 extra days in culture.   
 
 
Species Initial Cell Density Reference 
Bovine 2.5x105 (Kawanishi et al., 2007) 
1.5x106 (Bernstein et al., 2009a) 
Human 2x105 (Tallheden et al., 2003) 
5x105 (Scotti et al., 2012) 
Rabbit 8x104 (Kato et al., 1988) 
Rat 1.6x105 (Ballock and Reddi, 1994) 
Equine 2x105 (Stewart et al., 2000) 
Chick 1-5x106 (Abbott and Holtzer, 1966) 
 
Table 4.1: Different cell densities used for pellet culture of chondrocytes. 
 
The small size of the pellets made processing using the automated 
programs on the tissue processor very difficult.  Therefore this was 
adapted slightly by embedding the pellets in 1% agarose (Fisher 
Bioreagents) after fixation in 10% neutral buffered formalin (NBF) and 
prior to processing.   The pellets were then processed using the tissue 
processor before being embedded in paraffin wax.  It proved difficult to 
obtain sections of these pellets due to the fact that the wax shattered 
when trying to section through the agarose gel.  In addition, their small 
size made it difficult to visualise them within the wax.  As the pellets 
were no bigger after 35 days, culture and processing was terminated 
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and the pellet culture was attempted again, aiming to generate larger 
pellets. 
 
 
Figure 4.1: Canine chondrocyte high density pellet culture.  (a) pellet cultured for 
21 days (b) and (c) pellet cultured for 35 days.  Pellets at both time points were very 
small and difficult to manipulate out of culture.  The size of the pellets did not appear 
to change from day 21 to day 35.  Pellets were photographed using a Sony Cyber-
Shot DSC-W30 digital camera.  
 
In order to generate a cell pellet large enough for embedding and 
sectioning, high density pellet culture was attempted for a second time 
with higher initial density.  Cryopreserved canine chondrocytes (P1 
when frozen) were revived and expanded in monolayer (passaged once) 
before being pelleted.    Another potential reason for the lack of growth 
seen in the previous pellets could have been inefficient gaseous 
exchange.  Therefore, the system was adapted to improve this and cells 
were pelleted in sterile eppendorfs with holes in the lids.  Two types of 
holes were made (Figure 4.2a and 4.2b).  All pellets had a starting cell 
density of between 1x106 and 2x106 cells.  After 21 days, some of the 
pellets were removed for fixing, embedding and sectioning (Figure 4.2c).  
a b c
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The pellets were very delicate and one broke up during the fixation 
period (Figure 4.2d).  As the pellets were still very small and the 
agarose teFKQLTXH XVHG SUHYLRXVO\ GLGQ¶W ZRUN VQDS IUHH]LQJ WKH
pellets in OCT after fixation in 10% NBF was attempted (Figure 4.2e).  
The sections were then stained with Haematoxylin and Eosin (H&E) 
(Figure 4.2f and 4.2g).  A considerable amount of the tissue had been 
lost.  There are two possible reasons for this; the fixation method used 
was not appropriate for the embedding technique opted for and the 
staining procedure washed away some of the material from the slide.  
Culture of the rest of the pellets was stopped after 35 days.  At this 
point they were fixed in 10% NBF and stored in 70% ethanol until 
processing.  These pellets were considerably larger than those 
generated after the first attempt of high density pellet culture (Figure 
4.2h).  The size of the pellet was unaffected by the type of hole made in 
the eppendorf, therefore, as the holes made using the hypodermic 
needle were consistently the same size, only these eppendorfs were 
used for further high density pellet culture studies. 
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Figure 4.2: Adjustment of high density pellet culture conditions and processing. 
(a) Diagram representing the lid of an eppendorf containing holes made using a 
hypodermic needle. (b) Diagram representing the lid of an eppendorf containing a hole 
made using a sterile scalpel. (c) Chondrocyte pellet after 21 days in culture in an 
eppendorf containing hypodermic needle holes in the lid (starting cell density: 
1.21x106 cells). (d) A broken up cell pellet, which was cultured for 21 days in an 
eppendorf with a scalpel hole in the lid (starting cell density: 1.21x106 cells).  (e) 
Chondrocyte pellet embedded in OCT.  (f) Haematoxylin and Eosin (H&E) stained 
pellet (5µm section, magnification: x50, scale bar: 500 µm). (g) The same section as in 
(f) but viewed at a magnification of x100 (scale bar: 100 µm). (h) Chondrocyte pellet 
after 35 days in culture.  Cell pellets were considerably larger than the previous 
attempt although some were very fragile and difficult to process.  Substantial sample 
loss was observed through histological staining which was probably due to 
incompatible fixation and processing. 
a d ec
b
f g
h
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The 35-day pellets were still very delicate and one broke-up whilst 
being transferred from the eppendorf to the tissue processing cassette.  
The two remaining pellets, which were both cultured in eppendorfs 
containing scalpel holes in the lids, were successfully transferred to the 
cassettes (Figure 4.3a and 4.3b).  Only one of these pellets was not 
destroyed in the tissue processor and was subsequently embedded in 
paraffin wax.  This pellet (starting density of around 2x106 cells) was 
analysed histologically using Alcian blue (Figure 4.3c) and H&E (Figure 
4.3d) staining.  This time the tissue was not lost and positive Alcian blue 
staining indicated glycosaminoglycan (GAG) production. 
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Figure 4.3: Canine chondrocyte high density pellets cultured for 35 days.  (a) 35-
day pellet; starting cell density: 1.18x106 cells. (b) 35-day pellet; starting cell density: 
2.27x106 cells.  (c)  The pellet in (b) stained with Alcian blue. (d) The pellet in (b) 
stained with H&E.  The pellet in (a) was destroyed in the tissue processor. (c) and (d) 
magnification: x200, scale bar: 50 µm., sections: 5µm. 
 
Due to the instability of the pellet cultures observed during culture and 
during processing for downstream applications it was decided that the 
cells would need a support mechanism for 3D culture.  The supporting 
material chosen was alginate.  Alginate was chosen because it has 
been used to culture chondrocytes from a variety of species including 
humans (Hauselmann et al., 1996, Chubinskaya et al., 2001), cows 
(Hauselmann et al., 1994, van Osch et al., 1998, Lee et al., 2003), 
rabbits (De Ceuninck et al., 2004), rats (Loty et al., 1998) and dogs (Rai 
et al., 2009). 
 
 
a b
c d
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4.2.2 Alginate Bead Culture 
 
 4.2.2.1 Size, Cell Density and Cell Viability 
 
The first stage of establishing the alginate bead culture was to identify 
the appropriate size of the bead and the initial cell density.  The size of 
each alginate bead is governed by the size of the needle used to 
dispense the alginate solution into the calcium chloride solution.  The 
calcium, which is a divalent catLRQ LQWHUDFWV ZLWK WKH Į-guluronic acid 
monomer in the alginate, forming ionic bonds between the copolymers 
(Martinsen et al., 1989, Paige et al., 1996, Shakibaei and De Souza, 
1997, Mierisch et al., 2002, Drury et al., 2004, Wilson et al., 2013). 
 
An array of needle sizes has been used in the literature to generate 
alginate beads.  They range from 20 gauge (20G) to 23G (Bonaventure 
et al., 1994, Hauselmann et al., 1994, Hauselmann et al., 1996, van 
Osch et al., 1998, Chubinskaya et al., 2001, Domm et al., 2002, Lee et 
al., 2003, De Ceuninck et al., 2004, Stoddart et al., 2006, Bernstein et 
al., 2009a, Brand et al., 2012, Caron et al., 2012).  Therefore, a range 
of needle sizes was assessed for the size of beads they produced 
(Figure 4.4a).  Two pipette sizes and the syringe itself was also 
assessed for bead generation.  Beads generated with an 18 gauge 
needle gave large, regular sized beads (Figure 4.4a1).  1ml pipettes 
also generated large, regular sized beads (Figure 4.4a8), however the 
dispensing of the alginate was more difficult to control with the pipette.  
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Like with the 1ml pipette, dispensing of alginate from a 5ml pipette was 
also difficult to control.  The two largest needle sizes (16G and 14G) 
generated beads that had a flattened edge, as opposed to the more 
spherical beads generated with the smaller gauge needles (Figure 
4.4a5 and 6).  18G needles were selected to be used for all alginate 
bead work, as they produced large, regular sized beads.  To confirm 
that beads were a regular size, alginate solution was dispensed through 
a 18G needle and 20 beads were selected at random and placed along 
a ruler (Figure 4.4b). In addition, four beads were randomly selected 
and weighed.  The average weight of the beads without chondrocytes 
was 11.1mg (range: 9.3mg-12.2mg). 
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Figure 4.4: Size evaluation of alginate beads.  (a)  Different sized needles and 
pipettes were used to determine the optimum size for alginate bead culture, 1: 21 
gauge (G) needle, 2: 20G needle, 3: 19G needle, 4: 18G needle, 5: 16G needle, 6: 
14G needle,  7: 10ml syringe, 8: 1ml pipette, 9: 5ml pipette. (b) Beads generated with 
an 18G needle; 20 beads were randomly selected and assessed for regularity in size. 
Beads were photographed using a Sony Cyber-Shot DSC-W30 digital camera.  
 
The next step of the alginate encapsulation process to be assessed 
was the seeding density of the chondrocytes.  This varies in the 
literature from 5x105 cells/ml of alginate using canine chondrocytes (Rai 
et al., 2009) to 1x107 cells/ml of alginate used in a bovine chondrocyte 
study (Lee et al., 2003).  In order to maximise the number of beads 
generated from the cells available, a cell density close to that used by 
Rai and colleagues (2009) was aimed for.  Due to limited availability of 
fresh tissue, cryopreserved canine chondrocytes (P1 when frozen) were 
revived and expanded in monolayer (until 100% confluence was 
21 3 4 5 6 7 8 9a
b
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reached) before being encapsulated into alginate beads.  The initial cell 
density used of 4x105 cells/ml of alginate was shown to be too low, 
through light microscopy (Figure 4.5b) and H&E staining (Figure 4.5c).  
The next time the beads were established, two different seeding 
densities were used.  The cells used for this were cryopreserved canine 
chondrocytes (P1 when frozen) expanded in monolayer to P4.  Some 
beads were seeded with 1x106 cells/ml of alginate whereas others were 
seeded with 2x106 cells/ml of alginate.  These two densities were 
chosen based upon the range of densities used in the literature (Table 
4.2).  Also taken into consideration was the quantity of tissue available 
and the potential number of beads that could be generated. Beads were 
observed under the light microscope DM IL microscope and DCF490 
camera (Leica) during culture (Figure 4.5e and f) and once culture had 
been terminated beads were fixed, embedded, sectioned and stained 
with H&E (Figure 4.5h-k).  Cells were in much closer contact with each 
other at the higher densities and it was decided that all future beads 
would need to contain a minimum of 2x106 cells/ml of alginate. 
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Table 4.2: Chondrocyte seeding densities within alginate beads in different 
species.  *Hauselmann and colleagues (1996) used two different densities depending 
on the downstream applications, the lower density being for metabolic studies; the 
higher density used for morphometric and biochemical analysis. 
Species Cell Density (cells/ml of 
alginate) 
Reference 
Human 3-4x106 (Bonaventure et al., 1994) 
4x106 *(Hauselmann et al., 1996) 
8x106 
4x106 (Chubinskaya et al., 2001) 
2x106 (Schulze-Tanzil et al., 2002) 
8x105 (Brand et al., 2012) 
Bovine 4x106 (Hauselmann et al., 1994) 
8x106 (van Osch et al., 1998) 
1x107 (Lee et al., 2003) 
4x106 (Stoddart et al., 2006) 
Rat 1x106 (Loty et al., 1998) 
Rabbit 2x106 (De Ceuninck et al., 2004) 
Canine 5x105 (Rai et al., 2009) 
Porcine 4x106 (Bernstein et al., 2009a) 
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Figure 4.5: Evaluation of cell density within alginate beads.  Cryopreserved 
canine chondrocytes were revived and expanded in monolayer before being seeded 
into alginate beads.  The first cell density trialled, 4x105 cells/ml of alginate (b) and (c), 
was too low.  Therefore in the next culture higher densities were trialled.  Specifically 
beads were seeded with 1x106 cells/ml of alginate (e), (h) and (j) and 2x106 cells/ml of 
alginate (f), (i) and (k).  (a), (d) and (g) are alginate beads without any chondrocytes 
seeded.  Cell density within the beads was monitored using light microscopy during 
culture (a)-(b) and (d)-(f) and H&E staining (c) and (g)-(k). The images in (a) and (b) 
were taken two days after the beads were established and (d)-(e) were taken one day 
after the beads were set-up. The bead in (c) was removed and fixed on day 23 of 
culture (day zero is when the beads were created). The beads in (g)-(i) were removed 
and fixed on day three and the beads in (j) and (k) on day seven. Images (a)-(f): 
magnification: x100, scale bars 100µm (a) and (b) and 250µm (c)-(f); (g)-(k) 
magnification: x200, scale bar 250µm.  Sections in (c) and (g)-(k): 5µm. 
a b c
d e f
g h i
j k
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In addition to observing the density of cells within the beads, the viability 
of the chondrocytes was also assessed.  As well as determining cell 
viability prior to seeding into alginate using trypan blue, some cells were 
seeded into wells of a 96-well plate and the Cyquant NF assay was 
perfomed.    Fluorescence was shown to increase with increasing 
number of seeded cells (Figure 4.6a).  To assess the viability of 
chondrocytes encapsulated within the beads, the Alamar Blue assay 
was used.  The Alamar Blue assay measures metabolic activity of the 
cells within the beads with metabolically active cells maintaining a 
reduced environment.  As non-viable cells would not be metabolically 
active, Alamar Blue data can be interpreted as giving an indication of 
cell viability within the construct.   Beads containing revived canine 
chondrocytes (initial seeding densities of 1x106 cells/ml of alginate and 
2x106 cells/ml of alginate) were cultured in normal culture medium 
(DMEM+10%FBS+2% antibiotics) at 37oC, 5% CO2 until day seven.  On 
day seven media was changed to contain various concentrations of 
sodium nitroprusside (SNP) (0.5µM, 1µM, 0.5mM and 1mM).  SNP was 
added to some cultures to induce cell death in order to check that the 
process of alginate culture did not have an adverse effect on the 
chondrocytes in terms of cell viability.  Control media had no SNP 
added.  SNP (Na2Fe++(CN)5NO.2H2O) is a nitric oxide donor and has 
been used in previous studies to induce and study cell death in a range 
of cell types including chondrocytes (Yamada et al., 1996, Notoya et al., 
2000, Rabkin and Kong, 2000, Del Carlo and Loeser, 2002, Kuhn and 
Lotz, 2003, Yoshioka et al., 2003, Kim et al., 2005). Beads were 
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incubated with the fresh media overnight under the same conditions.  In 
the beads with the lower starting density the lower concentrations of 
SNP (0.5µM and 1µM) appeared to improve the viability of the cells 
within the beads (Figure 4.6c). The same affect was seen in the higher 
density beads incubated with 1µM SNP (Figure 4.6d).  In both groups 
the two highest concentrations of SNP (0.5mM and 1mM) appeared to 
decrease the viability of the chondrocytes within the beads.  Due to a 
loss of some beads during the culture and analysis only two beads were 
analysed for each concentration.  Therefore, another batch of beads 
were incubated with SNP overnight.  In this experiment the beads were 
seeded with P2 canine chondrocytes with an initial starting density of 
2x106 cells/ml of alginate.  Two additional lower concentrations (0.5nM 
and 1nM) were added to see if they also had beneficial effects on cell 
viability.  Three beads were tested at each concentration.  0.5nM had 
little impact on cell viability and 1nM caused a slight decrease in cell 
viability.  0.5µM, 1µM and 0.5mM increased viability, with it peaking in 
the beads incubated with 1µM.  The highest concentration decreased 
cell viability, however none of the results were statistically significant. 
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Figure 4.6: Cell viability prior to seeding and within alginate beads.   Revived 
canine chondrocytes were expanded in monolayer up to P4.  Some of these P4 cells 
were seeded at known densities into wells of a 96-well plate for the Cyquant NF assay 
(a); another aliquot of cells were seeded into wells of  a 24-well plate at known 
densities to generate the standard curve for the Alamar blue assay (b).  The remaining 
cells were seeded into alginate at two different densities, 1x106 and 2x106 cells/ml of 
alginate.  Beads were cultured for seven days before being incubated with various 
concentrations of SNP (0.5µM, 1µM, 0.5mM and 1mM) overnight. (c) 1x106 beads and 
(d) 2x106 beads post SNP incubation (N=2  for each SNP concentration).  A second 
batch of beads seeded with P2 canine chondrocytes at an initial density of 2x106 
cells/ml of alginate were incubated with the same concentrations of SNP along with 
two other concentrations; 0.5nM and 1nM. (e) Standard curve, (f) cell viability after 
incubation with SNP (N=3 for each concentration). (c)-(f) Alamar Blue Assay data. No 
concentration of SNP significantly affected the health of the cells within the beads. 
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  4.2.2.2 Processing Alginate Beads for Histological 
Analysis 
 
Different research groups have used various methods for fixing and 
alginate beads for histological analysis.  Hauselmann and colleagues 
(1994) incubated alginate beads with 2.5% glutaraldehyde for two hours, 
whereas Stoddart et al (2006)  embedded beads in OCT prior to fixation.  
Another group incubated beads in 4% PFA (in 29mM NaH2PO4x1H2O, 
28mM NaHPO4, 53mM saccharose and 10mM CaCl2) for 30 minutes 
(Domm et al., 2002), whereas Chubinskaya and colleagues (2001) fixed 
beads in 4% PFA, 0.1M cacodylate buffer (pH7.4) containing 10mM 
CaCl2 for four hours at 20oC.  Bernstein et al (2009a) used two different 
methods of fixation for histology and immunohistology.  For the former, 
the authors fixed the beads in acetone for five minutes at -20oC 
followed by methanol for five minutes at -20oC (Bernstein et al., 2009a).  
For the latter the authors state 4% PFA was used but the incubation 
time is not provided (Bernstein et al., 2009a).  In a more recent study 
beads were fixed in 70% ethanol overnight (Brand et al., 2012).  In 
order to generate sections of beads for histological staining, a suitable 
fixation and embedding process had to be defined.  
 
Taking into consideration the differences in fixatives used in the 
literature, the first fixative to be trialled was 4% PFA for 1.5 hours at 4oC.  
These beads were extremely fragile and could not be manipulated for 
processing and embedding. This fragility could have been caused by 
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calcium leaching out of the beads, weakening the ionic bonds between 
the polymers in the alginate.  For the next batch of alginate beads 
different fixatives, containing different ratios of 4% PFA and 102mM 
CaCl2 (PFA only, 90:10, 70:30, 50:50, 30:70 and 10:90) were tested.  
The incubation time was kept the same as before.  These conditions 
were first tested on alginate-only beads. The beads in 4% PFA only 
dissolved, whereas all the other beads were still intact and were 
successfully removed from the six-well plate into tissue processing 
cassettes. Fixatives containing ratios of 4% PFA and 102mM CaCl2 
were then applied to alginate beads containing P1 canine chondrocytes 
and another set of alginate only beads.  Five beads were incubated in 
each of the five fixation solutions as before.  All beads from all fixatives 
were successfully transferred to tissue processing cassettes post 
fixation. As these beads were stable enough to transfer to the tissue 
processing cassettes post fixation, the processing protocol was 
continued.  Cassettes were placed in the tissue processor in which the 
beads were gradually dehydrated before being prepared for embedding.  
The exact solutions and times used are summarised in Table 4.3.  None 
of the beads were still intact after being in the tissue processor. There 
are two possible reasons for this: (1) the PFA was diluted to less than 
4%, so the beads may not have been fixed for long enough (2) the 
beads may have melted in the wax, as the wax has to be heated to 
55oC to be in liquid form.  Therefore, in the next batch of fixation 
solutions a final concentration of 4% PFA was ensured by starting with 
a more concentrated stock solution.  The three solutions with the 
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highest PFA content were selected for the next test (PFA: CaCl2 ratios: 
90:10, 70:30 and 50:50). 
 
Container Solution Time (mins) Process 
1 70% Ethanol 30  
 
Gradual 
dehydration of 
the tissue 
2 80% Ethanol 30 
3 95% Ethanol 30 
4 100% Ethanol 15 
5 100% Ethanol 15 
6 100% Ethanol 15 
7 100%Ethanol 15 
8 Histoclear 30  
Preparation for 
the wax 
9 Histoclear 30 
10 Histoclear 30 
11 Paraffin 30 Preparation for 
embedding 
12 Paraffin 45 
 
Table 4.3: Solutions and times used in the tissue processor to prepare samples 
for embedding in wax.  The tissue processor has a variety of automated programs 
where the times in the solutions vary. 
 
In addition to this, the processing protocol was reduced and performed 
manually.  Although it was suspected that the beads may have melted 
in the wax, they could have been destroyed earlier on in the process.  
Due to the small size of the beads, incubation in each solution was 
severely reduced.  The manual protocol up to the last Histoclear 
incubation is summarised in Table 4.4.  To assess the survival of the 
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beads within the paraffin wax, beads were observed in the molten wax 
and timed.  Molten wax was placed into a metal mould, which was 
placed on a heated stirrer (Heidolph MR 3001) with a thermometer 
attached.  The wax was heated to 55oC, keeping the conditions the 
same as in the tissue processor.  The beads fixed in the 90:10 solution 
only lasted 90 seconds in the wax.  The 70:30 beads were still intact 
even after seven minutes in the wax and the 50:50 beads were still 
intact after five minutes.  It was decided that the 90:10 solution would 
be discarded as a potential fixative and that five minutes would be the 
optimum incubation in molten wax.   
 
Solution Time (mins) 
70% Ethanol 5 
80% Ethanol 5 
95% Ethanol 5 
100% Ethanol 5 
100% Ethanol 5 
Histoclear 5 
Histoclear 5 
 
Table 4.4: Solutions and times used for manually preparing alginate beads for 
embedding in wax. The solutions are the same as those used in the automated 
process but the timings have been severely reduced. 
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Alginate beads seeded with canine chondrocytes were fixed using the 
70:30 or 50:50 fixation solutions.  These beads were then processed 
manually using the solutions and timings in Table 4.3.  The final stage 
of processing before embedding was a five-minute incubation in molten 
wax.  These beads were sectioned and stained with H&E and alcian 
blue (Figure 4.7).  Little difference in staining was observed between 
the beads fixed with the different solutions, however the structure of the 
beads and the cells within them appeared to be marginally better 
preserved by the 50:50 solution (Figure 4.7b and d) compared to the 
70:30 solution (Figure 4.7a and c).  Therefore the 50:50 solution was 
used for all subsequent fixation of alginate beads.  A basic overview of 
the processes involved in successfully fixing and processing the beads 
is provided in Figure 4.8. 
 
One problem highlighted during this test was the intense background 
staining of the alginate with the Alcian Blue.  This may be because 
alginate is an anionic polymer (Lee and Mooney, 2012) and alcian blue 
contains cationic isothiouronium groups which are thought to interact 
with polyanionic molecules within tissues via electrostatic bonds (Myers 
et al., 2008).  Thus the Alcian Blue staining protocol had to be 
evaluated to determine a method which would differentiate between 
staining of the alginate and staining of GAGs produced by the 
chondrocytes within the beads. 
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Figure 4.7: Optimisation of fixation and processing of alginate beads seeded 
with canine chondrocytes.  Alginate beads were fixed with solutions containing 
different ratios of 4% PFA and 102mM CaCl2; either 70:30 (a) and (c) or 50:50 (b) and 
(d).  Beads were manually processed, embedded in wax and sectioned.  5µm sections 
were stained with H&E (a) and (b) or alcian blue (c) and (d).  There was minimal 
difference between the two fixation solutions; the 50:50 solution seemed marginally 
better at preserving the cells within the beads, so this was selected for all subsequent 
fixation of alginate beads.  All images were taken with a magnification of x200, scale 
bars: 100µm. 
 
 
 
 
 
 
 
 
a b
c d
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Figure 4.8:  Overview of the processes involved in successfully fixing and 
processing alginate beads for histological analysis. 
 
Beads fixed with 4% PFA for 1.5 hours at 4oC
Beads extremely fragile and difficult to manipulate
4% PFA repeated alongside fixatives containing different ratios of 
4%PFA and 102mM CaCl2 - incubation conditions kept the same
4% PFA only 90:10 70:30 50:50 30:70 10:90
Beads 
dissolved
Beads successfully transferred to tissue processing 
cassettes
Beads destroyed in tissue processor
Possible reason: PFA diluted to 
less than 4%
Possible reason: Beads may 
have melted in the wax
Fixation repeated ensuring PFA 
concentration maintained at 4%
Beads processed manually
90:10 70:30 50:50
Beads dissolved in 
the molten wax after 
90 seconds
Beads remained intact 
after five minute incubation 
in molten wax
Both fixatives repeated. Beads processed, embedded, sectioned and 
stained with H&E and Alcian Blue
Minimal difference between the two fixatives; the structure of the beads 
appeared to be slightly better preserved with the 50:50 solution
  
253 
 
   4.2.2.3 Alcian Blue Optimisation 
 
The steps taken to reduce the background staining of the alginate with 
alcian blue are summarised in Figure 4.9. Briefly, various conditions 
were changed throughout the optimisation process, beginning with 
increasing the length of the washing step.  The problem with intense 
background staining was initially observed in beads seeded with canine 
chondrocytes.  The optimisation of staining was performed on alginate-
only beads.  This was to ensure that the stain would specifically 
indentify GAGs produced by the chondrocytes within the beads as 
opposed to staining the alginate.  Reducing the incubation times and 
altering the washing times still resulted in a uniform, strong staining of 
the alginate.   The most effective condition for reducing staining of the 
alginate was having the alcian blue at a concentration of 0.02%, dipping 
the slides in this solution three times and then washing the slides for ten 
minutes (Figure 4.9).  The pH of the alcian blue solution was kept 
constant at 2.5 throughout the optimisation process. 
 
As the background staining of the alginate had been reduced to 
acceptable level, which should enable the differentiation between 
staining of alginate and GAGs produced by the chondrocytes; day three 
beads seeded with canine chondrocytes (initial density of 2x106 cells/ml 
of alginate) were stained using the 0.02% alcian blue (three dips, ten 
minute wash).  Staining of the alginate was very weak; however, there 
was no specific staining indicating GAG production (Figure 4.10a and b).   
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1% alcian blue, 30mins followed by wash in running water for 
2mins
Increased washing time to 10mins
Reduced incubation  and washing times to 15mins and  
5mins respectively
Reduced incubation and 
washing time
Reduced incubation time 
and increased washing time
Reduced alcian blue concentration. Incubation 
time: 30secs, washing time: 10mins
0.1% 0.05% 0.02%
30secs; 
10mins
10secs; 
10mins
3 dips 
10mins
I: 30secs 
W: 1min
Reduced 
incubation time
10secs 3 dips
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Figure 4.9: Optimisation of Alcian Blue staining of alginate beads.  Various 
factors in the alcian blue staining process were altered in order to reduce to 
background staining of the alginate.  A combination of reducing the incubation time 
with and concentration of alcian blue as well as increasing the washing time was 
found to significantly reduce the background staining.  The lowest background was 
observed with 0.02% alcian blue, three dips and 10mins washing.  The pH of the 
alginate was kept at 2.5 throughout.  Images: magnification: x50, scale bars: 500µm. 
 
It was decided to increase the incubation time to ten and twenty 
seconds (Figure 4.10c-f).  Again only generic background staining was 
observed.  There are two possible reasons for this; 0.02% is too weak 
to stain for GAGs or there was insufficient GAG production after three 
days in culture to be detected by the histological stain Alcian Blue.  In 
addition to optimising the Alcian Blue staining conditions, it was thought, 
due to the small size of the beads, that the fixation time could be 
reduced.  Some beads were fixed for one hour at 4oC and another 
group were fixed for 10mins at room temperature.  It was difficult to 
determine whether there was any difference between the two fixing 
periods from the Alcian Blue images, so some sections were stained 
with H&E (Figure 4.10g and h).  The H&E images show little difference 
between the two fixation times.  As the beads appeared to be 
sufficiently fixed after ten minutes, this shorter incubation was adopted 
in all future work. 
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Figure 4.10: Alcian Blue and H&E staining of alginate beads seeded with canine 
chondrocytes.  Initial seeding density for alginate beads: 2x106 cells/ml.  Beads were 
either fixed for one hour at 4oC (a, c, e and g) or ten minutes at room temperature (b, 
d, f and h).  Slides were dipped three times in Alcian Blue (a and b) or incubated with 
the stain for ten (c and d) or twenty (e and f) seconds.  Sections in (g) and (h) were 
stained with H&E.  Only generic background staining was seen in all the sections 
stained with alcian blue.  There appeared to be no difference between samples fixed 
for different lengths of time.  All images taken with a magnification of x200, scale bars: 
100µm. 
a b
c d
e f
g h
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   4.2.2.4 Safranin O 
 
Due to the lack of specific staining observed with Alcian Blue, a different 
stain was tested.  Safranin O has been used in the literature to stain for 
GAGs produced by chondrocytes in alginate beads (Chubinskaya et al., 
2001, Chubinskaya et al., 2007, Chubinskaya et al., 2008).  Safranin O 
is a positively charged dye that binds to polyanions (molecules or 
chemical complexes containing multiple negatively charged sites) 
(Rosenberg, 1971), therefore it will bind to the negatively charged 
chondroitin 6-sulphate or keratan sulphate (Rosenberg, 1971).  
3URIHVVRU6XVDQ&KXELQVND\D¶VJURXSDW5XVK8QLYHUVLW\URXWLQHO\VWDLQ
chondrocyte seeded alginate beads with Safranin O and their method 
was followed for the staining of alginate beads in this study.  Their 
protocol was adapted from that given in (Rosenberg, 1971).  Some 
VOLGHV ZHUH VHQW WR 3URIHVVRU &KXELQVND\D¶V JURXS IRU VWDLQLQJ
Although the alginate stained intensely, like with the Alcian Blue, the 
staining for GAGs could be differentiated from this background staining 
(Figure 4.11). 
 
 
 
  
258 
 
 
Figure 4.11: Safranin O staining of alginate beads.  (a) Alginate-only bead (b) 
chondrocyte seeded bead (arrows indicate staining for GAGs).  Images: magnification: 
x2006HFWLRQVP1RVFDOHEDUVZHUHSURYLGHGE\3URIHVVRU&KXELQVND\D¶VJURXS 
 
As staining of alginate and GAGs could be differentiated with Safranin 
O, this was used to stain test samples. 
 
   4.2.2.5 Phenotype of Canine Chondrocytes of 
Different Passages Cultured within Alginate Beads 
 
Having established the 3D culture system of encapsulating 
chondrocytes within alginate beads, it was decided to test different 
passages within this environment to see if their differentiation 
capabilities differed depending on the length of time spent in monolayer 
culture. It had been reported previously that chondrocytes lose their 
ability to redifferentiate after prolonged monolayer culture (Benya and 
Shaffer, 1982). Canine chondrocytes were expanded in monolayer and 
encapsulated within alginate beads at passages two, three and four.  
The cells were seeded into alginate beads at an initial density of 2x106 
cells/ml of alginate.  Beads were culture in culture medium 
a b
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(DMEM+10%FBS+2% antibiotics) at 37oC, 5% CO2 for 28 days.  GAG 
production within the beads was assessed by Safranin O staining 
(Figure 4.12). Staining was observed in beads seeded with 
chondrocytes from all three passages (Figure 4.12b-d).  There was no 
clear difference in the staining between the different beads. 
 
 
Figure 4.12 Alginate beads seeded with canine chondrocytes from different 
passages stained for GAG production using Safranin O.  (a) Alginate-only bead, 
(b) bead seeded with P2 cells, (c) bead seeded with P3 cells, (d) bead seeded with P4 
cells.   Arrows indicate staining of GAGs; staining appeared to be similar in all beads, 
regardless of the passage of the cells seeded.  Sections: 5µm.  Images taken with a 
magnification of x400, scale bar: 150µm.   
 
The chondrogenic phenotype of the cells encapsulated within the beads 
was assessed by detecting for collagen types I and II and CD44 by 
a
c
b
d
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immunohistochemistry and western blotting.  The staining for collagen 
type I in the beads seeded with P2 and P3 canine chondrocytes looked 
similar to that observed in the isotype control (Figure 4.13b-f) with 
intense staining immediately surrounding the cells.  Some intense 
staining was also seen in the same area in the beads seeded with P4 
cells (Figure 4.13g); however in some sections there was some lighter, 
marginally more widespread staining. 
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a b
c d
e f
g h
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Figure 4.13:  Expression of collagen type I in alginate beads seeded with P2, P3 
and P4 canine chondrocytes. (a) Canine tendon tissue stained for collagen type I 
(positive control), (b) alginate bead seeded with P2 canine chondrocytes incubated 
with an isotype control primary antibody (c-h) alginate beads seeded with 
chondrocytes from different passages stained for collagen type I; P2 (c-d), P3 (e-f) 
and P4 (g-h).   Staining in the P2 and P3 beads appears similar to the isotype control, 
indicating non-specific staining.  There are areas similar to the isotype control in the 
P4 beads but there are also areas of more diffuse staining. Sections: 5µm.  Images 
taken with a magnification of x400, scale bars: 50µm. 
 
Staining for collagen type II within the P2-seeded beads had the same 
distribution as the isotype control (immediately surrounding the cells) 
but was more intense (Figure 4.14b-d).  Beads seeded with P3 
chondrocytes also stained intensely for collagen type II in the area 
immediately surrounding the cells (Figure 4.14e-f).  Staining was 
strongest where there was a cluster of cells present. Collagen type II 
expression appeared to be the strongest in P4-seeded beads (Figure 
4.14g-h).  Intense staining was observed around the cells as well as a 
lighter staining throughout bead. 
 
CD44 staining was observed immediately surrounding the cells (Figure 
4.15d-e).  Staining appeared to be more intense and specific in all 
samples compared to the isotype control; the latter showed light 
staining of the alginate and slighter darker pockets of staining around 
the cells (Figure 4.15c).  The strongest detection of CD44 was observed 
in beads seeded with P4 chondrocytes. 
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Figure 4.14: Expression of collagen type II in alginate beads seeded with P2, P3 
and P4 canine chondrocytes.  (a) Canine cartilage tissue stained for collagen type II 
(positive control), (b) alginate bead seeded with P2 canine chondrocytes incubated 
with an isotype control primary antibody (c-h) alginate beads seeded with 
chondrocytes from different passages stained for collagen type II; P2 (c-d), P3 (e-f) 
and P4 (g-h).  The strongest staining was seen in beads seeded with P4 canine 
chondrocytes and was dispersed throughout the bead. Sections: 5µm.  Images taken 
with a magnification of x400, scale bars: 50µm. 
a b
c d
e f
g h
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Figure 4.15: Expression of CD44 in alginate beads seeded with P2, P3 and P4 
canine chondrocytes.  (a) Canine mammary tumour tissue stained for CD44 
(positive control) (unstained tissue section and anti-canine CD44 antibody (MAB5449, 
R&D Systems) kindly provided by Dr Cinzia Allegrucci, University of Nottingham), (b) 
Canine cartilage tissue stained for CD44 (positive control), (b) alginate bead seeded 
with P2 canine chondrocytes incubated with an isotype control primary antibody (c-h) 
alginate beads seeded with chondrocytes from different passages stained for CD44; 
P2 (c-d), P3 (e-f) and P4 (g-h). Sections: 5µm.  Images taken with a magnification of 
x200 (a), scale bar: 100µm and a magnification of x400, scale bars: 50µm (b-i). 
 
To further investigate the expression of collagen types I and II and 
CD44 by the cells encapsulated within the beads, beads were 
a b c
d e
f g
h i
  
265 
 
dissociated and a cell lysate was generated for use in western blotting.  
For the sample (P2), 10 beads and 20 beads were both dissociated to 
generate a cell lysate for western blotting. The protein concentration in 
both samples was too low to obtain an accurate value.  Therefore, in 
subsequent samples the number of beads used to generate cell lysates 
was increased to 50 beads.  The P2 samples were freeze-dried to 
concentrate the protein within the sample.  The larger sample (20 beads) 
produced a high enough protein concentration to load 25µg on to the 
SDS-PAGE gel.  25µg of all samples were loaded onto the SDS-PAGE 
gel.   
 
In the blots for collagen type I, two bands were detected in the samples 
from the P3 and P4 beads (Figure 4.16a).  The lower band is not visible 
in the blot for P2 beads; the densitometry result for this sample may 
have been influenced by the shadowing from the positive control band 
(Figure 4.16d).  The densitometry for the higher molecular weight band 
indicates that collagen type I expression is highest in the beads seeded 
with P2 chondrocytes (4.16b).  Collagen type II expression was also 
highest in the P2 seeded beads (Figure 4.16e-h).  CD44 expression 
was lowest in the beads seeded with P2 chondrocytes (i-k).  There was 
a peak in CD44 expression in P3 seeded beads.
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Figure 4.16: Expression of collagen types I and II and CD44 by chondrocytes 
cultured within alginate beads.  Cells were expanded in monolayer and seeded into 
alginate at P2, P3 and P4.  Chondrocytes were cultured in alginate beads for 28 days. 
(a) western blot for collagen type I (b) corresponding beta actin blot (c) densitometry 
for the upper band on the blot in (a), (d) densitometry for the lower band on the blot in 
(a); (e) western blot for collagen type II, (f) corresponding beta actin blot, (g) 
densitometry for the upper band on the blot in (e), (h) densitometry for the lower band 
on the blot in (e); (i) western blot for CD44, (j) corresponding beta actin blot, (k) 
densitometry for the blot in (i).   25µg of each bead lysate was loaded onto the gel.  All 
lysates were generated from 50 beads except P2 which was generated from 20 beads. 
Exposures: (a) and (e): one minute 30 seconds, (i): three minutes, (b), (f) and (j): one 
second.  The P2 chondrocytes had the highest expression of both collagen types and 
the lowest expression of CD44.  T: canine tendon lysate ȝO & FDQLQH FDUWLODJH
O\VDWH ȝO 6 FDQLQH VSOHHQ O\VDWH ȝJ  )or original western blot images see 
Appendix D. 
 
4.3 Discussion 
 
Many research groups have used various methods of 3D culture to 
maintain the chondrocyte phenotype, induce chondrogenic 
differentiation and generate articular cartilage in vitro.  One of the most 
common methods used is high density pellet culture and as such this 
technique was initially adopted for this study.  However, pellets were 
very unstable during culture and processing.  Therefore, it was decided 
that the chondrocytes would need a supporting material for 3D culture.  
Although it must be acknowledged that some research groups use an 
alternative method for generating high density pellets.  Instead of 
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centrifugation, some researchers have seeded chondrocytes at high 
densities into 48 (Ibold et al., 2009) and 96 (Lubke et al., 2005) well 
plates.  This could be considered as an alternative to providing a 
supporting structure. 
 
Alginate was chosen because it has been used to culture chondrocytes 
from a variety of species including humans (Hauselmann et al., 1996, 
Chubinskaya et al., 2001), cows (Hauselmann et al., 1994, van Osch et 
al., 1998, Lee et al., 2003), rabbits (De Ceuninck et al., 2004), rats (Loty 
et al., 1998) and dogs (Rai et al., 2009).  Alginate is a naturally 
occurring polymer found in the intercellular spaces and cell walls of 
brown algae (Nussinovitch and Nussinovitch, 2011, Lee and Mooney, 
2012).  
 
Seeding the cells into alginate beads created a more stable 3D culture, 
which could be manipulated and processed for downstream analysis.  
When the viability of the cells within the beads was assessed using 
different concentrations of SNP, it was found that 1µM, 0.5µM and 1nM 
increased cell viability and 0.5nM and 0.1nM only slightly decreased cell 
viability.  Results for 0.5mM SNP were variable and 1mM SNP 
consistently reduced cell viability although none of this data was 
statistically significant.  Chondrocyte cell death induced by 1mM SNP 
incubation has also been reported in the literature (Notoya et al., 2000, 
Kim et al., 2005, Cherng et al., 2008).  Another group reported 
significant cell death of chondrocytes after incubation with 1.6mM SNP 
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(Kuhn and Lotz, 2003).  Two papers found 0.5mM SNP decreased 
chondrocyte viability (Notoya et al., 2000, Cherng et al., 2008), however 
only Cherng and colleagues (2008) found this to be significant.  
 
There are differences in the literature in terms of how alginate beads 
are processed for downstream applications, fixation for histological 
techniques being one example.  Considerable work was involved in 
developing a technique for the successful fixation, processing, 
embedding and sectioning of alginate beads. 
 
It had been previously reported that chondrocytes lose their ability to 
redifferentiate after prolonged monolayer culture (Benya and Shaffer, 
1982).  In addition to this, different research groups have seeded 
chondrocytes into alginate at different passages including P0 
(Bonaventure et al., 1994, Hauselmann et al., 1994, Hauselmann et al., 
1996, Chubinskaya et al., 2001), P2 (Bonaventure et al., 1994), P3 (Rai 
et al., 2009), P4 (Bernstein et al., 2009a) and P5 (Caron et al., 2012).  
One group recommend that human chondrocytes passaged no more 
than three or four times should be used for alginate encapsulation 
(Brand et al., 2012).  Therefore, once the alginate bead culture had 
been established, chondrocytes from different passages were seeded 
into the beads to see if passage number had an effect on 
redifferentiation capacity.    Canine chondrocytes were expanded in 
monolayer up to P4 and cells from P2, P3 and P4 were seeded into 
alginate beads at a density of 2x106 cells/ml of alginate.  Beads 
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containing cells from each passage were assessed for the presence of 
collagen types I and II and CD44 using immunohistochemistry.   
Staining for collagen type I was non-specific as the staining observed 
was similar to that in the isotype control.  Sections stained for collagen 
type II exhibited a similar pattern to that of the negative control apart 
from beads seeded with P4 chondrocytes which had positive staining 
throughout the beads.  Staining for CD44 also appeared to be strongest 
in beads seeded with P4 chondrocytes.  To provide a clearer insight 
into the proteins expressed by the chondrocytes within the beads, 
western blotting was performed. 
 
Collagen type I expression was highest in beads seeded with P2 
chondrocytes, followed by P4-seeded beads and P3-seeded beads 
respectively.  A similar pattern was observed for collagen type II 
expression; although for one of the bands, intensity was slightly lower in 
for P4 beads compared to P3.  CD44 expression was considerably 
lower in P2-seeded beads compared to those seeded with P3 and P4 
chondrocytes.  Expression peaked in beads seeded with P3 
chondrocytes.  The majority of studies involving chondrocytes seeded 
into alginate beads use cells from one passage.  One group did 
compare mRNA expression of collagen type X and aggrecan by P0 and 
P2 cells encapsulated in alginate (Bonaventure et al., 1994).  They 
found that expression of both genes were higher in P0 cells 
(Bonaventure et al., 1994).  The authors also show that collagen type II 
mRNA was expressed in P2 cells but no data is shown for the P0 cells 
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(Bonaventure et al., 1994).  This would seem to suggest that the P2 
chondrocytes have retained at least some of their native phenotype by 
still expressing collagen type II. Lee and colleagues (Lee et al., 2003) 
cultured bovine chondrocytes in monolayer up to P4 and subsequently 
seeded cells in alginate and cultured them for seven days.  Alongside 
this, they also seeded freshly isolated cells into alginate and passaged 
cells into new batches of alginate, again up to P4 (Lee et al., 2003).  
The immunohistochemistry data presented was just for P4 (Lee et al., 
2003).  The images show that cells previously expanded in monolayer 
prior to alginate culture were positive for collagen type I but were 
negative for both collagen type II and chondroitin sulphate (Lee et al., 
2003).  However, for cells passaged in alginate the opposite was the 
case (Lee et al., 2003).  Part of this data contrasts with the data 
presented in this chapter as collagen type II expression was clearly 
identified the P4 group through western blotting.  Another group 
assessed the redifferentiation of P5 human chondrocytes (Caron et al., 
2012).  The authors compared redifferentiation in monolayer, alginate 
and pellet culture.  All cells were cultured in the same chondrogenic 
medium (DMEM/F12, 1% antibiotic/antimycotic and 1% NEAA, 
supplemented with 1% insulin-transferrin-sodium selenite medium 
supplement (ITS), 1% L-ascorbic acid-2-phosphate and 10ng/ml TGF-
ȕ (Caron et al., 2012).  Interestingly, mRNA expression of collagen 
type II was higher in alginate beads and pellets, however the highest 
protein expression was seen in monolayer cultures (Caron et al., 2012).  
This would seem to suggest that there is a difference seen in mRNA 
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and protein expression in different culture conditions and could be an 
interesting avenue to explore further with the work in this thesis.  
Although collagen type II was detected in alginate beads seeded with 
P4 canine chondrocytes, levels were lower than P3 and P2, suggesting 
a reduced ability to synthesise collagen type II with increasing passage.  
Collagen type II expression was also observed in monolayer culture at 
all passages (P1-P5) (see Chapter 3, Figure 3.18), although there was 
a decrease with increasing passage.  This would appear to contrast 
ZLWK &DURQ¶V JURXS ZKR REVHUYHG KLJK OHYHOV RI FROODJHQ W\SH ,, LQ
monolayer culture at P5.  Collagen type I mRNA and protein expression 
was highest in alginate beads (Caron et al., 2012).  This would suggest 
that alginate culture does not completely redifferentiate monolayer 
expanded chondrocytes.  This is in agreement with the findings in this 
thesis as dedifferentiation markers CD44 and collagen type I were 
expressed in all alginate cultures.  
 
4.4 Conclusion 
 
The majority of the work presented in this chapter focused on 
establishing a 3D culture system for canine articular chondrocytes, 
which could be manipulated for downstream applications and analysis.  
After initial problems with the high density pellet culture method, a 
supporting material was chosen.  Alginate beads were successfully 
established and after adjusting the preparation of samples, the 
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phenotype of the cells encapsulated within the beads could be 
assessed using immunohistochemistry and western blotting. 
 
The final part of this chapter was to see if passage number of the 
monolayer cultures had an impact on chondrocyte redifferentiation.  In 
terms of collagen type II and CD44 expression, P2-seeded alginate 
beads appeared to contain cells with a more chondrocyte-like 
phenotype.  However, collagen type I expression was still high in these 
beads.  These initial results suggest that P2 chondrocytes have a 
greater capacity for redifferentiation; however 3D culture alone is not 
enough to promote complete redifferentiation.  The next chapter 
focuses on ways of enhancing the redifferentiation process. 
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5. Enhancement of Chondrocyte 
Redifferentiation in 3D Culture 
 
5.1 Background 
 
The in vitro environment in which chondrocytes are cultured in varies 
considerably from their native, in vivo environment.  Therefore, there 
are many factors which can have an impact on chondrocyte 
dedifferentiation and subsequent redifferentiation in vitro.  Altering the 
culture environment from 2D to 3D alone is not enough to reverse or 
prevent the dedifferentiation of chondrocytes in vitro.  Therefore 
additional changes must be made to the culture system to enhance 
chondrocyte redifferentiation.  Broadly speaking, these adjustments can 
be grouped into adding soluble factors to culture media or changing the 
physical conditions surrounding the 3D constructs. 
 
Although the exact compositions of media used to maintain the 
chondrocyte phenotype in vitro vary, ascorbate is a common feature.  
Ascorbate (Vitamin C) is crucial for collagen synthesis as it acts as a 
cofactor for the hydroxylation of prolines and lysines, which form the 
intermolecular bonds in the collagen triple helix (Barnes, 1975, Pinnell, 
1985, Stabler and Kraus, 2003).  Schiltz and colleagues (1977) found 
that ascorbate affected the hydroxyproline content of collagen in tooth 
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germs.  In another paper studying human fibroblasts, incubation with L-
ascorbic acid and D-isoascorbic acid was found to increase collagen 
expression (Murad et al., 1981).  In the same study, enzymes involved 
in the hydroxylation of lysine and proline (lysyl hydroxylase and prolyl 
hydroxylase respectively), were found to be upregulated in ascorbate 
treated cultures.  However, the latter enzyme was only upregulated by 
treatment with L-ascorbic acid for 24 hours (Murad et al., 1981).  In a 
later study, the same group also showed that collagen production by 
human fibroblasts was increased by various forms of ascorbate (L-
ascorbate, D-isoascorbate, D-ascorbate and L-dehydroascorbate) 
(Murad et al., 1983).  In fact, it was shown that L-ascorbate induced 
large increases at much lower concentrations compared to the other 
forms of ascorbate.  Lysyl hydroxylase activity was also increased by all 
forms of ascorbate and again L-ascorbate had the biggest impact 
(Murad et al., 1983).   
 
In addition to this, ascorbate is often included in chondrogenic media 
used to direct MSCs to differentiate down the chondrogenic lineage (Ma 
et al., 2003, Koerner et al., 2006, Richardson et al., 2006, Csaki et al., 
2007, Giovannini et al., 2008, Stewart et al., 2008, Vidal et al., 2008, 
Colleoni et al., 2009, da Silva Meirelles et al., 2009, Vieira et al., 2009).  
It has also been shown that gene expression of collagen type II, Sox9 
and aggrecan increased in mouse embryonal carcinoma-derived cell 
line (ATDC5) cells following incubation with ascorbate (Altaf et al., 
2006).  However it must also be noted that gene expression of collagen 
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type X was also enhanced in these cells following ascorbate incubation 
(Altaf et al., 2006), indicating hypertrophic differentiation.   
 
In addition to adding soluble factors to culture media, it is thought that 
mimicking the in vivo environment as closely as possible will enhance 
chondrocyte redifferentiation.  There are many elements to the in vitro 
culture of chondrocytes which differ greatly from the natural 
chondrocyte environment.  One such condition is oxygen tension.  
Traditionally, in vitro cell culture is conducted at atmospheric conditions, 
which means the oxygen tension chondrocytes are exposed to is 
around 21% (160mmHG).  The oxygen tension within the joint is 
considerably lower than this.  Lund and colleagues (1970)  measured 
oxygen tension within 103 human knee joints.  They found that oxygen 
tension ranged from 26.53mmHG (3.5%) in patients suffering with 
rheumatoid arthritis to 42.92mmHG (5.6%) in osteoarthrosis joints.  
Another group measured oxygen tensions within the knee joints of 
naïve, pre-arthritic and arthritic mice, finding tensions of 29mmHG 
(3.8%), 25mmHG (3.3%) and 15mmHG (2.0%) respectively 
(Etherington et al., 2002).  Zhou et al (2004) reviewed the oxygen 
tensions within rabbit knee, dog knee, bovine ankle and knee and 
human knee cartilage using mathematical modelling.  They found that 
the lowest oxygen tensions ranged from ~5% in the rabbit knee to 
~1.5% in the human knee (Zhou et al., 2004).  It has been said that 
hypoxia (a term used to describe low oxygen conditions) alongside 
mechanical loading, are two factors that have a major impact on adult 
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cartilage (Lafont, 2010).  One study has shown that human 
chondrocytes cultured in monolayer downregulated 101 genes which 
were subsequently upregulated following incubation in hypoxic 
conditions (Lafont et al., 2008).  Gene expression of aggrecan and 
collagen type II was found to be significantly upregulated following 
culture under reduced oxygen conditions (Lafont et al., 2008).  Hypoxia-
inducible factors -Į+,)-ĮDQG-Į+,)-ĮDUHYLWDOIRr chondrocyte 
survival in low oxygen conditions (Schipani, 2005, Lafont et al., 2007, 
Lafont, 2010).  In oxygen tensions above 5%, these proteins are rapidly 
degraded (Lafont, 2010).  In hypoxic conditions, HIF- Į ZLOO ELQG WR
HIF-ȕ ZKLFK LV FRQVWLWXWLYHO\ H[SUHVVHG E\ WKH FHOO (Lafont, 2010).  
This heterodimer will then translocate to the nucleus to activate gene 
expression (Lafont, 2010).  In one paper, it is suggested that HIF-Į up-
regulates cartilage matrix gene expression through induction of Sox9 
(Lafont et al., 2007). 
 
Taking into consideration the various and complex conditions used to 
help maintain or induce the chondrocytic phenotype in vitro, it was 
decided that a soluble factor and a change in physical condition should 
be tested in the first instance for their impact on redifferentiation.  Due 
to the fact that ascorbate appears frequently in chondrogenic media and 
is a key cofactor in collagen synthesis, this was chosen as the soluble 
factor.  In terms of changing the physical environment surrounding the 
alginate beads, it was decided to lower the oxygen tension.  This 
condition was chosen as reducing the oxygen tension would be one 
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way of trying to more closely mimic in vivo conditions.  Specifically, an 
oxygen tension of 2.4% was used for the experiments detailed in this 
chapter.  Oxygen tension levels within the joint, quoted in the literature, 
range from 1.5% to 5% (Lund-Olesen, 1970, Etherington et al., 2002, 
Zhou et al., 2004), therefore it was decided to use the lowest tension 
possible within this range.  Due to equipment constraints, this level was 
set at 2.4%.  It was decided to test these factors in isolation initially to 
assess their individual contribution to chondrocyte redifferentiation.    
  
It was also thought to be important to include a factor that would inhibit 
chondrocyte redifferentiation, in order to confirm that the process of 3D 
culture encourages redifferentiation before additional changes to the 
culture conditions were made.  This would then help to illustrate that 
any enhancement seen by the addition of ascorbate or incubation under 
reduced oxygen conditions were caused by these changes in culture 
conditions.  For this part of the study, the inflammatory cytokine, IL-ȕ
was chosen.  IL-ȕ LV PDLQO\ SURGXFHG E\ PRQRF\WHV DQG LQGXFHV
production of neutral metalloproteinases and serine proteinases in 
chondrocytes (Goldring et al., 1988).  It is also has a major involvement 
in the pathogenesis of OA (Wojdasiewicz et al., 2014), so the effect of 
IL-ȕ RQ WKH SKHQRW\SH RI FXOWXUHG FHOOV PD\ KDYH implications on 
cellular treatments for degenerative joint disease.  It has also previously 
been shown to reduce matrix production (Cook et al., 2000) and 
expression of collagen type II in canine chondrocytes (Kuroki et al., 
2004).  In addition to this, IL-ȕKDVEHHQGHVFULEHGDVDIDFWRUWKDWFDQ
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be used to accelerate the dedifferentiation of chondrocytes in 
monolayer culture (Goldring et al., 1994).  Goldring and colleagues 
(1994) have shown that expression of collagen type II by immortalised 
human chondrocytes decreased with increasing culture time in the 
presence of IL-ȕ  $ PRUH UHFHQW SDSHU E\ D GLIIHUHQW JURXS DOVR
showed a reduction in expression of collagen type II with IL-1ȕ E\
immortalised human chondrocytes in monolayer (Robbins et al., 2000).  
Il-ȕ LQFXEDWLRQKDG WKHRSSRVLWHHIIHFWRQFROODJHQ W\SH ,H[SUHVVLRQ
This group also demonstrated similar findings with chondrocytes 
cultured in alginate (Robbins et al., 2000).  Another research group 
investigate the effects of short exposure to IL-ȕ RQH WKUHH DQG VL[
hours) on equine chondrocytes (Takafuji et al., 2005).  A significant 
decrease in collagen type II expression was only observed after six 
hours of exposure (Takafuji et al., 2005).  This would suggest that short 
term exposure has little effect on the dedifferentiation of chondrocytes 
in culture.  
 
Therefore the aim and subsequent hypotheses for this chapter were as 
follows: 
 
Aim: To identify factors that will enhance chondrocyte redifferentiation in 
3D culture. 
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+\SRWKHVLV2QH$GGLWLRQRIDVFRUELFDFLGȝJPOWRWKHFHOOFXOWXUH
medium will enhance the redifferentiation of canine 
chondrocytes cultured three dimensionally following 
expansion in monolayer culture. 
 
Hypothesis Two:     Culturing chondrocytes in a 3D system in an oxygen 
concentration of 2.4% will enhance the 
redifferentiation of monolayer expanded canine 
chondrocytes. 
 
Hypothesis Three:  Addition of IL-ȕ QJPO WR WKH FHOO FXOWXUH
medium will inhibit the redifferentiation of canine 
chondrocytes cultured three dimensionally following 
expansion in monolayer. 
 
5.2 Results 
 
5.2.1 Expression of Collagen Types I and II and CD44 by 
Chondrocytes Cultured within Alginate Beads in Response to 
Ascorbate, Reduced Oxygen Tension and IL-ȕ 
 
Alginate beads were seeded with P2 canine chondrocytes and were 
cultured for 35 days.  Beads were placed in culture medium 
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(DMEM+10%FBS+2% antibiotics) at 37oC, 5% CO2, 20% oxygen for 
four days, in order to allow the cells to settle into the beads.  On day 
four (day zero being the day cells were seeded into alginate) the beads 
were grouped into different treatments.  Control beads remained in the 
same conditions. The IL-ȕ JURXS ZDV FXOWXUHG LQ PHGLD FRQWDLQLQJ
10ng/ml IL-ȕ  %HDGV WUHDWHd with ascorbate were cultured in media 
containing 25µg/ml ascorbate. The beads in the reduced oxygen 
tension group were cultured in the same medium as the control group 
but were incubated in 2.4% oxygen, 5% CO2.  Beads were created from 
chondrocytes isolated from two different animals.  Beads from each 
animal were selected and pooled for downstream assays. 
 
Expression of collagen type I was initially assessed using 
immunohistochemistry.  Dark areas of staining surrounding the cells 
was seen in the isotype control (Figure 5.1b).  This staining was also 
seen in the control and IL-ȕ EHDGV )LJXUH F DQG G  6WDLQLQJ
appeared different to the isotype control in beads incubated with 
ascorbate or in reduced oxygen conditions (Figure 5.1e and f).  
However in all sections the staining surrounding the cells appeared to 
be non-specific. 
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Figure 5.1:   Alginate beads seeded with P2 canine chondrocytes incubated in 
various conditions for 35 days, stained for collagen type I.  (a) canine tendon 
stained with collagen type I (positive control), (b) representative isotype control (day 
14 control bead incubated with an isotype control primary antibody), (c) control bead 
(culture medium, 37oC, 5% CO2, 20% oxygen), (d) IL-ȕ EHDG FXOWXUH PHGLXP
supplemented with 10ng/ml, 37oC, 5% CO2, 20% oxygen), (e) ascorbate bead (culture 
medium supplemented with 25µg/ml ascorbate, 37oC, 5% CO2, 20% oxygen) and (f) 
reduced oxygen bead (culture medium, 37oC, 5% CO2, 2.4% oxygen).  The majority of 
the staining appeared to be non-specific as it was similar in the test samples and the 
isotype control.  There was more disperse, lighter staining in (e) and (f) which could 
indicate higher expression of collagen type I in tKHVHJURXSVDV WKLV VWDLQLQJ ZDVQ¶W
present in the isotype control.  Images taken with a magnification of x400, scale bars: 
50µm.  Sections: 5µm. 
 
There was strong staining for collagen type II immediately surrounding 
the cells in all of the treatment groups and the control group (Figure 
5.2c-d); however there was also evidence of similar staining in the 
isotype control (Figure 5.2b).  There appeared to be stronger staining 
and more disperse staining in the ascorbate treated beads (Figure 5.2e), 
which could indicate higher collagen type II production in this group.  
Although the staining of the reduced oxygen beads appeared to be 
stronger than the isotype control (Figure 5.2f), it was similar to control 
group beads, suggesting that collagen type II synthesis was not 
enhanced in this group.  
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Figure 5.2:   Alginate beads seeded with P2 canine chondrocytes incubated in 
various conditions for 35 days, stained for collagen type II.  (a) canine cartilage 
stained with collagen type II (positive control), (b) representative isotype control (day 
14 control bead incubated with an isotype control primary antibody), (c) control bead 
(culture medium, 37oC, 5% CO2, 20% oxygen), (d) IL-ȕ EHDG FXOWXUH PHGLXP
supplemented with 10ng/ml, 37oC, 5% CO2, 20% oxygen), (e) ascorbate bead (culture 
medium supplemented with 25µg/ml ascorbate, 37oC, 5% CO2, 20% oxygen) and (f) 
reduced oxygen bead (culture medium, 37oC, 5% CO2, 2.4% oxygen).  The greatest 
staining was observed in the ascorbate treated alginate beads. Staining surrounding 
the cells was present in all samples however a similar pattern of staining was 
observed in the isotype control.  Images taken with a magnification of x400, scale bars: 
50µm.  Sections: 5µm. 
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CD44 staining appeared to be non-specific in the control, IL-ȕ DQG
ascorbate groups as the pattern of staining seen surrounding the cells 
was similar in the isotype control (Figure 5.3b-e).  However the light 
background staining was not seen in any of the test samples.  Beads 
incubated in reduced oxygen conditions were negative for CD44 (Figure 
5.3f). 
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Figure 5.3:   Alginate beads seeded with P2 canine chondrocytes incubated in 
various conditions for 35 days, stained for CD44.  (a) canine cartilage stained with 
CD44 (positive control), (b) representative isotype control (day 14 control bead 
incubated with an isotype control primary antibody), (c) control bead (culture medium, 
37oC, 5% CO2, 20% oxygen), (d) IL-ȕ EHDG FXOWXUH PHGLXP VXSSOHPHQWHG ZLWK
10ng/ml, 37oC, 5% CO2, 20% oxygen), (e) ascorbate bead (culture medium 
supplemented with 25µg/ml ascorbate, 37oC, 5% CO2, 20% oxygen) and (f) reduced 
oxygen bead (culture medium, 37oC, 5% CO2, 2.4% oxygen).  Staining surrounding 
the cells was present in all samples except those incubated in reduced oxygen 
conditions; however a similar pattern of staining was observed in the isotype control.   
Beads incubated in reduced oxygen conditions appeared to be negative for CD44.  
Images taken with a magnification of x400, scale bars: 50µm.  Sections: 5µm. 
 
In many cases, the staining for all three antigens appeared similar to 
the isotype controls, indicating non-specific staining.  Therefore in order 
to get a clearer idea of the expression of collagen types I and II and 
CD44 by the cells within these beads, western blotting was used.  
Protein lysates were generated by lysing 50 beads (25 beads were 
selected from each animal).  Collagen type I expression was lower in 
the IL-ȕWUHDWHGJURXSFRPSDUHGWRWKHFRQWURODQGFRQVLGHUDEO\ORZHU
in the reduced oxygen group (Figure 5.4a-c).   
 
Two bands were detected in the collagen type II blot (Figure 5.4d).  For 
the higher molecular weight band, expression was slightly higher in the 
IL-ȕ JURXS FRPSDUHG WR WKH FRQWURO )LJXUH G DQG I  ([SUHVVLRQ
was considerably higher in the ascorbate group and lower in the 
reduced oxygen group when compared to the control sample.  
  
287 
 
Expression of the lower molecular weight form was higher in all 
treatment groups compared to the control group, with expression 
peaking in the ascorbate group (Figure 5.4g).  
 
 
 
CD44 was not detected in any sample except the ascorbate treated 
group (Figure 5.4h) 
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Figure 5.4: Expression of collagen types I and II and CD44 in alginate beads 
seeded with P2 canine chondrocytes cultured in various conditions for 35 days. 
(a) western blot for collagen type I (b) corresponding beta actin blot (c) densitometry 
for the bands in the blot in (a); (d) western blot for collagen type II (e) corresponding 
beta actin blot, (f) densitometry on the upper band in the blot in (d), (g) densitometry 
on the lower band in the blot in (d); (h) western blot for CD44, (i) corresponding beta 
actin blot. C: control (culture medium, 37oC, 5% CO2, 20% oxygen), IL: IL-ȕFXOWXUH
medium supplemented with 10ng/ml, 37oC, 5% CO2, 20% oxygen), A: ascorbate 
(culture medium supplemented with 25µg/ml ascorbate, 37oC, 5% CO2, 20% oxygen) 
and R: reduced oxygen (culture medium, 37oC, 5% CO2, 2.4% oxygen). Each protein 
sample was generated from 50 beads.  Exposures: (a) three minutes, (d) 30 seconds, 
(h) five minutes, (b, e and i) one second.  Expression of both collagen types was 
highest in the ascorbate treated group; although collagen type I expression was only 
marginally higher than the control.  CD44 was only detected in the ascorbate treated 
group. 
 
5.2.2 Change in GAG Production in Response to Ascorbate, 
Reduced Oxygen Tension and IL-ȕ 
 
Staining for GAGs was observed in all groups (Figure 5.5b-e).  Staining 
appeared to be more prevalent in the ascorbate treated group, however 
this may be due to the presence of clusters of cells; although the 
staining was weaker in the cell cluster in the IL-ȕWUHDWHGEHDG,QWKH
reduced oxygen group, staining appeared to be intense immediately 
surrounding the cells but there was also some weaker staining further 
away from the cells.  To get a better indication of the GAG production in 
the different groups, the DMMB assay was performed (Figure 5.5f).  
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Beads incubated with IL-ȕFRQWDLQHGVLJQLILFDQWO\ OHVV*$*VWKDQWKH
control beads (p=<0.001), whereas cells within the beads incubated 
with ascorbate and reduced oxygen produced significantly more GAGs 
(p=<0.05 and <0.001 respectively) (Figure 5.5f).  However, to get a true 
sense of the significance of this data, the DNA content of the beads 
should have been analysed and GAG data normalised to this 
information. 
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Figure 5.5: GAG staining and production in alginate beads seeded with P2 
canine chondrocytes incubated in various conditions for 35 days.  (a)-(e) beads 
stained with Safranin O, (a) alginate only bead, (b) control (culture medium, 37oC, 5% 
CO2, 20% oxygen) (c) IL-ȕ FXOWXUHPHGLXPVXSSOHPHQWHGZLWKQJPOoC, 5% 
CO2, 20% oxygen), (d) ascorbate (culture medium supplemented with 25µg/ml 
ascorbate, 37oC, 5% CO2, 20% oxygen) (e) reduced oxygen (culture medium, 37oC, 
5% CO2, 2.4% oxygen); MagniILFDWLRQ[VFDOHEDUȝP (f) DMMB assay for 
GAG production.  Three replicates of five beads were used for each treatment.  Beads 
were selected and pooled from the two different animals. * p=<0.05 and ***p=<0.001 
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5.3 Discussion 
 
There are many different factors used in the literature to maintain the 
chondrocyte phenotype both in monolayer and 3D cultures.  Two 
factors were chosen to enhance redifferentiation, reduced oxygen 
tension and ascorbate.  Treatment of beads with IL-ȕZDVLQFOXGHGDV
a catabolic factor which inhibits chondrocyte redifferentiation. 
 
Assessment of collagen types I and II and CD44 expression was initially 
assessed by immunohistochemistry.  However, the majority of the 
staining seen in the bead sections was non-specific.  Therefore, to get a 
clearer indication of the phenotype of the cells within these beads, 
western blotting was carried out.  Alongside the immunohistochemistry 
and the western blotting, beads were assessed for GAG production 
through Safranin O staining and the DMMB assay. 
 
Collagen type I expression was considerably lower in the reduced 
oxygen group compared to all other groups.  Two bands were detected 
for collagen type II, with expression of the larger form being less than 
the control and the smaller being greater than the control in the reduced 
oxygen group.  CD44 expression was absent in the reduced oxygen 
treated group.  GAG production was significantly higher in reduced 
oxygen beads compared to the control group, although it must be noted 
that this data was not normalised to the DNA content of the beads, 
which may have an impact on the significance of the data.  Duval and 
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colleagues (2009), cultured P2 human chondrocytes in alginate beads 
at a density of 1x107cells/ml at 5% oxygen (termed hypoxia) and 21% 
oxygen (termed normoxia).  They found that when compared to P2 
monolayer cells, beads from both groups had lower expression of 
collagen types I and III. However, expression was marginally higher in 
the hypoxic beads.  This contrasts with the western blotting data 
presented in this chapter as a band for collagen type I was not detected 
in the reduced oxygen sample.  However it must be noted that there 
may be differences seen between protein and mRNA expression.  
Collagen type II gene expression was significantly higher in both bead 
groups but was considerably higher in the hypoxia group compared to 
those incubated under normoxia.  This is different to the data presented 
in this chapter where there was little enhancement of collagen type II 
synthesis in the reduced oxygen group.  However it must be noted that 
this experiment was only conducted once and different results may be 
seen with an increased N number.  Aggrecan gene expression was also 
higher in the beads but this difference was only significant in the beads 
incubated in hypoxic conditions (Duval et al., 2009).   
 
Another group incubated bovine chondrocytes in reduced oxygen 
conditions in monolayer and 3D pellet culture. Egli et al (2008) 
incubated chondrocytes growing in monolayer in 1.5% oxygen and 21% 
oxygen.  Proliferation was significantly slower in the 1.5% oxygen group.  
Pellets were incubated at three oxygen tensions, 1.5%, 5% and 21%.  
Gene expression results were only shown for the two monolayer 
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conditions and the 21% oxygen pellet group.  Collagen type I 
expression was upregulated in all groups, whereas collagen type II was 
downregulated compared to fresh chondrocytes.  Aggrecan was 
marginally upregulated in all groups whereas Sox9 was downregulated 
in the pellets (Sox9 expression was not detectable in the monolayer 
groups).  Safranin O staining was found to be strongest in pellets 
cultured in 21% oxygen regardless of the oxygen concentration used for 
monolayer expansion.  The authors also found that there was no 
difference between the 21% oxygen pellets seeded with cells incubated 
at 1.5% oxygen and 21% oxygen in terms of immuno-staining for 
collagen type II (Egli et al., 2008).  This would suggest that oxygen 
conditions for monolayer expansion do not have an impact on the 
phenotype of cells cultured three dimensionally.  Monolayer 
chondrocytes in this study were incubated at 21% oxygen and although 
it appeared to have little impact on the end phenotype it would be an 
interesting consideration for future work in this project.  Babur and 
colleagues (2013) used slightly different oxygen tensions to represent 
hypoxia (2%) and normoxia (20%).  This group looked at macro- and 
micropellets.  Macropellets were formed by centrifuging 2x105 cells 
whereas micropellets were formed using microwell inserts and 
contained 166 cells per pellet.    Total sulphated GAG synthesis by both 
pellets was significantly higher in hypoxic cultures.  This supports the 
data shown in this chapter with respect to reduced oxygen conditions 
enhancing GAG production.  However the authors did observe 
differences between GAG content within the pellets and in the media 
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between the two pellet sizes.  This could be a consideration for future 
work; to analyse what is being released into the medium by the 
chondrocytes within the alginate beads.  In terms of gene expression, 
these authors observed similar patterns to Egli¶VJURXS, however there 
were differences between the macro and micro pellets.  For example, 
aggrecan expression was significantly higher in micropellets incubated 
in 2% oxygen when compared with all other pellets.  However, 
expression in the 2% macropellet was found to be lower than that 
incubated in 20% oxygen.  Collagen type II gene expression was higher 
in both 2% pellets but only significantly higher in the micropellets.  
Collagen type I expression was also significantly higher in the 2% 
oxygen micropellet compared to the 20% and 2% oxygen macropellets.  
Collagen type X expression showed a similar pattern except the 
expression in the 2% oxygen micropellets was significantly higher 
compared to all other pellet groups.  Sox9 expression was significantly 
lower in the 2% macropellet group compared to all other pellet groups.  
This would seem to suggest that pellet size may have an impact on 
gene expression.  All alginate beads generated for the work in this 
thesis were the same size but varying the size could provide an 
interesting comparison.  Immunofluorescence staining indicated that 
pellets cultured in 20% oxygen had a more hypertrophic phenotype, 
staining strongly for collagen type X.  These pellets also stained 
strongly for collagen type I.  Pellets cultured in 2% oxygen stained 
weakly for collagen type X but stained strongly for collagen type II.  
Staining for the latter was weak in the 20% oxygen group (Babur et al., 
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2013).  This is in contrast to the immunohistochemistry data presented 
in this chapter where staining for collagen type II appeared to be similar 
in beads incubated in 21% and 2.4% oxygen.  In another recent paper 
researchers looked at the effect of oxygen concentration on healthy and 
osteoarthritic human chondrocytes in pellet culture (Markway et al., 
2013).    For both healthy and OA chondrocytes, collagen type II and 
aggrecan gene expression was higher in 2% oxygen cultures compared 
to 20% cultures.  The opposite pattern was the case for collagen types I 
and X, with expression being higher in the 20% oxygen cultures.  
Although a clear reduction in collagen type I expression was observed 
in the study in this thesis, in the reduced oxygen group, only slight 
changes in collagen type II expression was evident.   Markway and 
colleagues (2013) also showed that intense staining of collagen type II 
in all groups, although it was visibly less in the 20% oxygen, healthy 
chondrocytes group.  Collagen type I staining was shown in all groups 
but staining was minimal in the 20% oxygen, healthy chondrocytes 
pellet.    Sulphated GAG was also higher in pellets cultured in 2% 
oxygen, for both cell types (Markway et al., 2013).   
 
Murphy and Polak (2004) assessed the effect of different oxygen 
concentrations on P3 human chondrocytes seeded into alginate beads.  
Collagen type I gene expression was considerably lower in the beads 
compared to P3 monolayer chondrocytes.  Statistical significance was 
only reported for the difference between the different oxygen tensions 
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(5% and 20%).  Although collagen type I expression was higher in 5% 
oxygen beads, the difference was not significant.  This is in contrast to 
the western blotting data presented in this chapter as collagen type I 
was clearly reduced in the reduced oxygen group.  However statistical 
analysis could not be applied to this data due to only one experiment 
being carried out.  Gene expression of collagen type II, aggrecan and 
Sox9 was higher in beads compared to monolayer cells.  However, the 
difference between the two oxygen conditions became significant at 
different stages of culture (5% oxygen beads expressed significantly 
higher quantities of collagen type II after 28 days, aggrecan after 14 
days and Sox9 after 7 days).  Beads incubated in 5% oxygen contained 
significantly more GAG than beads incubated at 20% oxygen (Murphy 
and Polak, 2004), supporting the data presented in this chapter.  Domm 
and colleagues (2002) also showed that chondrocytes seeded in 
alginate beads cultured in 5% oxygen exhibit a more chondrogenic 
phenotype compared to the cells cultured at 21% via 
immunocytochemistry.  Staining for collagen types II and IX was 
stronger in the lower oxygen group, whereas staining for collagen type I 
was much stronger in the 21% oxygen group.  This group also 
demonstrated, via western blotting that collagen type II was upregulated 
in alginate beads containing freshly isolated chondrocytes incubated at 
5% oxygen.  They also showed that collagen type II expression was 
absent in beads containing dedifferentiated chondrocytes incubated at 
21% oxygen whereas a band for collagen type II was detected in 
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alginate beads containing dedifferentiated chondrocytes incubated at 
5% oxygen (Domm et al., 2002). 
 
IL-ȕWUHDWHGEHDGVKDGDORZHUH[SUHVVLRQRIFROODJHQW\SH,FRPSDUHG
to control beads.  IL-ȕZDVXVHGDVDQLQKLELWRUWRUHGLIIHUHQWLDWLRQ LQ
order to emphasise the redifferentiation induced by 3D culture alone 
and then subsequently the enhancement of this process with the altered 
cultured conditions.  IL-ȕZDVFKRVHQDVLWKDGSUHYLRXVO\EHHQVKRZQ
to reduce matrix production by chondrocytes (Cook et al., 2000) and it 
has a major involvement in the pathogenesis of OA (Wojdasiewicz et al., 
2014).  Expression of collagen type II was higher than the control for 
both forms detected, although the difference for the higher molecular 
weight form was only slight.  As with the reduced oxygen treated group, 
CD44 expression was absent in the IL-ȕ WUHDWHG JURXS  6HFWLRQV RI
beads treated with IL-ȕ VWDLQHG SRVLWLYHO\ IRU *$*V EXW quantitative 
data showed that GAG production within these beads was significantly 
lower compared to the control group.  Sandell and colleagues (2008) 
examined the effect of IL-ȕRQWKHJHQHH[SUHVVLRQRIKXPDQDUWLFXODU
chondrocytes.  They showed that incubation with 10ng/ml IL-ȕIRU
hours reduced collagen type II and aggrecan expression.  The result for 
collagen type II is in contrast to the data presented in this chapter.  
They also looked at the expression of many chemokines, CCL20, CCL2, 
CX3CL1, CXCL6 and CXCL1 expression increased in IL-ȕ WUHDWHG
chondrocytes.  This group also tested a range of IL-ȕFRQFHQWUDWLRQV
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on the human chondrocytes (0.01, 0.1 and 1ng/ml).  All concentrations 
decreased expression of aggrecan and collagen type II and the 
reduction in expression increased with increasing IL-ȕ FRQFHQWUDWLRQ
When assessing the effect of 0.1ng/ml IL-ȕ LQFXEDWLRQ DW GLIIHUHQW
timepoints (0 hours, 1 hour, 4 hours, 8 hours, 12 hours and 24 hours) it 
was shown that aggrecan and collagen type II expression was only 
reduced in the 24 hour incubation group.    This group also found that 
IL-ȕGHFUHDVHGDJJUHFDQDQGFROODJHQ W\SH ,,H[SUHVVLRQ LQFDUWLODJH 
explants (Sandell et al., 2008). 
 
Ley and colleagues (2011) looked at the effect of 5ng/ml IL-ȕ RQ
equine chondrocytes cultured in 3D pellets.  Compared to untreated 
pellets, Safranin O staining for GAGs was less intense in IL-ȕWUHDWHG
pellets.  Gene expression of collagen types I and II and aggrecan was 
significantly lower in the IL-ȕ WUHDWHG SHOOHWV (Ley et al., 2011).  
Although collagen type I expression was clearly reduced in the IL-ȕ
group in this study, collagen type II expression only varied slightly 
between beads incubated at 2.4% and 21% oxygen.  It must also be 
acknowledged that experiment in this chapter needs to be repeated so 
that statistical analysis can be applied.  
 
One research group has examined the effect of a combination of 
oxygen tension and IL-ȕ RQKXPDQ DUWLFXODU DQG QDVDO FKRQGURF\WHV
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grown in pellets (Scotti et al., 2012).  Pellets were cultured at 19% or 
5% oxygen and treated with 50pg/ml IL-ȕ  6RPH SHOOHWV ZHUH
incubated for a further seven days post IL-ȕ WUHDWPHQW WR HQDEOH
recovery.  In addition to this, the authors tested immature and mature 
cultures; immature pellets were cultured for seven days prior to IL-ȕ
treatment, whereas mature pellets were cultured for 14 days prior to 
treatment.  In immature pellets seeded with articular chondrocytes, 
GAG staining was strongest in the recovery group (pellets incubated 
without IL-ȕIRUDZHHNIROORZLQJWUHDWPHQW for both oxygen conditions, 
suggesting that the effects of IL-ȕ can be reversed.  GAG staining was 
more intense in the mature pellets but the weakest staining was 
observed in the IL-ȕWUHDWHGJURXS  This would suggest that IL-ȕ still 
has an effect on the mature pellets but the longer culture period prior to 
treatment allowed for greater GAG synthesis. A similar pattern was 
observed in the pellets seeded with nasal chondrocytes.  Pellets 
seeded with articular chondrocytes were negative for collagen type II 
when cultured in 19% oxygen, except in the recovery group.  This 
contrasts with the data presented in this chapter as collagen type II 
expression in the IL-ȕ JURXS was detected at similar levels to the 
control group.  All pellets cultured in 5% oxygen stained positively for 
collagen type II but such staining was weaker in the IL-ȕJURXS  This 
would suggest that oxygen conditions have an impact on the effect of 
IL-ȕ  Pellets containing nasal chondrocytes stained positively for 
collagen type II in all groups (staining was shown to be marginally 
stronger in the 5% oxygen groups).  IL-ȕ WUHDWHG EHDGs exhibited 
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weaker staining for collagen type II compared to the control and 
recovery groups (Scotti et al., 2012). 
 
Ascorbate treated beads showed a slightly higher expression of 
collagen type I compared to the control group.  The highest level of 
collagen type II expression, for both forms detected, was seen in the 
ascorbate group.  Beads cultured in medium supplemented with 
ascorbate stained positively for GAGs and produced significantly more 
GAGs than control beads.  Benya et al (1984) showed that 
proteoglycan synthesis in rabbit articular cartilage discs increased with 
the addition oI ȝJPO DVFRUEDWH WR WKH FXOWXUH PHGLD  $QRWKHU
UHVHDUFK JURXS H[DPLQHG WKH HIIHFW RI ȝJPO DVFRUEDWH RQ ERYLQH
chondrocytes expanded in monolayer (Daniel et al., 1984).   The 
authors found that cultures incubated with ascorbate had a more 
developed ECM containing dense fibrillar collagen, compared to the 
sparse and loose collagen network seen in control cultures.  However 
when analysing the specific collagen types, collagen type II expression 
was found to be similar in the ascorbate group compared to controls, 
however, collagen type I expression appeared to be greater in the 
ascorbate group (Daniel et al., 1984), This would suggest that addition 
of ascorbate in monolayer encourages the production of matrix but does 
not prevent chondrocyte dedifferentiation in terms of collagen type I 
synthesis.  Collagen type I expression in the study in this chapter was 
also marginally increased in the presence of ascorbate.     
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Two research groups have looked at different types of ascorbate (Clark 
et al., 2002, Ibold et al., 2009).  Clark and colleagues (2002), incubated 
guinea pig cartilage explants with, L-ascorbic acid, D-isoascorbic acid, 
sodium L-ascorbate, sodium D-isoascorbate or Mg ascorbyl-2-
phosphate.  All types were tested at three concentrations designated as 
ORZ ȝ0 PHGLXP ȝ0 DQG KLJK ȝ0  2XW RI WKH UHVXOWV
shown, only the high dose of sodium L-ascorbate enhanced aggrecan 
expression compared to the control (untreated) group.  Collagen 
synthesis was enhanced in all treatment groups but the increase was 
only significant in the high and low dose sodium L-ascorbate group and 
the high sodium D-isoascorbate or Mg ascorbyl-2-phosphate groups 
(Clark et al., 2002).  In a later study, Ibold et al (2009), incubated high 
density pellets containing bovine chondrocytes with L-ascorbate, 
sodium ascorbate or L-ascorbate-2-phosphate.  These authors also 
WHVWHG WKUHHFRQFHQWUDWLRQVȝ0ȝ0DQGȝ0 7KHDXWKRUV
report that although there was no difference in pellet thickness or cell 
density between treatments, control SHOOHWV GLGQ¶W IRUP D VWDEOH
cohesive matrix.  This differs from Daniel and colleagues who observed 
considerable matrix formation in monolayer with the addition of 
ascorbate (Daniel et al., 1984).  Staining for collagen types I and II 
appeared to be similar between treatments.  Gene expression of 
collagen type I was downregulated in all ascorbate groups except in 
pellets incubated with the highest concentration of L-ascorbate.  Again 
WKLV GLIIHUV IURP 'DQLHO¶V UHVHDUFK JURXS ZKR IRXQG FROODJHQ W\SH ,
expression to be greater in ascorbate treated cultures.  The 3D culture 
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may explain this difference to a certain extent.  The combination of 3D 
high density pellet culture and ascorbate may be more effective at 
maintaining the chondrocyte phenotype and thereby reducing collagen 
type I expression.  The alginate cultures in this thesis were incubated 
with ȝJPODVFRUEDWHZKLFKHTXDWHV WRȝ0DVFRUEDWH &ROODJHQ
type I expression was marginally upregulated in these cultures which 
FRQWUDVWV ZLWK ,EROG¶V ZRUN  All treatments enhanced collagen type II 
gene expression (Ibold et al., 2009).  This is in agreement with the 
results shown in this chapter.  Although Ibold and colleagues used 
various forms of ascorbate, on the whole, there appears to be little 
difference between the different types suggesting that all forms of 
ascorbate have similar effects on chondrocyte phenotype.  
 
 
5.4 Conclusion 
 
It is important to note that, the data presented in this chapter represents 
initial work into the enhancement of chondrocyte redifferentiation.  
Alginate beads would need to be incubated under the conditions 
discussed in this chapter at least two more times to confirm the effects 
reported and generate data to which statistical analysis could be 
applied.  This was attempted; however both batches of beads became 
contaminated during the culture process. In addition, in future work the 
DNA content of the beads should be analysed so GAG data can be 
normalised to this information. 
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Despite this, the initial results suggest that incubation with ascorbate or 
under reduced oxygen conditions enhance GAG synthesis whereas IL-
ȕ DSSHDUV WR UHGXFH *$* SURGXFWLRQ  ,Q WHUPV RI H[SUHVVLRQ RI
collagen types I and II and CD44, the immunohistochemistry data was 
not very conclusive.  The western blotting data showed that ascorbate 
enhanced expression of both collagen types.  Collagen type I 
expression was considerably downregulated in the reduced oxygen 
group.  For collagen type II, two bands were detected; one showed 
increased expression in the reduced oxygen group but the other 
showed a decrease compared to the control group.  CD44 expression 
was only detected in the ascorbate group. 
 
As well as repeating the experiment detailed in this chapter, future work 
could include combining the conditions tested in this chapter as well as 
adding additional factors.  As discussed in the introduction, ascorbate is 
a common feature of chondrocyte culture media and there are some 
studies that have investigated oxygen tension with media containing 
ascorbate (Domm et al., 2002, Malda et al., 2004). In the earlier paper, 
the authors show that immunocytochemical staining for collagen type I 
was strong in beads at 21% oxygen but absent at 5% oxygen.  The 
opposite was the case for collagen type II.  They also showed by 
western blotting that collagen type II expression was higher in alginate 
cultures containing freshly isolated chondrocytes, incubated at 5% 
oxygen.  In addition, they showed that monolayer expanded 
  
305 
 
chondrocytes subsequently cultured in alginate did not express collagen 
type II when cultured at 21% oxygen.  The opposite was the case at 5% 
oxygen (Domm et al., 2002).  In the later paper, GAG content within 
high density pellets increased with decreasing oxygen conditions.  
Staining was the strongest in pellets incubated in 1% oxygen.  
Interestingly staining for collagen type II appeared stronger at 5% 
oxygen than 1% and staining for collagen type I was weakest at 5% 
(Malda et al., 2004).  Investigating the combination of ascorbate and 
reduced oxygen conditions may result in enhanced collagen synthesis 
(caused by the ascorbate) with a reduction in the synthesis of collagen 
type I (a consequence of the reduced oxygen conditions). 
 
The analytical techniques used in this chapter could also be reviewed.  
Perhaps techniques less heavily reliant on antibodies could be 
considered.  Many of the papers reviewed in this discussion have 
VWXGLHGJHQHH[SUHVVLRQKRZHYHUFKDQJHV LQP51$H[SUHVVLRQGRQ¶W
always translate to changes in protein expression.  The potential next 
stages of this work, including reviewing analytical techniques, are 
discussed in greater detail in the next chapter. 
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6. Discussion 
 
Articular cartilage can be damaged directly through injury or OA (Clar et 
al., 2005).  It can also be damaged spontaneously as part of the 
condition osteochondritis dissecans (Clar et al., 2005). 
 
Osteoarthritis (OA) is a debilitating disease which affects a range of 
species.    It is estimated worldwide that 9.6% of men and 18.0% of 
women aged over 60 have symptomatic arthritis (World Health 
Organization, 2013).  Out of those suffering with OA, 80% will 
experience restricted movement and a quarter will be prevented from 
carrying out daily tasks (World Health Organization, 2013).  Dogs are 
also affected by OA, with up to 20% of dogs over one year old suffering 
with the condition (Clements et al., 2010).  The dog has also been used 
as model for OA, with most studies inducing OA via transection of the 
anterior cruciate ligament (Altman et al., 1984, Fife, 1986, Pelletier et al., 
1988, Pelletier et al., 1992, Matyas et al., 1999, Liu et al., 2003, Matyas 
et al., 2004, Rogachefsky et al., 2004, Kuroki et al., 2011, Gharbi et al., 
2013).  The dog is a very useful model because the canine knee is 
anatomically very similar to that of a human and many features 
including the articular cartilage, synovium and joint capsule are highly 
conserved between species (Cook et al., 2010). 
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Articular cartilage is very poor at repairing itself for two major reasons; 
the first being that it is an avascular tissue and therefore has limited 
access to mediators of repair (Newman, 1998, Lewis et al., 2006).  The 
second reason is chondrocytes do not divide and are surrounded by 
their own matrix, so they cannot migrate to the injured section of the 
cartilage (Newman, 1998, Lewis et al., 2006).  There is currently no 
completely successful treatment for damaged cartilage with surgical 
treatments often producing poor quality repair tissue (Stoddart et al., 
2009).  Autologous Chondrocyte Implantation (ACI), first introduced in 
1987 (Brittberg, 2010), has been used to repair cartilage defects over 
4cm2 (Schulze-Tanzil, 2009, Oldershaw, 2012).  A major disadvantage 
of ACI is the requirement to expand chondrocytes in monolayer, in 
order to generate enough cells to repair the defect.  ACI has been 
modified in an attempt to combat the problem of chondrocyte 
dedifferentiation (Brittberg, 2010).  However successful repair of 
cartilage lesions is still a major challenge (Filardo et al., 2013). 
 
In a bid to successfully repair cartilage tissue, research into tissue 
engineering and regenerative medicine has been extremely active over 
the past two decades (Johnstone et al., 2013).  However as of yet, no 
ideal scaffold and cell combination has been identified which 
successfully restores articular cartilage to its native form.   
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The first aim of this thesis was to examine the phenotype of canine 
chondrocytes expanded in monolayer and confirm dedifferentiation.  
Canine chondrocytes expanded up to P5 were shown dedifferentiate 
through the decreased expression of collagen type II and increased 
expression of collagen type I and CD44.   An increase in collagen type I 
expression with increasing passage has also been observed in the 
literature (Brodkin et al., 2004, Darling and Athanasiou, 2005, Yang et 
al., 2006b, Munirah et al., 2010, Nadzir et al., 2011, Hamada et al., 
2013).   In terms of CD44 expression, one group found an increase in 
expression in chondrocytes after 24 hours (Diaz-Romero et al., 2005) 
whereas another group reported an increase in expression from P0-P3 
and a minimal decrease in expression from P3 to P4 (Hamada et al., 
2013).  A decrease in collagen type II expression with increasing 
passage has also been observed by others (Brodkin et al., 2004, 
Darling and Athanasiou, 2005, Yang et al., 2006b, Eleswarapu et al., 
2007, Tew et al., 2008, Munirah et al., 2010, Hamada et al., 2013).  
 
Two drawbacks with working with canine tissue were identified during 
Chapter Three.  The first, which is echoed throughout this project, is the 
limited and sporadic availability of tissue.  This is not a problem 
confined to sourcing canine tissue, others have reported difficulties in 
obtaining human samples (Diaz-Romero et al., 2005, Hamada et al., 
2013).  The other issue encountered was identifying antibodies that 
cross-react with canine tissue.  Although dogs are important companion 
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animals and are a useful model for OA, there are a limited number of 
commercial antibodies available known to cross-react with canine tissue, 
particularly for the antigens studied in this work.  Initially, the plan was 
to assess the expression of collagen types I and II, CD44 and Sox9.  
However, after screening several antibodies, a suitable antibody for 
Sox9 was not identified and was therefore removed from the study.  
Sopp and colleagues (2007) evaluated the cross-reactivity of 
monoclonal antibodies to human CD antigens to bovine antigens.  They 
found that out of 52 antibodies, only 26 reacted with a bovine 
homologue to the human antigen.  A further seven were found to 
recognise different forms of the antigen in bovine samples.  When 16 of 
these antibodies were selected for use in western blotting, only two 
detected bands on the blots.  However, the authors do acknowledge 
that this may not be a lack of cross-reactivity issue but that the 
antibodies may not recognise the denatured forms of the proteins (Sopp 
et al., 2007).  A recent review has also demonstrated that there are 
difficulties in identifying the exact materials used in a paper (Vasilevsky 
et al., 2013).  Vasilevsky et al (2013) found that only 46% of commercial 
and 43% of non-commercial antibodies were identifiable. 
 
Having shown the canine chondrocytes dedifferentiated in monolayer 
culture, the next aim of this thesis was to redifferentiate the cells 
through three-dimensional culture.  The stiff two dimensional monolayer 
culture environment causes cellular spreading and actin stress fibre 
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formation (Schuh et al., 2012).  Culture on tissue plastic forces the cells 
to have a apical-basal polarity (Baker and Chen, 2012).  This polarity 
LVQ¶W XQXVXDO IRU VRPH FHOOV OLNH HSLWKHOLDO FHOOV EXW LV XQQDWXUDO IRU
chondrocytes (Baker and Chen, 2012).  It is also important to note that 
chondrocytes are surrounded by their own matrix in their native 
environment.  This extracellular matrix has a key role in regulating the 
spatial distribution of growth factors, cytokines, oxygen and nutrients 
(Baker and Chen, 2012).  In 2D monolayer expansion, chondrocytes 
are not able to become completely surrounded in their own matrix, 
which no doubt contributes to the dedifferentiation process. 
 
A common approach used to culture chondrocytes three-dimensionally 
is to generate high density pellets (Stewart et al., 2000, Tallheden et al., 
2003, Zhang et al., 2004).   Pellet culture is also often used to 
differentiate mesenchymal stem cells down the chondrogenic lineage 
(Johnstone et al., 1998, Csaki et al., 2007, Stewart et al., 2007, Stewart 
et al., 2008, Vidal et al., 2008, Lettry et al., 2010).  Therefore initial 
attempts at 3D culture used a high density pellet system.  However, all 
pellets were extremely fragile and in some cases, the cells did not form 
a cohesive pellet.  This has been experienced by other researchers; 
Ibold and colleagues reported that their control pellets did not form a 
stable and cohesive matrix (Ibold et al., 2009).  A possible reason for 
the cells not forming cohesive pellets is the low levels of matrix being 
produced by the dedifferentiating cells.  Another research group looking 
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into the chondrogenic differentiation of human adipose tissue derived 
stem cells also commented that their control pellets were loose and 
fragile (Pilgaard et al., 2009).  The possible explanation they give for 
this is having a high cell to matrix ratio within the pellets (Pilgaard et al., 
2009).  Therefore, it was decided that the cells would need a supporting 
scaffold for 3D culture.  Many different scaffolds have been used in the 
literature to culture chondrocytes three-dimensionally (Table 6.1).  
Alginate was chosen as the supporting scaffold as it has frequently 
been used for the 3D culture of chondrocytes (Table 6.1).  It is also a 
naturally occurring polymer (Nussinovitch and Nussinovitch, 2011, Lee 
and Mooney, 2012), which if used for cell transplantation is 
biocompatible with the host and the encapsulated cells (Ghidoni et al., 
2008). 
 
After establishing the alginate bead culture system and adjusting 
downstream assays, beads were seeded with different passages to see 
if the length of monolayer expansion had an impact on redifferentiation.  
A limited number of studies have assessed the redifferentiation 
capabilities of chondrocytes of different passages.  The work in this 
thesis found that beads seeded with P2 canine chondrocytes appeared 
to contain cells with a more chondrocyte-like phenotype compared to 
P3 and P4 chondrocytes.  However, these cells still expressed relatively 
high levels of collagen type I, suggesting that 3D culture alone is not 
enough to induce complete redifferentiation. 
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Therefore, the final aim of this thesis was to enhance the 
redifferentiation of monolayer-expanded canine chondrocytes through 
altering the culture environment.  As discussed in previously, different 
researchers have used a variety of methods to enhance chondrocyte 
redifferentiation.   Two conditions were chosen for this part of the study; 
adding ascorbate to the media and culturing the beads under reduced 
oxygen tension.  The results from this work suggest that culturing beads 
in reduced oxygen conditions enhanced chondrocyte redifferentiation as 
collagen type I expression was lower than in control beads and CD44 
expression was absent.  However, collagen type II expression was 
variable.  Ascorbate enhanced collagen type II expression but it also 
increased collagen type I expression.  In addition, CD44 was only 
detected in the ascorbate treated beads.  As discussed in Chapter Five, 
these results are initial data and would need to be repeated to confirm 
the findings and apply statistical analysis. 
 
Now the bead culture has been established, there are many possibilities 
for testing additional factors and conditions, to identify optimal 
conditions for maintaining the chondrocyte phenotype.  In the first 
instance, future work could include combining the culture conditions of 
ascorbate and reduced oxygen.  Other future work could include adding 
other factors to the culture system.  For example, bone morphogenetic 
protein-2 (BMP-2) and TGF-ȕKDYHEHHQVKRZQ WR LQFUHDVHFROODJHQ
type II expression in P1 embryonic mouse chondrocytes (Gouttenoire et 
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al., 2010).  Another growth factor to consider could be IGF-1 as Pei and 
colleagues (2002) showed that chondrocytes seeded into PGA 
scaffolds and cultured in the presence of IGF-1 expressed high levels of 
collagen type II and relatively low levels of collagen type I.  In another 
study, it was shown that high density pellets containing human 
chondrocytes incubated with IGF-1 during monolayer culture expressed 
higher levels of collagen type II and cartilage-specific proteoglycan 
compared to controls (Shakibaei et al., 2006).  This study also showed 
that monolayer cells incubated with IGF-1 consistently expressed Sox9 
up to P10, whereas expression was almost completely lost by P9 in 
control cultures (Shakibaei et al., 2006).  It has also been found that a 
combination of TGF-ȕDQG,*)-1 enhanced chondrogenesis in equine 
bone marrow derived MSCs (Worster et al., 2001).  Another potential 
factor to explore is the delivery of these growth factors.  Traditionally, 
these factors are added to the culture medium and therefore have to 
diffuse through the scaffold to the cells.  However, they could be 
delivered in the form of microparticles.  Microparticles have been 
developed for the slow release of BMP-2 (White et al., 2013)  and TGF-
ȕ(Lu et al., 2000).  
 
Finally, another aspect of this study and the potential future work to be 
considered is the approach used to assess the phenotype of the 
redifferentiated chondrocytes.  Due to the initial problems identifying 
suitable antibodies which cross-react effectively with canine tissue and 
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the inconclusive immunohistochemistry data, it may be beneficial to 
look at alternative forms of analysis which do not rely on antibodies.  
One potential alternative technique could be to measure mRNA levels 
of chondrocyte de- and re- differentiation markers using quantitative 
PCR (qPCR) (VanGuilder et al., 2008).  However, an increase in mRNA 
expression may not always translate to an increase in protein 
expression.  Another alternative would be to use proteomic analysis, 
which involves separating proteins via SDS-PAGE and identifying the 
bands through mass spectrometry.  The use of proteomics for cartilage 
proteins is reviewed in (Wilson et al., 2008). 
 
Overall, this study has confirmed the dedifferentiation of canine 
chondrocytes in monolayer culture in line with other chondrocyte 
studies.  The redifferentiation of these expanded cells cultured in 
alginate beads has also been shown.  However culture in a 3D 
environment was not enough to induce complete redifferentiation.  
Reduced oxygen tension and addition of ascorbate to the culture media 
appeared to enhance certain aspects of the redifferentiation process.  
The alginate culture system is now at a stage to be altered to identify 
optimal chondrocyte redifferentiation conditions, which could ultimately 
lead to more successful regeneration of articular cartilage. 
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Appendix A: Sources and Uses of Canine Material 
Breed Sex Age (years)  Reason for 
Euthanasia or 
Cause of Death 
(if known) 
Usage 
Rottweiler Male Two Aggressive Cell culture (freshly 
isolated counts 
referred to) 
Staffordshire 
Bull Terrier 
Cross 
Female Unknown Parvovirus Cell culture (freshly 
isolated counts 
referred to) 
Staffordshire 
Bull Terrier 
Male Unknown Parvovirus Western Blotting 
positive control 
tissues 
Staffordshire 
Bull Terrier 
Male Three Unknown Sample sent by Dr 
Rebecca Lewis 
Rottweiler Female Four Severe haem 
diarrhoea 
Multiple passage 
study 
Staffordshire 
Bull Terrier 
Unknown Unknown Unknown 
(suspected to be 
behavioural) 
Immunofluorescence 
(antibody screening) 
Tibetan 
Spaniel 
Male Eight Back legs 
paralysed 
Immunofluorescence 
(antibody screening) 
St Bernard Male Eight or 
Nine 
(suspected) 
Unknown cause 
of death 
Initial Cyquant work; 
Cell density and 
SNP alginate work 
German 
Shepherd 
Male Unknown Behaviour Cryopreserved 
chondrocytes 
English 
Springer 
Spaniel 
Male Eleven Congestive heart 
failure 
Passage Two SNP 
alginate 
Labrador Male Five or Six History of blood 
in urine 
Multiple passage 
beads 
Labrador Female Three Regurgitation 
and weight loss 
Beads cultured in 
various conditions 
Rottweiler Male Two Aggressive Beads cultured in 
various conditions 
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Appendix B: Recipes 
Calcium Chloride (CaCl2) (102mM) 
x 11.322g CaCl2 in 1L of nanopure H2O 
NB: For sterile CaCl2, the solution was autoclaved 
Coomassie Blue 
x Dissolve 450mg Coomassie Blue in 112.5ml methanol, then add 
45ml acetic acid 
x Add RO H2O to 450ml 
Destaining Buffer 
x 50% Methanol 
x 40% nanopure H2O 
x 10% acetic acid 
1,9-dimethylmethylene blue (DMMB) solution (pH1.5) 
x Dissolve the following in 1L of RO H2O 
o 0.016g DMMB 
o 2g sodium formate 
o 5ml 100% ethanol 
o 2ml formic acid 
x Adjust pH to 1.5 
x Store in the dark for up to three months 
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Papain Buffer (pH6.5) 
x Dissolve the following in 90ml of RO H2O 
o 1.42g dibasic sodium phosphate 
o 0.079g cysteine hydrochloride 
o 0.186g EDTA 
x Adjust the pH to 6.5 using 1M HCL 
x Add further RO H2O to make a total volume of 100ml 
x Store at 4oC for up to three months 
Paraformaldehyde (8%) 
x Heat 800ml of RO H2O to 55oC 
x Add 80g of paraformaldehyde and stir continuously 
x Add 1M NaOH drop by drop until the solution clears 
x Filter using filter paper 
x Make up to 1L using RO H2O 
x Store at 4oC for up to one month or aliquot and freeze at -80oC 
NB: Preparation of PFA should be undertaken in a fume cupboard 
Phosphate Buffered Saline (PBS) 
x 1 PBS tablet in 500ml of RO H2O 
NB: For sterile PBS, the solution was autoclaved 
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RIPA buffer 
x 105mM NaCl 
x 50mM Tris.HCl (pH 7.5) 
x 5mM EGTA 
x 1% Triton X-100 
x 0.5% Sodium Deoxycholate 
x 0.1% Sodium Dodecyl Sulphate (SDS) 
Resolving Gel (10%) 
x 2.5ml 1.5M Tris pH8.8 
x 3.3ml 30% Acrylamide 
x 4.1ml RO H2O 
x ȝOSDS 
x ȝODPPRQLXPSHUVXOSKDWH 
x ȝO7(0(' 
Running Buffer (10x) 
x 30.3g TrisBase 
x 144.1g Glycine 
x 5g SDS 
x Mix in RO water to 1L 
Sample Buffer (5x) 
x 3.12ml 2M Tris-HCl pH6.8 
x 1.88ml milli-Q water 
x 10ml Glycerol 
  
375 
 
x 2.0g SDS 
x 5ml 2-mercaptoethanol 
x Small quantity of Bromophenol Blue 
NB: This makes 20ml, so can be aliquotted and stored at -20oC 
Stacking Gel (4%) 
x 2.5ml 0.625M Tris pH6.8 
x 1.3ml 30% Acrylamide 
x 6.1ml RO H2O 
x ȝO6'6 
x ȝODPPRQLXPSHUVXOSKDWH 
x ȝO7(0(' 
Sodium Chloride (NaCl) (0.155M)  
x 9.058g NaCl in 1L of nanopure water 
NB: For sterile NaCl, the solution was autoclaved 
Tris Buffered Saline (TBS) (10x) 
x 24.4g TrisBase 
x 175.3g NaCl 
x Mix in 500ml RO H2O and adjust pH to 8.0 
x Make up to 2L with RO H2O following setting pH 
TBS-Tween 
x To 1L of 1xTBS add 1ml Tween20 
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Transfer Buffer 
x 7.2g Glycine 
x 1.5g TrisBase 
x 200ml Methanol 
x 800ml RO water 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
377 
 
Appendix C: Tissue Processing Programme Used 
for Articular Cartilage 
 
Solution Time (hours) 
70% Ethanol 1.0 
80% Ethanol 1.5 
95% Ethanol 1.5 
100% Ethanol 1.0 
100% Ethanol 1.0 
100% Ethanol 1.5 
100% Ethanol 1.5 
Histoclear 1.0 
Histoclear 1.5 
Histoclear 0.5 
Paraffin 2.0 
Paraffin 3.0 
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Appendix D: Western Blotting Raw Data 
Original western blot images of those shown in Figure 4.16.  (a) western blot for 
collagen type I (b) corresponding beta actin blot; (c) western blot for collagen type II, 
(d) corresponding beta actin blot; (e) western blot for CD44, (f) corresponding beta 
actin blot.  25µg of each bead lysate was loaded onto the gel.  All lysates were 
generated from 50 beads except P2 which was generated from 20 beads. Exposures: 
(a) and (c): one minute 30 seconds, (e): three minutes, (b), (d) and (f): one second.  T: 
FDQLQH WHQGRQ O\VDWH ȝO&FDQLQHFDUWLODJH O\VDWH ȝO6FDQLQHVSOHHQ O\VDWH
ȝJRed boxes indicate bands of interest and the lanes that were shown in Figure 
4.16 
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